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Abstract 
Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR) 
inhibitors, are currently the pharmaceutical intervention strategy of choice for the primary 
and secondary prevention of atherosclerotic disorders that are related to 
hypercholesterolemia. In most recipients, statin therapy is effective and well tolerated, 
however the most significant barrier to cardiovascular disease (CVD) risk reduction is the 
development of adverse effects, of which statin-related myopathies (SRM) are the most 
frequently reported. The aetiological basis of SRM is both complex and multifaceted, with no 
clear dose-response relationship and a plethora of generalised and genetic risk factors 
identified to date.  However, the deleterious effects of statins upon mitochondrial function 
has been implicated as one of several putative mechanisms by which myopathic symptoms 
may be potentiated in some patients.  
Therefore, the aim of this research was to establish the effects of statin chemical species (i.e. 
inactive lactones versus active β-hydroxy acids) upon the functionality of the mitochondrial 
electron transport chain using high resolution respirometry. Thereafter, the remainder of the 
thesis focussed upon the development of three-dimensional, bioengineered micro-tissue 
models of human skeletal muscle to identify functional bioenergetic factors which may 
confer enhanced or diminished risk of statin-mediated mitochondrial dysfunction. Finally, 
due to the governance of respiratory chain assembly, stability and functionality by the 
mitochondrial genome, next generation sequencing (NGS) of patient mitochondrial DNA was 
performed for a statin myopathy case-control cohort to determine if there was an 
association between mitochondrial genotype and patient phenotype.  
Preliminary in vitro investigations performed using the L6 myoblast cell line identified 
succinate dehydrogenase (complex II) driven respiration as a major, but not an exclusive 
target of simvastatin-mediated mitochondrial dysfunction over acute and extended dosing 
regimens. Following the assessment of simvastatin-mediated mitochondrial dysfunction in a 
murine cell line, a cohort of statin-naïve, statin-tolerant and statin-intolerant patients were 
recruited via the Liverpool Musculoskeletal Biobank (LMB) before isolation of satellite cells 
from skeletal muscle biopsy samples. The satellite cells were then used to generate 
biomimetic, engineered micro-tissues known as myobundles. Examination of baseline 
bioenergetic parameters in patient derived myobundles showed that individuals belonging 
to the statin-tolerant group exhibited a greater spare respiratory capacity than both the 
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statin-naïve and statin-intolerant patients, a trait linked to increased succinate 
dehydrogenase activity and cell survival. 
Finally, the mitochondrial DNA haplogroups of 264 statin myopathy cases, 291 statin-
tolerant controls and 342 healthy volunteers were resolved using NGS and HaploGrep2 
software (phylotree build 17) before performing a haplogroup-disease association study. 
Within this study, a significant association between mitochondrial macro-haplogroup 
assignment and statin related myopathy was not identified. The distribution of mitochondrial 
haplogroups in both the case and control groups resembled that of the healthy volunteer 
cohort and the Northern European population. 
To conclude, statin-mediated mitochondrial dysfunction has a role to play in the 
development of myopathic symptoms amongst susceptible patients. However, this research 
has also identified enhanced spare respiratory capacity as a potential protective factor 
amongst statin-tolerant individuals. What is less clear is the relative contributions of direct 
respiratory inhibition and/or modulation of peripheral pathways which interact with the 
wider mitochondrial signalling network, to the overall pathophysiological mechanism.   
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1.1 Cardiovascular Disease and Statin Therapy 
Atherosclerotic cardiovascular disease (CVD) is the leading cause of morbidity and mortality 
worldwide, accounting for > 17 million deaths globally per annum, a figure currently 
projected to rise to > 23 million by 2030 (Forouzanfar et al., 2016). Studies conducted in the 
mid 1900’s first identified the relationship between hypercholesterolemia and the onset of 
cardiovascular disease by utilising ultracentrifugation to separate the different lipoproteins 
present in patient plasma by floatation (Egom and Hafeez, 2016). It was found that not only 
did CVD correlate with elevations in plasma cholesterol but that the cholesterol was 
associated with low density lipoprotein (LDL) specifically. Assimilation of epidemiological 
studies underpinning this concept have been meta-analysed by The Emerging Risk Factors 
Collaboration to implicate LDL-cholesterol as one of the main risk factors for developing CVD 
and high dietary lipid intake as a cause of pathological LDL-cholesterol levels (Danesh et al., 
2007). The results of such studies provided the impetus for the discovery of cholesterol and 
lipid lowering medications.  
1.1.1 The Statin Drug Class  
Statins, also known as 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoAR) 
inhibitors, have been the treatment of choice for atherosclerotic disorders that are related 
to elevated cholesterol levels (hypercholesterolemia) since their introduction to the clinic in 
1987 (Sathasivam, 2012; Feng et al., 2012; Golomb and Evans, 2008). The drug class is 
extremely effective in reducing both the morbidity and mortality associated with adverse 
cardiovascular and cerebrovascular events, particularly CVD and stroke in high-risk 
populations (Silva et al., 2006). 
Statins represent the most popular prescription drug class in the developed world, with an 
estimated 25 % of the global population > 65 years taking statins to manage CVD 
(Sathasivam, 2012; du Souich et al., 2017). In the UK, the number of patients prescribed 
statins is increasing due to a review of the eligibility guidelines in 2014 by the National 
Institute for Health and Care Excellence (NICE). The review broadened eligibility for statin 
prescription from  20 % 10-year risk of cardiovascular disease to  10 % 10-year risk. 
Ultimately this has the potential to increase the number of patients receiving statin therapy 
from ~7 million to ~11.5 million (Matthews et al., 2016; Trusler, 2011). 
1.1.2 Physicochemical Characteristics  
Statins are comprised of two principle components; a β-hydroxy heptanoic acid 
pharmacophore which is conserved across all statins, and a covalently bonded hydrophobic 
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ring which is crucial for the close binding to HMG-CoA reductase (Figure 1.1) (Hamelin, 1998; 
Gazzerro et al., 2012). The pharmacophore is a ‘HMG-like’ moiety and is able to competitively 
and reversibly bind to HMG-CoAR with three times more affinity than that of its natural 
substrate HMG-CoA (Tiwari and Khokhar, 2014). 
 
The chemical makeup of the hydrophobic ring structure defines both the solubility of the 
statin along with many of the pharmacological properties. Simvastatin, lovastatin and 
pravastatin have a partially reduced naphthalene rings, whereas atorvastatin has a pyrrole, 
fluvastatin an indole, rosuvastatin a pyrimidine, cerivastatin a pyridine and pitavastatin a 
quinoline (Gazzerro et al., 2012). 
Statins are generally grouped into two types based on their origin. Type 1 statins are 
natural/fungal derived statins (lovastatin, simvastatin and pravastatin) whereas type 2 
statins are synthetically derived. The major functional differences between the two groups 
are their ability to interact with HMG-CoAR and their overall lipophilicity. Type 2 statins are 
able to form more interactions with the HMG-CoAR enzyme thus rendering them 
(rosuvastatin in particular) extremely efficient in reducing enzymatic activity in relation to 
dosage (Gazzerro et al., 2012; Davidson, 2002). 
Figure 1.1 Chemical structures of the 8 HMG-CoAR inhibitors. All compounds are represented in their 
open β-hydroxy heptanoic acid conformation except for lovastatin and simvastatin (red box) which 
are in their closed lactone ring conformation. 
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1.1.3 Chemical Species Interconversion 
Unlike the other statins, both simvastatin and lovastatin are administered as inactive lactone 
‘pro-drugs’ which must undergo either enzymatic or non-enzymatic hydrolysis to form an 
active -hydroxy acid (Figure 1.2) (Hamelin, 1998; Skottheim et al., 2008).  
 
The open acid molecular conformation is essential for the interaction and subsequent 
inhibition of HMG-CoAR.  In vivo, all statins whether administered as an active acid or inactive 
lactone have the potential to interconvert between the two chemical conformations, as well 
as forming several short lived active metabolites (Prueksaritanont, Subramanian, et al., 2002; 
Hoffmann and Nowosielski, 2008; Shitara and Sugiyama, 2006). 
Figure 1.2 Summary of statin chemical species interconversion. Diagram adapted from (Shitara and 
Sugiyama, 2006). Abbreviations: CYP450, cytochrome P450; UGT, uridine diphosphate (UDP)-
glucuronosyl-transferase. 
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In the case of simvastatin and lovastatin particularly, the primary mechanism of lactone 
hydrolysis is thought to be mediated by microsomal carboxyl esterases in the liver, however 
there is also evidence to suggest that at near physiological or alkaline pH, statin lactones are 
less stable and equilibrium will substantially favour hydrolysis of the lactone ring and 
formation of the -hydroxy acid (Taha et al., 2016, 2017). 
Conversely, the lactonisation of active statins in vivo has been hypothesised to serve as an 
intermediate step in statin metabolism whereby the drugs interconvert between the acid 
and lactone forms until an equilibrium is established. A potential reason for this occurrence 
is that lactonisation provides a more suitable substrate for the action of cytochrome P450 
(CYP) isoform 3A4, an enzyme heavily implicated in the phase I metabolism of lipophilic 
statins, ultimately aiding in overall drug clearance (Schirris et al., 2015).  
The mechanistic basis of statin lactonisation is still under debate, the active -hydroxy acid 
is thought to undergo lactonisation non-enzymatically in the presence of low pH conditions 
such as those in the gastrointestinal tract. However, the leading theory which appears to be 
conserved across multiple species is the conversion of the statin hydroxy acids to lactones 
by uridine diphosphate (UDP)-glucuronosyl-transferase (UGTs) conjugation in the liver. UGTs 
can catalyse the formation of coenzyme A or acyl glucuronide intermediates that, due to 
instability, rapidly decay to lactones (Schirris et al., 2015; Hoffmann and Nowosielski, 2008). 
1.1.4 Statin Pharmacokinetics  
At the pharmacokinetic level (i.e. the absorption, distribution, metabolism and excretion of 
a given drug), the statin class exhibits several important differences between compounds, 
including half-life, systemic exposure, maximum plasma concentration (Cmax), bioavailability, 
lipophilicity, metabolism and excretion routes (Table 1.1). The liver is the primary site of 
biotransformation for all statins. Their low overall systemic bioavailability is consequential of 
an important hepatic first-pass effect. With the exception of pravastatin, which is 
enzymatically transformed in the cytosol of hepatocytes, all other statins undergo 
microsomal metabolism by the cytochrome P450 (CYP450) isoenzyme family (Bellosta et al, 
2004).  
Statins are generally hepato-selective with respect to inhibition of HMG-CoAR, an important 
property given that the majority of endogenous cholesterol biosynthesis takes place in the 
liver. The mechanisms contributing to the hepato-selective nature of statins are governed by 
the relative solubility of the compound. Lipophilic statins are able to passively diffuse 
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through the hepatocyte cell membrane whilst hydrophilic statins are reliant upon carrier-
mediated uptake (Schachter, 2005).  
Table 1.1 Summary of statin pharmacokinetic properties adapted from (Stefano et al., 2004). 
 Statin 
Atorva Fluva Lova Pitava Prava Rosuva Simva 
Tmax (h) 2-3 0.5-1 2-4 1-1.8 0.9-1.6 3 1.3-2.4 
Cmax (ng/mL) 27-66 448 10-20 ~60 45-55 37 34-920 
Bioavailability 
(%) 
12 19-29 5 >60 18 20 5 
Lipophilicity 
(Log P) 
1.11 1.27 1.70 1.49 -0.84 -0.33 1.60 
Protein 
Binding (%) 
80-90 % >99 >95 >99 % 43-55 88 94-98 
Metabolism CYP3A4 CYP2C9 CYP3A4 CYP2C9 Sulfation CYP2C9/2C19 CYP3A4 
Metabolites Active Inactive Active Inactive Inactive 
Active 
(minor) 
Active 
Transporter 
Protein 
Substrate 
Yes No Yes Yes Yes Yes Yes 
T ½ (h) 15-30 0.5-2.3 2.9 8-9 1.3-2.8 20.8 2-3 
Urinary 
excretion (%) 
2 6 10 15 20 10 13 
Fecal 
excretion (%) 
70 90 83 79 71 90 58 
Based on a 40 mg oral dose, with the exception of pitavastatin (2 mg) and simvastatin (7.5 mg/kg). 
Table generated using data compiled from (Stefano et al., 2004; Catapano, 2010; Jung et al., 2012; 
Morgan et al., 2012; Corsini et al., 1999; White, 2002; Ahmed et al., 2013).  
Whilst the lipophilicity of the compound promotes efficient hepatic shunting, the same 
property results in the increased potential for permeation of extra-hepatic tissues. For this 
reason, hydrophilic statins exhibit greater hepato-selectivity than their lipophilic 
counterparts (Schachter, 2005). 
1.1.5 Regulation of Cholesterol Biosynthesis by Statins  
The liver is the primary site of de novo cholesterol synthesis in the body, accounting for up 
to two thirds of endogenous cholesterol production (Hamelin, 1998). Endogenous 
cholesterol is produced in the endoplasmic reticulum (ER) of hepatocytes via the mevalonate 
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pathway. Statins are used for the rational therapeutic manipulation of the mevalonate 
pathway through the competitive inhibition of HMG-CoAR. HMG-CoAR is a key enzymatic 
regulator at the apex of the biosynthetic pathway, dictating the rate limiting step that 
catalyses the conversion of HMG-CoA to mevalonic acid. In addition to cholesterol, the 
mevalonate pathway is responsible for the synthesis of isoprenoids, steroid hormones and 
bile acid precursors (Figure 1.3). 
 
Isoprenoids are an essential by-product of the pathway, required for the post-translational 
modification of proteins (i.e prenylation, farnesylation, geranyl geranylisation). Inhibition of 
the pathway and subsequent isoprenoid deficiency is thought to have a plethora of 
heterogeneous downstream effects such as impaired synthesis of transfer RNAs, 
glycoproteins, respiratory chain proteins heme A and ubiquinone (CoQ10) and small GTPases 
(i.e. RhoA, RAP1, Ras) essential for both cell signalling, intracellular protein trafficking and 
Figure 1.3 HMG-CoAR catalyses the conversion of HMG-CoA to mevalonic acid, the rate limiting step 
of the biosynthetic pathway. Mevalonic acid is an intermediary metabolite of cholesterol and several 
other sterol isoprenoids including dolichol (transmembrane carrier of glycosyl units), electron 
transport chain proteins Heme A and ubiquinone (CoQ10), Geranylgeranyl pyrophosphate (GGPP) and 
farnesyl pyrophosphate (FPP). GGPP and FPP are also implicated in the post-translational modification 
of up to 2 % of total cellular proteins including small GTPases and nuclear lamins. 
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attenuation of apoptotic signalling (Baer and Wortmann, 2007; Flint et al., 1997b; Tricarico 
et al., 2015).  
Secondary to the reduction of de novo cholesterol synthesis, decreased intracellular 
cholesterol activates low density lipoprotein receptor (LDL-R) gene transcription, instigating 
the over expression of LDL-R on the hepatocyte plasma membrane. Overexpression of LDL-
R increases the reuptake of LDL-cholesterol from systemic circulation, decreasing the total 
LDL-cholesterol plasma concentration (Duriez, 2003). 
1.2 The Safety of Statins 
Statin treatment is one of the most effective pharmaceutical intervention strategies available 
for the primary and secondary prevention of atherosclerotic cardiovascular and 
cerebrovascular disease. In the majority of recipients, statin therapy is safe and well 
tolerated. However, statins are associated with rare, life-threatening side effects, such as 
rhabdomyolysis and hepatotoxicity and have been linked to an increased incidence of new-
onset, type 2 diabetes mellitus (Sakamoto and Kimura, 2013; Thapar et al., 2013; Sattar and 
Taskinen, 2012). Patients increasingly report symptomatic side effects such as joint pain or 
proximal muscle pain and/or weakness which prevent the continuation of treatment, a 
condition collectively referred to as statin intolerance.  
1.2.1 The Economical and Clinical Significance of Adverse Drug Reactions 
Adverse drug reactions (ADRs) are defined as “an appreciably harmful or unpleasant 
reaction, resulting from an intervention related to the use of a medicinal product, which 
predicts hazard from future administration and warrants prevention or specific treatment, 
or alteration of the dosing regimen, or withdrawal of the product” (Edwards and Aronson, 
2000). 
ADRs have been estimated to be responsible for the attrition of ~30 % of candidate 
pharmaceuticals. Consequently, this has contributed to the high economical cost of drug 
development, especially when adverse effects are not recognised until late phase clinical 
trials or post marketing (Guengerich, 2011). The cost of profitable drug development has 
been increasing for many years, with recent research and development outlay estimates 
approaching $1.4 billion per new compound (DiMasi et al., 2016).  
Drug withdrawal during the research and development phase has been most commonly 
associated with hepatic, cardiovascular and to a lesser extent skeletal muscle liabilities 
(Guengerich, 2011; Waring et al., 2015). However, xenobiotic-induced myopathies have 
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become an area of increasing concern due to the widespread and prolific use of 
hypolipidemic medications such as statins and fibrates. The problem was highlighted by the 
withdrawal of cerivastatin from the market in 2001 due to an unacceptable incidence of 
rhabdomyolysis resulting in ~100 patient deaths (Thompson et al., 2003; Baker and 
Tarnopolsky, 2001).  
From a clinical standpoint, ADRs increase the burden upon the healthcare system by 
promoting non-adherence to medications, increasing hospitalisation, prolonging hospital 
stays and increasing the need for additional clinical investigations in more serious cases. 
Furthermore, ADRs may elicit prescription cascades whereby new medications are 
prescribed to treat conditions which are consequential of another drug. Not only does this 
increase the cost of pharmacotherapy but it also compounds the risk of further ADRs 
occurring (Sultana et al., 2013). 
1.2.2 Statin-Related Hepatic Injury  
Clinical trials have demonstrated that statin therapy is associated with elevations in serum 
alanine aminotransferase (ALT) levels in approximately 3 % of recipients. In most cases, these 
elevations are not clinically significant, indeed ALT levels 3X the upper limit of normal (ULN) 
are rarely observed. However with continued administration, mild elevations in serum ALT 
generally resolve (Thapar et al., 2013). In contrast, clinically important drug-induced liver 
injury (DILI) is rarely seen with statin use. The spectrum of hepatic abnormalities observed 
include: (1) asymptomatic elevations in ALT: usually transient (ALT <3X ULN) as previously 
described; (2) hepatitis with ALT >3X ULN and clinical symptoms of liver disease; (3) 
cholestatic or mixed hepatitis; and (4) autoantibody-associated DILI (Thapar et al., 2013).  
Acute liver failure (ALF) develops in a very small minority of statin recipients, with the 
incidence not differing from that of the general population. The overall risk of developing 
DILI from statin therapy is estimated to be 1 in 100,000, whereas the estimated risk of ALF is 
1 in 1,000,000 (Russo et al., 2009).  
1.2.3 New Onset Type 2 Diabetes Mellitus  
The risk of developing type 2 diabetes mellitus (DM) through statin use has been studied in 
both randomised controlled clinical trials and via meta-analyses (Navarese et al., 2013; Sattar 
et al., 2010; Baker et al., 2010; Rajpathak et al., 2009). Based upon the results of the 
aforementioned studies, risk of new onset DM has been added to the labels of statins by the 
US Food and Drug Administration (FDA). However, it is important to consider that DM is often 
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associated with dyslipidaemia, hypertension, obesity and elevated glucose levels, therefore 
it remains unclear if only patients who are pre-disposed to developing DM are susceptible to 
statin-induced DM or if it also extends to individuals who are at low risk for type 2 DM. 
Despite the mounting evidence for a higher incidence of DM with statin use, the 
pathomechanism remains unclear. Statins may directly decrease insulin biosynthesis or 
reduce secretion, thus exacerbating insulin resistance or modifying signalling to peripheral 
tissues (Sattar and Taskinen, 2012; Koh et al., 2012). Conversely, others have suggested that 
the inhibition of the mevalonate pathway by statins and the consequential reduction in 
cholesterol synthesis induces DM and not the drug itself (White et al., 2016). 
1.2.4 Statin-Related Myopathy  
The most significant barrier to atherosclerotic disease risk reduction is the development of 
statin-related myopathy (SRM). Whilst mild myotoxicity from the use of statins is generally 
self-limiting and will resolve itself with the cessation of treatment, it can foster poor patient 
compliance, reduced quality of life and reduced treatment efficacy. The clinical spectrum of 
musculoskeletal complications from statin therapy can vary significantly from patient to 
patient. At one end of the scale, individuals can be asymptomatic with elevated CK levels, or 
possess mild proximal muscle pain and weakness teamed with elevated CK. Conversely, 
patients can present with biopsy affirmed inflammatory myositis or in extremely rare cases 
(0.003-0.1 %) rhabdomyolysis with elevated CK and potential for acute kidney injury 
(Apostolopoulou et al., 2015).  
The reported incidence of statin-linked muscle complaints of varying severities are thought 
to range between 1-5 % in randomised clinical trials (Kashani et al., 2006), however the true 
case rate of myopathy may fall between 7-29 % when all disease phenotypes are taken into 
consideration (Stroes et al., 2015). Unfortunately the lack of a unifying classification system 
for the report of myopathic symptoms results in discrepancies in these figures, thus a truly 
representative case rate is particularly difficult to quantify.  To address this Alfirevic et al., 
proposed an algorithm to standardise nomenclature, outline phenotypic definitions and rank 
severity to aid both clinicians and researchers (Table 1.2) (Alfirevic et al., 2014). 
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Table 1.2 Statin-related myopathy (SRM) phenotype classification adapted from (Alfirevic et al., 2014).  
SRM Classification Phenotype Definition 
SRM 0 CK elevation < 4X ULN No muscle symptoms 
SRM 1 Myalgia, tolerable Muscle symptoms without CK elevation 
SRM 2 Myalgia, intolerable 
Muscle symptoms, CK < 4X ULN, complete 
resolution upon dechallenge 
SRM 3 Myopathy 
CK elevation > 4X ULN < 10X ULN ± muscle 
symptoms, complete resolution upon 
dechallenge 
SRM 4 Severe myopathy 
CK elevation > 10X ULN < 50X ULN ± 
muscle symptoms, complete resolution 
upon dechallenge 
SRM 5 Rhabdomyolysis 
CK elevation > 10X ULN with evidence of 
renal impairment + muscle symptoms or 
CK > 50X ULN 
SRM 6 
Autoimmune-mediated 
necrotising myositis 
HMG-CoAR antibodies, HMG-CoAR 
expression in the muscle biopsy, 
incomplete resolution upon dechallenge 
Abbreviations: SRM, statin-related myopathy; CK, creatine kinase; ULN, upper limit of normal; HMG-
CoAR, 3-hydroxy-3-methylglutaryl-coenzyme A reductase.  
 
1.2.4.1 Patient Risk Factors for Statin-Related Myopathy 
The identification of patients with an increased proclivity for developing myopathic 
symptoms when challenged with statins could allow the clinician to make more cost effective 
decisions and improve patient safety. Several generalised factors have been uncovered 
which have been shown to confer an elevated risk of SRM in statin recipients (Table 1.3) 
(Harper and Jacobson, 2007). 
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Table 1.3 Compilation of general risk factors for the development of statin-related myopathy (Feng 
et al., 2012; Harper and Jacobson, 2007). 
Type  Risk Factor  
Generalised Advanced age (>80 years) 
Female gender 
Hypertension  
Low body mass index (BMI) 
Strenuous exercise  
Alcohol abuse 
Drug abuse  
Low vitamin D levels  
Familial history of myopathy   
Smoking 
Surgery  
Renal disease  
Hepatic disease  
High drug dose  
Lipophilicity of statin 
Metabolic  Diabetes mellitus  
Hypothyroidism  
Metabolic muscle disease  
McArdle disease  
Carnitine palmitoyl transferase II deficiency 
Myoadenylate deaminase deficiency 
Co-medications Fibrates  
Nicotinic acid  
Cyclosporine  
Azole antifungals  
Macrolide antibiotics  
Protease inhibitors  
Nefazadone  
Verapamil  
Amiodarone  
Warfarin  
Grapefruit Juice 
Genetic Polymorphisms  CYP450 isoenzymes  
SLCO1B1  
ABCB1/ABCC2 
Abbreviations: CYP450, cytochrome-P450, SLCO1B1, solute carrier organic anion transporter family 
member 1B1; ABCB1/C2, ATP-binding cassette subfamily B1/C2; UGT1, UDP-glucuronosyltransferase 
1. 
 
In addition, there are suggestions within the literature that patients with subclinical 
mitochondrial insufficiencies or fully realised metabolic disorders are more likely to manifest 
myopathic symptoms following the administration of a statin (Antons et al., 2006; 
Apostolopoulou et al., 2015).  
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1.2.5 Pathomechanisms of Statin-Related Myopathy  
The pathomechanistic nature of SRM is as yet unresolved, however there are numerous 
hypotheses which have been proposed in order to rationalise their manifestation. 
Cholesterol is a key structural and functional component of the cell plasma membrane, 
therefore modulation of the mevalonate pathway by statins may result in changes to both 
membrane fluidity and ion channel conductance, altering muscle membrane excitability 
(Pierno et al., 1995).  
Isoprenoids are yet another essential by-product of the mevalonate pathway, required for 
the post-translational modification of proteins (i.e prenylation, farnesylation, geranyl 
geranylisation, N-glycosylation). Inhibition of the pathway and subsequent isoprenoid 
deficiency is thought to have heterogeneous downstream effects such as impaired synthesis 
of tRNAs, glycoproteins, respiratory chain cofactors, and small GTPases (i.e. RhoA, RAP1, Ras) 
essential for both cell signalling, intracellular protein trafficking and attenuation of apoptotic 
signalling (Flint et al., 1997b; Baer and Wortmann, 2007).  
Indeed, defects associated with the proximal mevalonate pathway are considered to be 
more closely associated with myopathy, whilst those of the distal pathway appear to be of 
lesser importance (Baer and Wortmann, 2007). This idea is substantiated when paired with 
studies demonstrating that mevalonate pathway blockade in vitro at the point of squalene 
synthesis, the first committed step in cholesterol synthesis, does not result in cytotoxicity 
(Flint et al., 1997b). Squalene synthesis is downstream from the formation of isoprenoid 
precursors such as farnesyl pyrophosphate (FPP) and geranylgeranyl pyrophosphate (GGPP), 
indicating that impaired post-translational modification of proteins and not altered 
membrane cholesterol content, may be more important in the development of myopathy 
(Flint et al., 1997a). Furthermore, supplementation of mevalonic acid, the product of HMG-
CoAR, in to the media of statin treated myocytes has been shown to abrogate the loss of cell 
viability (Sacher et al., 2005). However, only 30-50 % of the reduction in viable cells was 
attributable to the inhibition of HMG-CoAR which is indicative of additional underlying 
toxicity mechanisms which may be independent of the inhibition of the mevalonate pathway 
(Dirks and Jones, 2006; Sacher et al., 2005).  
It has also been reported that statins may have a direct effect on the sarcoplasmic chloride 
concentration by modulating ClC-1 chloride channel activity and altering resting chloride 
conductance (gCl) in the muscle. Decreased ClC-1 mRNA expression has been detected in 
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rats receiving fluvastatin or atorvastatin resulting in a 30 % reduction in gCl (Pierno et al., 
2009).  
In skeletal muscle, MCT1 and MCT4 are responsible for mediating lactate flux relative to the 
lactate concentration and proton gradient, either into or out of the myocyte. MCT1 is 
thought to be predominantly expressed in type I oxidative fibers whilst MCT4 is expressed 
primarily in type II glycolytic fibers (Bonen, 2001). Both transporters are located on the 
sarcolemmal and mitochondrial membranes. Several studies have demonstrated that 
lipophilic statins in particular may block MCT1/4, thereby increasing sarcoplasmic lactate 
concentrations (Kobayashi et al., 2006, 2005; Kobayashi, 2015). 
 A role for the activation of atrophy related genes have been identified in statin mediated 
muscle fiber damage. In particular the upregulation of two E3 ubiquitin ligases, Atrogin-1 and 
MuRF1, which are members of the muscle-specific ubiquitin proteasome (Hanai et al., 2007; 
Goodman et al., 2015). Atrogin-1 expression is thought to be upregulated early in the 
induction of atrophy, preceding the loss of muscle mass. Patients who exhibit SRM 
demonstrate elevated Atrogin-1 mRNA expression in biopsies of quadriceps muscle (Cao et 
al., 2009). 
1.2.6 Mitochondria and Statin-Related Myopathy  
Mitochondrial dysfunction is now one of the most widely accepted and well-studied 
pathomechanisms of SRM. However, the exact nature, extent and type of mitochondrial 
dysfunction(s) elicited by statin therapy still remains unclear. Previous studies seeking to 
establish the aetiological basis of SRM have demonstrated impairment of multiple 
mitochondrial process.  
1.2.6.1 Drug-induced Mitochondrial Dysfunction  
Recognition of the ability for specific compounds to perturb mitochondrial function (e.g. 
oligomycin, carbon monoxide and 2,4,-dinitrophenol) dates back more than 60 years. It 
wasn’t until 2007 and the release of several landmark papers spearheaded by Yvonne Will 
and James Dykens, that the appreciation for the role of mitochondrial dysfunction in the 
aetiology of adverse drug reactions was truly recognised (Dykens and Will, 2007; Marroquin 
et al., 2007). Compounds that induced mitochondrial dysfunction can do so through multiple 
mechanisms, encompassing both direct (e.g. respiratory complex inhibition) and indirect 
(e.g. altered cross-talk with the nucleus) targets. 
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Growing understanding of chemical-induced mitochondrial dysfunction has also been 
paralleled with an increased awareness of the implication of mitochondrial dysfunction in 
disease. Many metabolic diseases are caused by mutations in both the nuclear and 
mitochondrial genomes, affecting roughly 1 in every 4,300 individuals (Gorman et al., 2015). 
An even greater proportion of people are affected by diseases which are associated with, yet 
may not necessarily be directly caused by, mitochondrial dysfunction (e.g. Parkinson’s 
disease). 
This raises the question, are individuals suffering from mitochondrial disease or harbouring 
subclinical mitochondrial insufficiencies more susceptible to mitochondrial toxicants? This 
topic has been reviewed in the context of drug-induced liver injury (DILI) as a means to 
explain its often idiosyncratic nature (Boelsterli and Lim, 2007). Later work using murine 
embryonic fibroblasts with distinct mitochondrial DNA (mtDNA) polymorphisms supported 
significant variability in response to mitochondrial toxicants, however this has yet to be 
reviewed in the context of drug-induced skeletal muscle injury (Pereira et al., 2012). 
1.2.6.2 Indirect Mitochondrial Effects  
Statin-associated mitochondrial dysfunction was originally thought to be mediated by the 
inhibition of CoQ10 synthesis, an important respiratory chain co-factor and a by-product of 
the mevalonate pathway. Lower CoQ10 levels were observed in the circulation and skeletal 
muscle of patients receiving statin treatment in tandem with higher lactate/pyruvate ratios, 
a clinical indicator of mitochondrial dysfunction (Laaksonen et al., 1994; De Pinieux et al., 
1996).  
A systematic review of the literature identified several studies that reported a decrease in 
plasma CoQ10 levels in statin myopathy cases. However, the reported decrease may have 
been due to the simultaneous decrease in circulating LDL-cholesterol, the primary 
transporter of CoQ10 to peripheral tissues (Marcoff and Thompson, 2007). CoQ10 does not 
circulate in any appreciable concentration as an unbound free molecule (Deichmann et al., 
2010). Furthermore, whilst circulating levels of CoQ10 may routinely decrease with statin 
treatment, this does not always correlate to changes in CoQ10 levels in skeletal muscle or to 
mitochondrial dysfunction (Laaksonen et al., 1996).  
Multiple clinical trials have evaluated the impact of oral CoQ10 supplementation as a means 
to prevent or treat statin myopathy, however these have yielded inconclusive results (Table 
1.4). 
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Table 1.4 List of placebo-controlled CoQ10 supplementation trials for the treatment of SRM. ↓ 
decrease, ↔ no change.  
Reference  CoQ10 Dose 
(Duration) 
Statin 
(Dose) 
Study Outcome 
(Caso et al., 2007) 100 mg/day, 30 days Variety  ↓ Muscle pain  
(Young et al., 2007) 200 mg/day, 12 weeks Simvastatin 
(10-40 mg) 
↔ Muscle pain, statin 
tolerance  
(Bookstaver et al., 
2012) 
60 mg/2x day, 3 
months 
Variety  ↔ Pain at 1 month  
(Bogsrud et al., 2013) 400 mg/day 12 weeks  Atorvastatin 
(10 mg) 
↔ Symptoms  
(Fedacko et al., 2013) 200 mg/day, 3 months Variety  ↓ Muscle pain, SRM 
cases  
(Skarlovnik et al., 2014) 50 mg/2x day, 30 days Variety  ↓ Muscle pain  
(Taylor et al., 2015) 600 mg/day, 8 weeks Simvastatin  
(20 mg) 
↔ Muscle pain, SRM 
cases  
Abbreviations: SRM, statin-related myopathy 
 
1.2.6.3 Direct Mitochondrial Effects  
Next to lowering CoQ10 levels in the skeletal muscle, statins were suggested to directly 
impair the functionality of the respiratory chain. A number of studies investigating statin 
mediated mitochondrial dysfunction have been conducted across a variety of platforms 
including in vitro culture, animal models and human trials.  
1.2.6.3.1 In Vitro and Ex Vivo Studies 
In 2005, Sirvent and colleagues demonstrated that acute application of high doses of 
simvastatin β-hydroxy acid to isolated human skeletal muscle fibers caused depolarisation of 
the inner mitochondrial membrane and Ca2+ release into the cytoplasm. This was followed 
by a larger Ca2+ release by the sarcoplasmic reticulum which precipitated the injurious effects 
of simvastatin (Sirvent et al., 2005b; Sirvent et al., 2005a). The same group later identified 
that inhibition of complex I of the respiratory chain initiated these effects in both human and 
rat skeletal muscle samples (Sirvent et al., 2005b). Subsequent studies have supported the 
described mitochondria/Ca2+ mechanism of acute in vitro toxicity in both rat and human 
skeletal muscle (Sacher et al., 2005; Liantonio et al., 2007; Nadanaciva et al., 2007a). 
Experiments using isolated mitochondria and high-throughput immune-capture assays have 
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also identified additional sites of respiratory complex inhibition which varied depending 
upon the statin administered (Nadanaciva et al., 2007a). 
The effect of statins on respiratory parameters has also been investigated using various cell 
lines. Application of lipophilic statins (100 µM) to the L6 rat skeletal muscle cell line impaired 
both mitochondrial membrane potential and phosphorylating respiration, whilst inducing 
mitochondrial swelling, DNA fragmentation and cytochrome c release (Kaufmann et al., 
2006). Similar deleterious effects on viability were observed in response to 5 µM simvastatin 
in rhabdomyosarcoma cells (Vaughan et al., 2013). Studies performed using the C2C12 
murine skeletal muscle cell line have also demonstrated perturbations in mitochondrial 
function, an effect which was not paralleled in the HepG2 hepatocarcinoma cell line. The 
differences between the two cell types was later found to be attributable to decreased 
phosphorylation of protein kinase B (Akt) in the C2C12 line, suggesting that modulation of 
the IGF-1/Akt signalling axis may be instrumental to the development of myotoxicity (Mullen 
et al., 2010, 2011).  
In addition, Skottheim and colleagues showed differential cytotoxicity between statin 
lactones and statin β-hydroxy acids in human skeletal muscle cells (Skottheim et al., 2008). 
Follow up studies suggested that respiratory complex III was a likely target for the reversible 
binding of statin lactones specifically. This was supplemented with in silico docking analyses 
which supported the possibility that lactones could bind to and inhibit the Q0 site of complex 
III. (Schirris et al., 2015). 
Whilst in vitro investigations such as these have proved insightful for elucidating the 
potential mechanistic basis of statin mediated mitochondrial dysfunction, it is important to 
acknowledge that the concentrations used in most cases are in excess of the plasma Cmax, 
thus the translational utility of the data is often called into question (Björkhem-Bergman et 
al., 2011).  
1.2.6.3.2 In Vivo Studies 
Although studies using animal models have shown muscle injury as a result of statin 
treatment, they do not consistently support a role for direct respiratory dysfunction. For 
example, treatment of male rabbits with simvastatin and pravastatin resulted in a decrease 
in muscle CoQ10 content but did not affect respiratory enzyme activity (Nakahara et al., 
1998). Similarly, female rats treated with cerivastatin for 15 days exhibited elevated CK 
levels, necrosis and swollen mitochondria whilst respiratory complex activities remained 
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unchanged (Schaefer et al., 2004). Nevertheless, there are studies which support 
mitochondrial involvement in SRM, documenting changes in mitochondrial morphology 
before the onset of necrosis (Obayashi et al., 2011), increased ROS production and decreased 
PGC-1α expression (Bouitbir et al., 2012). 
Mitochondrial involvement in the pathophysiological mechanism of SRM has also been 
investigated in statin treated patients. Elevated lactate/pyruvate ratio in statin treated 
patients versus controls provided the initial evidence that statin therapy may perturb 
mitochondrial function and provided the impetus for further investigation (De Pinieux et al., 
1996). Observations performed on four patients experiencing SRM without CK elevation 
showed increased lipid storage (oil red O staining), ragged red fibers (Gomori trichrome 
staining) and cytochrome c oxidase (COX) negative fibers. Parameters which are considered 
to be clinical characteristics of mitochondrial disease and respiratory chain dysfunction 
(Phillips et al., 2002). Further studies have shown impaired complex I driven respiration in 
symptomatic patients versus asymptomatic and control groups (Sirvent et al., 2012), whilst 
others demonstrate impaired complex II driven respiration in response to high dose 
simvastatin in combination with altered calcium homeostasis (Galtier et al., 2012). These 
data support the possibility that complex I may not be the only respiratory complex targeted 
by statins and that different statins may affect mitochondrial function in different ways 
(Sirvent et al., 2012).  
1.3 Drug-Induced Myopathies of Skeletal Muscle 
Drug-induced myopathies represent both a clinically and pathologically diverse group of 
musculoskeletal disorders, which can be caused by a variety of recreational and medicinal 
compounds, venoms, and biological toxins (Mastaglia and Needham, 2012). Drug –induced 
myopathy is classically defined as a subacute or rarely acute manifestation of myopathic 
symptoms (Table 1.5) which occur in patients without prior muscle disease when exposed to 
therapeutic doses of certain drugs (Husband, 2009). 
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Table 1.5 Definitions of various terms used in the literature to describe drug-induced muscle injury. 
Myositis definition is based upon the recommendation of the ACC/AHA/NHLBI clinical advisory of the 
use and safety of statins. Myositis may also be defined as biopsy affirmed muscle inflammation 
(Pasternak et al., 2002) 
Terminology 
 
Definition  
Myopathy Blanket term for a disease of the musculoskeletal system 
Myositis 
Muscle symptoms accompanied by elevated creatine kinase (CK) 
levels < 10X upper limit of normal (ULN). 
Myalgia Muscle pain without elevation of CK 
Rhabdomyolysis 
Severe muscle symptoms, elevation of CK 10X ULN, myoglobinuria 
and renal failure. 
Asymptomatic Myopathy Elevated CK in the absence of muscle symptoms. 
 
Myotoxic agents are capable of inducing myopathy in a number of ways by (a) directly and 
focally affecting the muscle tissue at the injection site; (b) targeting subcellular organelle 
such as the mitochondria, endoplasmic reticulum, lysosomes and myofibrillar proteins; (c) 
altering muscle antigens and inducing an inflammatory response; and (d) inducing general 
systemic effects such as electrolyte imbalance (e.g potassium or phosphorous) and 
malabsorption which may extend to have secondary effects on the muscle tissue (Dalakas, 
2009). 
In contrast to many other pathologies of skeletal muscle, drug-induced myopathies can be 
self-limiting and potentially resolved with the cessation of the offending compound. 
However, in other instances toxicity may be irreversible as was the case with fialuridine, a 
nucleoside analogue that caused irreversible neuromuscular damage due its successive 
incorporation into the mtDNA of recipients (Johnson, 2008). 
1.3.1 Compounds Associated with Drug-Induced Myopathies  
The clinical manifestation and mechanisms of drug-induced muscle toxicity can vary 
significantly between different compounds. Drug-induced myopathies are relatively 
uncommon in clinical practice with the exception of those that are associated with lipid-
lowering compounds and glucocorticoids. However, it is still critical to understand toxic 
myopathies in order to facilitate timely diagnosis, cessation of treatment with the offending 
compound and patient recovery.  There are a wide variety of compounds which are known 
to illicit detrimental effects on the skeletal muscle, therefore they are often categorised 
according to the type of injury induced in the muscle fiber or to the subcellular organelle. 
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Table 1.6 provides a list of both medicinal and recreational compounds which are more 
commonly associated with the onset of myopathic symptoms in recipients along with their 
injury categorisation (Pasnoor et al., 2014). 
Table 1.6 Table of compounds associated with drug-induced skeletal muscle injury. 
Compound Class Compound(s) Classification Reference(s) 
Lipid lowering  
Statins   Necrotising 
myopathy 
 Rhabdomyolysis 
 Mitochondrial 
myopathy 
 Inflammatory 
myopathy  
(Sathasivam, 
2012; Mammen 
et al., 2012; 
Sakamoto and 
Kimura, 2013; 
Vaklavas et al., 
2009) 
Fibrates   Necrotising 
myopathy 
 Rhabdomyolysis  
(Guis et al., 
2003; Pasnoor 
et al., 2014; 
Prueksaritanont, 
Tang, et al., 
2002), 
Recreational  
Cocaine   Rhabdomyolysis  (Goldstein et al., 
2009; Richards, 
2000; Welch et 
al., 1991; 
Pasnoor et al., 
2014) 
Amphetamines  Rhabdomyolysis (Green et al., 
2004; Carvalho 
et al., 2012) 
Phencyclidine   Rhabdomyolysis (Richards, 2000; 
Kuncl and 
Meltzer, 1974; 
Patel et al., 
1979; Cogen et 
al., 1978) 
Ethanol   Necrotising 
myopathy 
 Hypokalaemic 
myopathy  
(Richards, 2000; 
Thapaliya et al., 
2014; 
Fernandez-Solà 
et al., 2007; 
Chawla, 2011) 
Anti-retroviral  
Zidovudine  Mitochondrial 
myopathy  
(Mammen, 
2012; Scruggs 
and Dirks 
Naylor, 2008; 
Chawla, 2011) 
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Fialuridine  Mitochondrial 
myopathy  
(Mammen, 
2012; Johnson, 
2008) 
Anti-malarial  
Chloroquine  Amphiphilic 
cationic drug 
myopathy 
 Lysosomal 
storage 
myopathy  
(Mammen, 
2012; Guis et 
al., 2003) 
Anti-gout  
Colchicine   Anti-
microtubular 
myopathy  
(Mammen, 
2012; Guis et 
al., 2003) 
Immunosuppressants  
Glucocorticoids  Hypokalaemic 
myopathy 
 Type II muscle 
fiber atrophy   
(Valiyil and 
Christopher-
Stine, 2010; 
Dirks-Naylor 
and Griffiths, 
2009; Gruver-
Yates and 
Cidlowski, 2013) 
General anaesthetics  
Volatile anaesthetics or 
succinylcholine  
 Malignant 
hyperthermia  
(Mammen, 
2012; Pasnoor 
et al., 2014) 
Anxiolytics 
Barbiturates  Rhabdomyolysis  (Mastaglia, 
1982) 
Opiate analgesics 
Opiate overdose 
(Morphine, 
dihydrocodiene & heroin) 
 Rhabdomyolysis  (Villalba Garcia 
et al., 1994; 
Sahni et al., 
2008; Blain et 
al., 1985) 
Antipsychotics 
Neuroleptic compounds 
(clozapine, risperidone, 
melperone, olanzapine, 
haloperidol, loxapine) 
 Type II fiber 
atrophy  
(Meltzer, 2000; 
Sieb and 
Gillessen, 2003) 
Other  
Ipecac (Emetine 
Hydrochloride) 
 Hypokalaemic 
myopathy 
 Myofibrillar 
myopathy   
(Silber, 2005) 
Interferon-α  Inflammatory 
myopathy  
(Mammen, 
2012; Valiyil and 
Christopher-
Stine, 2010; 
Greenberg et 
al., 2005) 
D-penicillamine  Inflammatory 
myopathy  
(Sieb and 
Gillessen, 2003) 
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1.4 Skeletal Muscle and Skeletal Muscle Modelling  
Skeletal muscle is one of three major muscle types within the body, the others being cardiac 
and smooth muscle. Skeletal muscle is a form of striated muscle that is under the control of 
the somatic nervous system and constitutes the effector organs of the locomotor system. In 
most healthy adults, skeletal muscle is thought to account for roughly 45 % of the total body 
mass and is characterised by its highly organised ultrastructural arrangement, extensive 
vasculature and high metabolic rate (Pette and Staron, 2000; Ostrovidov et al., 2014).  
Skeletal muscle is fundamental for the execution of dynamic events such as prehension, 
ocular movements, directional motion as well as gravitational tasks such as postural support. 
Skeletal muscle is also a remarkably heterogeneous tissue, diverse in fiber composition and 
capable of extensive metabolic reprogramming in response to changing physiological 
demands (Vainshtein et al., 2015). 
1.4.1 Ultrastructural Arrangement  
Single skeletal muscle fibers (Figure 1.4), when isolated from muscle tissue and examined 
microscopically are comprised of multinucleated syncytia of fused myotubes. The muscle 
fiber itself is enclosed within a plasma membrane, which in turned is sheathed by an 
extracellular basement membrane, the two compartments being collectively termed the 
Figure 1.4 Schematic representation of the ultrastructural arrangement of individual skeletal muscle 
fibers (Lieber, 2002).  
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sarcolemma. Myonuclei are positioned along the length of the fiber, immediately beneath 
the sarcolemmal layer (Vye, 1976).  
The cytoplasm of the muscle fiber is occupied by numerous cylindrical filaments called 
myofibrils which run parallel to the long axis of the fiber. Myofibrils consititue the basic 
structural unit of the muscle fiber and are the smallest component to retain the striated or 
‘banded’ patterning owing to the presence of repeating contractile modules called  
sarcomeres.  Within the sarcomere unit, the larger dark band is known as the anisotropic 
band (A-band), the smaller lighter bands the isotropic bands (I-band). The I-band is bisected 
by the Z-line, with two adjacent Z-lines enclosing the sarcomere (Vye, 1976; Pette and Staron, 
1990). 
Both the A- and I-bands are comprised of an array of highly ordered filamentous, contractile 
protein complexes. The interaction between the two sets of myofilaments is responsible for 
the force generation required to execute muscle contractions. The thinner of the filaments 
is found predominantly in the I-band and is made up from the protein actin and to a lesser 
extent, tropomyosin and troponin. The thicker of the filaments, which is located exclusively 
in the A-band, is an aggregate of arranged myosin subunits (Lieber, 2002; Vye, 1976). 
Mitochondria, essential subcellular organelle implicated in the generation of adenosine 
triphosphate (ATP), are located in both the sub-sarcolemmal space and between myofibrils 
in the I-bands. Sub-sarcolemmal mitochondria occur in clusters often occupying the 
perinuclear space. Within the I-bands, paired mitochondria are located between myofibrils 
on either side of the Z-line. Mitochondria located within the I-band display a highly 
convoluted structure in order to conform to the spatial restrictions between myofibrils. The 
number of mitochondria per muscle fiber can be extremely variable. For example, fibers 
which are more reliant on aerobic respiration for energy generation may be rich in 
mitochondria, whereas those which are more dependent on anaerobically generated energy 
from glycolysis may have fewer or smaller mitochondrial networks. Muscle fibers which have 
prolonged or sustained energy demands may possess numerous mitochondria, each of which 
display extensive infolding of cristae (Lieber, 2002; Vye, 1976). 
Muscle fibers possess a highly modified smooth endoplasmic reticulum, which is arranged 
into an extensive and ordered system of tubules referred to as the sarcoplasmic reticulum. 
The tubules of the sarcoplasmic reticulum are in close contact with the myofibrils and are 
primarily implicated in the storage of calcium ions (Ca2+). Transverse tubules (T-tubules), 
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which are extensions of the sarcolemmal membrane that protrude into the interior of the 
fiber, are closely associated with specific regions of the sarcoplasmic reticulum known as the 
terminal cisternae, the primary site of Ca2+ release (Vye, 1976).  
1.4.2 Muscle Fiber Types  
Within the muscle tissue, different groups of fibers are charged with carrying out different 
roles, ranging from low intensity gravitational tasks to bursts of vigorous activity. To achieve 
such diversity in function, individual muscle groups possess a range of biophysical and 
bioenergetic properties as summarised in Table 1.7 (Arany, 2008; Vainshtein et al., 2015). 
Table 1.7 Summary of the major biophysical properties of mammalian skeletal muscle fiber types.  
Abbreviations: OXPHOS, Oxidative Phosphorylation. 
 
In adult mammalian skeletal muscle, there are four major muscle fiber types: I, IIa, IIx and 
IIb, defined by both the type of myosin heavy chain (MHC) predominantly expressed and the 
contraction-relaxation profile. It is the myosin ATPases that are the driving force behind the 
actin/myosin cycling machinery in tandem with ancillary sarcomeric/sarcolemmal proteins 
which regulate Ca2+ flux. Thus, the MHC type dictates the overall biophysical properties of a 
muscle fiber (Arany, 2008; Obayashi et al., 2011; Neunhäuserer et al., 2011). 
 
Slow Oxidative 
(SO) 
Fast 
Oxidative/Glycolytic 
(FOG) 
Fast Twitch 
Glycolytic 
MHC Type I IIa IIx/IIb 
Fiber Size Small Intermediate Large 
Myoglobin Content High (Red) High (Red) Low (White) 
Glycogen Content Low Intermediate High 
Mitochondrial 
Density 
High High/Intermediate Low 
ATP Source OXPHOS OXPHOS/Glycolysis Glycolysis 
Major Substrate 
Store 
Triglycerides 
Phosphocreatine/ 
Glycogen 
Phosphocreatine/ 
Glycogen 
Contraction Velocity Slow Moderate/Fast Fast 
Fatigue Resistance High Moderate Moderate/low 
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Under resting conditions, it is widely accepted that the energetic demands of muscle tissue 
are predominantly met by the catabolism of fatty acids through the β-oxidation metabolic 
pathway. In vivo, skeletal muscle has limited permeability to glucose due to the expression 
of the primary glucose transporter GLUT4 on intracellular vesicles. Translocation of GLUT4 
to the cell membrane is promoted by elevated circulating insulin levels or during exercise, 
thereby increasing glucose flux into the muscle. The glucose transporter GLUT1 is thought to 
be important for basal uptake of glucose into myocytes, however other hexose transporters 
such as GLUT3, GLUT5 and GLUT12 are also present (Cheng et al., 2014; Leone et al., 2005).  
Once internalised, glucose can be utilised for ATP generation, be stored as glycogen in order 
to meet long-term energy demands or to be used when β-oxidation of fatty acids is reduced. 
During routine, low intensity activity, skeletal muscle is capable of consuming significant 
amounts of ATP through two main mechanism; ATP hydrolysis by the S1 head of the myosin 
protein and the Ca2+ ATPase which returns calcium ions to the sarcoplasmic reticulum 
following contraction of the muscle. It is therefore essential for the ATP pool to be 
continuously replenished. Medications that disrupt the cellular pathways of energy 
generation in skeletal muscle, can often lead to toxic outcomes (Westerblad et al., 2010; 
Jones et al., 2014; Richter and Hargreaves, 2013).  
MHC type I fibers, classically known as slow oxidative (SO) or slow twitch fibers are 
characterised by a slower contraction-relaxation profile. Type I fibers are known to be rich in 
myoglobin, mitochondria and mitochondrial networks, favouring aerobic modalities of ATP 
production such as β-oxidation of fatty acids over anaerobic glycolysis (Arany, 2008). Type I 
fibers acquire fatty acids for metabolism from three principle sources, the first and most 
important is from adipose tissue by hormone-sensitive lipases. Sources of lesser importance 
include plasma very low density lipoprotein (VLDL) mobilised by lipoprotein lipase and fatty 
acids formed by the hydrolysis of intramuscular triacylglycerol (Salway, 2004).  
MHC type II fibers, otherwise known as fast twitch fibers can be further sub-categorised into 
three types, type IIa, IIb and IIx. Whilst type IIb fibers (fast glycolytic) are present in most 
mammalian species, it is important to note that they are absent in humans. Therefore, only 
three fiber types: type I and types IIa/IIx meet the functional needs of the musculoskeletal 
system. Type IIa fibers are fast oxidative/glycolytic (FOG) fibers and possess intermediate 
biophysical properties whereas type IIx have the fastest contraction-relaxation profiles 
(Westerblad et al., 2010; Neunhäuserer et al., 2011). Type II muscle fibers have a greater 
reliance on anaerobic modalities of ATP production, especially during ‘explosive’ bursts of 
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muscle activity such as sprinting. Much of the ATP produced during this period is derived 
from the catabolism of  the phosphagen, phosphocreatine and a 1000 fold increase in 
glycolysis (Salway, 2004). 
In addition to the ‘pure’ fiber types, which express only a single MHC isoform, hybrid fibers 
also exist. Such fibers are comprised of two or more MHC isoforms, bridging the gap between 
the pure fiber types and forming a continuum within the musculoskeletal system (Pette and 
Staron, 2000).  
1.4.3 Muscle Plasticity  
One of the key features of skeletal muscle is its ‘plasticity’ or ability to adapt in the face of 
enhanced or diminished physical activity, exogenous stimuli or disease. Whilst basal muscle 
fiber type is largely determined during embryonic development, adult skeletal muscle retains 
a significant capacity for fiber type transition (Arany, 2008). 
The transcriptional co-activator, peroxisome proliferator–activated receptor (PPAR)-γ 
coactivator 1α (PGC-1α), regulates the molecular mechanism by which muscle plasticity and 
oxidative fiber transitions are mediated. The PGC-1 family have a number of biological 
functions as outlined in Figure 1.5, most of which are linked to the promotion of oxidative 
metabolism, mitochondrial biogenesis and fatty acid oxidation (Wende et al., 2007). 
Transgenic expression of PGC-1α in murine fast-twitch muscle fibers at physiological levels 
results in the activation of genetic pathways and the transcription of myofibrillar proteins 
characteristic of slow oxidative muscle fibers (Lin et al., 2002). The skeletal muscle of the 
mice are more resistant to contraction-induced fatigue, which is indicative of an oxidative 
fiber type transition mediated by PGC-1α. In contrast, PGC-1α deficient murine muscle is 
prone to contraction-induced fatigue and exercise intolerance (Leone et al., 2005). 
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Therefore, PGC-1α acts to drive a complex phenotypic switch which couples both the 
metabolic and contractile phenotypes of mammalian skeletal muscle fibers, functionally 
transitioning glycolytic fast-twitch fibers into oxidative slow-twitch fibers and increasing 
mitochondrial biogenesis (Lin et al., 2002, 2005). 
1.4.4 Developmental Myogenesis and Regeneration  
Mammalian skeletal muscle possesses an impressive capacity for regeneration after injury, 
a process which shares many parallels with muscle development during embryogenesis. In 
order to gain an appreciation for the regeneration process, it is important to first understand 
the basics of myogenesis (Figure 1.6).  
During development, progenitor cells derived from the paraxial mesoderm (somites) give rise 
to skeletal muscle. The activation of the Pax3/7 genes is instrumental to the migration of 
progenitor cells and their eventual commitment to the satellite cell lineage. Satellite cells 
Figure 1.5 Schematic diagram illustrating the role of PGC-1α in muscle plasticity. Physiological cues 
(row 1) initiate key signalling pathways (row 2), promoting the expression of PGC-1α mRNA and the 
synthesis of the PGC-1α protein. In turn, PGC-1α co-activates a number of key transcription factors 
(row 3), leading to the activation of broad genetic programmes (row 4). Diagram adapted from Arany, 
2008. 
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then receive signals from peripheral tissues, initiating the expression of transcription factors 
known as myogenic regulatory factors (MRFs). 
Myogenic cells which express the MRFs myf5 and MyoD are otherwise known as myoblasts. 
Upregulation of second tier MRFs, myogenin (MyoG) and MRF4 promotes the terminal 
differentiation of myoblasts into myotubes. Myotubes are characterised by the expression 
of mature muscle proteins such as myosin heavy chain (MHC) and creatine kinase (CK) and 
will eventually fuse, giving rise to adult skeletal muscle fibers (Karalaki et al., 2009). 
During the late stages of myogenesis, a pool of satellite cells fail to differentiate and remain 
closely associated with the muscle fiber in a quiescent state. This reservoir of 
undifferentiated Pax7 positive satellite cells is central to muscle regeneration after injury, 
during routine maintenance or in response to increased functional demand. Moreover, the 
pool of quiescent satellite cells are capable of self-renewal in order to re-establish the 
population for subsequent rounds of regeneration (Karalaki et al., 2009). 
1.4.5 Modelling Skeletal Muscle In Vitro 
As with all human organ systems, there is a need to develop physiologically relevant in vitro, 
drug screening platforms that can reliably predict in vivo effects in both rodent models and 
Figure 1.6 Activation and commitment of satellite cells to a myogenic fate during muscle development 
and regeneration. Diagram adapted from Karalaki et al., 2009. 
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human patients. The use of cell lines and primary cells to develop functional (i.e. contractile) 
models of skeletal muscle has been desirable for some time. However, due to the inherent 
architectural complexity of skeletal muscle, loss of key ion channel and receptor expression 
in vitro and a lack of processes which contribute to the mechanical activation of myocytes in 
culture, progress has been limited (Allen et al., 2005). Hence, cells that can reliably reproduce 
myogenesis in culture i.e. the fusion and terminal differentiation of myoblasts into mature 
multinucleated myotubes have been the mainstay of skeletal muscle modelling for some 
time.  
1.4.5.1 Two Dimensional Monoculture: Cell lines   
As highlighted in prior discussion, skeletal muscle cells that can successfully recapitulate 
myogenesis in culture are preferential as they more closely mimic a mature myocyte 
phenotype. One of the most notable and widely used examples is the mouse derived C2C12 
myoblast line, originally established by Yaffe and Saxel in 1977 (Yaffe and Saxel, 1977). The 
C2C12 line is capable of rapid differentiation upon serum reduction, forming contractile 
myotubes which express myogenic regulatory factors (MRFs) such as MyoG, MyoD and MRF4 
(Wei and Paterson, 2001). However, one of the most significant caveats of C2C12 myocytes 
is that they require intense surveillance as they undergo terminal differentiation upon 
reaching confluence, consequently depleting the proliferative myoblast population. A similar 
model, the L6 rat neonatal myoblast line was originally isolated by Yaffe in 1968 (Yaffe, 1968), 
whereby primary cultures of rat quadriceps were maintained for the first two passages in 
methyl cholanthrene. L6 cells are capable of fusing in culture upon serum reduction to form 
multinucleated myotubes and striated fibers. However, the fusion potential of the cells 
declines with serial passages, resulting in the need for periodic re-cloning and selection for 
fusion competent cells (Allen et al., 2005). 
1.4.5.2 Two Dimensional Monoculture: Primary Cells  
Satellite cells can be isolated from biopsy samples of adult, mammalian skeletal muscle and 
cultivated to generate a proliferating myoblast population, which can subsequently be 
differentiated into myotubes in culture (Aas et al., 2013). 
Primary myocyte cultures are an essential model in the biomedical field; often facilitating the 
effective therapeutic translation of results generated using clonal animals or cell lines. They 
possess the most relevant genetic background for the investigation of human disease, closely 
mimic the protein expression patterns of mature muscle and allow for the investigation of 
the innate characteristics of the donor (Aas et al., 2013). The most prominent drawbacks of 
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using primary cell cultures derived from human muscle biopsy samples are their purity post 
isolation, their limited proliferative capacity and variation in phenotype when amplified in 
vitro due to progressive cellular senescence with successive population expansions 
(Mamchaoui et al., 2011). Human myotubes from myoblast cultures undergoing senescence 
exhibit defects in both lipid and glucose metabolism and a diminished fusion potential 
(Nehlin et al., 2011). 
Further developments in myocyte culture have allowed for the creation of stably 
immortalised cell lines from myoblasts isolated from human biopsies. This has been 
instrumental in creating a robust collection of cell lines produced from pathological tissues 
that can be used to study a variety of neuromuscular disorders (Mamchaoui et al., 2011).  
1.4.5.3 Three Dimensional Muscle Tissue Engineering 
The concept of skeletal muscle tissue engineering (SMTE) focuses upon the culture of 
myocytes that are isolated from patients, donors or preclinical species, with or without the 
aid of scaffolds to generate functional micro-tissues in vitro (Figure 1.7).  
Figure 1.7 Representation of the concept of skeletal muscle micro-tissue engineering from biopsy 
derived myocytes. The diagram illustrates the isolation of proliferative satellite cells, their amplification 
in vitro as well as three different established methods of generating fabricated micro-tissue constructs. 
Adapted from (Ostrovidov et al., 2014; Kwee and Mooney, 2017). 
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The goal of SMTE is to produce tissues as structurally similar to their in vivo counterparts so 
function is optimised as it is within the body (Lam et al., 2009). With this in mind, SMTE was 
originally developed in order to repair or replace the normal function of defective muscle by 
creating micro-tissues from the donor’s own cells for eventual re-implantation (Ostrovidov 
et al., 2014).  However, SMTE has shown great promise for a number of applications, not 
limited to predictive pharmaceutical testing, hybrid mechanical/muscle actuators and 
engineered meat production.  
In the early 1990s, Strohman (Strohman et al., 1990), described the first three dimensional 
skeletal muscle constructs produced from murine myoblasts grown on top of Saran wrap. 
After differentiation, the myocytes would ‘roll up’ to form a 3D contractile muscle tissue, 
later termed myooids by Dennis (Dennis and Kosnik, 2000), who incorporated stainless steel 
µ-posts and braided silk sutures coated in laminin to act as artificial tendons, aiding cellular 
anchorage (Figure 1.7).   
More recent developments by Lam (Lam et al., 2009), showed that by pre-aligning murine 
myoblasts by topographical micro-patterning on a ‘wavy’ polydimethylsiloxane (PDMS) 
surface before incorporating a fibrin hydrogel solution, they could produce a free-standing 
3D muscle construct with superior muscle fiber content and force production capacity. More 
importantly, they demonstrated that pre-alignment of myocytes was pivotal to the 
successful engineering of skeletal muscle with increased muscle fiber formation. To this end, 
many nano/microfabrication techniques such as soft lithography, photolithography, 
electrospinning, passive and active stretching or electrical field stimulation have been 
employed to promote cell alignment (Ostrovidov et al., 2014; Zorlutuna et al., 2012; 
Ostrovidov et al., 2013). 
In 2015, Madden and co-workers described the development and validation of the 
‘myobundle’ model, a biomimetic human micro-tissue platform with potential applications 
in clinically relevant in vitro studies of muscle physiology and pharmaceutical testing 
(Madden et al., 2015). The purpose of the model was to recapitulate key functional aspects 
of human skeletal muscle, in logical progression from previous iterations of the myobundle 
platform using cells derived from pre-clinical species (Juhas and Bursac, 2014). The system is 
reliant on the encapsulation of myogenic cells within a fibrin hydrogel formed in a PDMS 
mould. Within the mould sits a nylon frame to which the cell/hydrogel mixture anchors, 
acting as an artificial tendon and keeping the myobundle under passive tension (Madden et 
al., 2015). Further studies have demonstrated their utility in long-term pharmacological 
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examination of contractile force measurement, monitoring of calcium transients and oxygen 
consumption rate due to their increased culture lifespan of ~42 days (Madden et al., 2015; 
Davis et al., 2017; Cheng et al., 2014).  
1.5 Mitochondrial Structure and Respiration  
Mitochondria are ubiquitous intracellular organelle whose dominant function is to produce 
energy in the form of adenosine triphosphate (ATP). Mitochondria can vary vastly in shape, 
size and number, ranging from a few discrete organelle per cell to the formation of 
interconnected and dynamic networks known as the mitochondrial reticulum (Glancy et al., 
2015). Despite the variance in number and morphology of mitochondria between cell types, 
all mitochondria share several highly conserved fundamental characteristics (Wojtczak and 
Zabłocki, 2008). 
1.5.1 Mitochondrial Structure  
As shown in Figure 1.8, two distinct lipid bilayer membranes bind all mitochondria. The outer 
mitochondrial membrane (OMM) forms the interface between the mitochondrion itself and 
the rest of the cellular metabolic network. The outer membrane is rich in cholesterol and is 
permeable to solutes and ions up to 10 kDa in size due to the presence of mitochondrial 
porin, also termed voltage-dependent anion channels (VDAC). The inner mitochondrial 
membrane (IMM) encapsulates an aqueous compartment, better known as the matrix, 
where the mitochondrial DNA (mtDNA) and enzymes of the tricarboxylic acid (TCA), and β-
oxidation pathways are located. The IMM is not freely permeable to ions or metabolites and 
instead requires the use of transport proteins in order to translocate select metabolites 
across the membrane. The impermeable nature of the inner membrane is pivotal for the 
structural and functional integrity of the mitochondrion and accounts for the generation of 
 35 
  
the electrochemical gradient that provides the proton motive force for ATP generation 
(Scatena et al., 2007; Wallace and Starkov, 2000; Wojtczak and Zabłocki, 2008).  
Unlike the lipid composition of the outer membrane, the inner membrane is distinctive in 
that it is virtually devoid of cholesterol and is abundant in a molecule called cardiolipin. 
Cardiolipin (diphosphatidylglycerol) is a unique, anionic phospholipid found only in cell 
membranes that function in electron transport. It is not a passive component of the IMM but 
in fact interacts with a number of inner membrane proteins and has been shown to be 
important for maximal electron transfer activity (Robinson, 1993). 
1.5.2 Oxidative Phosphorylation  
Greater than 90 % of the energy produced by organisms that utilise aerobic metabolism 
occurs by oxidative phosphorylation (OXPHOS). The mitochondria are often considered as 
cellular ‘powerhouses’, converting the energy released during substrate oxidation into ATP 
for use in other cellular processes. OXPHOS consists of two functionally independent 
processes: the oxidation of reduced substrates by the enzymatic complexes of the proximal 
respiratory chain and the phosphorylation of ADP to ATP by in inorganic phosphate and ATP 
synthase (Fo/F1 ATPase) (Figure 1.9). The coupling of the two processes is highly dependent 
upon the impermeability of inner mitochondrial membrane and the generation of a proton 
motive force (∆p)  (Wojtczak and Zabłocki, 2008).  
Figure 1.8 Simplified cross sectional diagram of the ultrastructural arrangement of a 'typical' 
mitochondrion. Cristae are presented as invaginations of the inner mitochondrial membrane however 
they are ‘bag-like’ structures separated from the intermembrane space by narrow tubular junctions 
(Colgliati et al., 2016). 
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The mitochondrial respiratory chain is composed of more than 85 proteins that are 
assembled into four enzymatic complexes. Complex I (NADH: ubiquinone oxidoreductase), 
complex III (ubiquinol: cytochrome c oxidoreductase) and complex IV (cytochrome c oxidase) 
are all located within the IMM whereas complex II (succinate dehydrogenase), which 
catalyses a step in the tricarboxylic acid (TCA) cycle is located on the matrix side of the IMM. 
The four complexes, along with diffusible electron donors/acceptors ubiquinone (CoQ10), 
ubiquinol (CoQ10H2) and cytochrome c (cyt c), function to catalyse electron transfer from 
reduced electron donors NADH and FADH2 to molecular oxygen (1/2 02) (Wojtczak and 
Zabłocki,  2008).  
 
 
Due to a large difference in redox potential between the electron donors and the final 
electron acceptor, passage of electrons down the respiratory chain is accompanied by a large 
increase in free energy (decreased Gibbs potential). The majority of the free energy is used 
to pump protons across the IMM into the IM space. The remaining energy is dissipated as 
heat. The proportion of energy that is dedicated to proton pumping or thermogenesis 
depends greatly upon the type and physiological status of the tissue from which the 
mitochondria were originally derived (Wojtczak and Zabłocki, 2008).  
1.5.2.1 The Electrochemical Gradient  
1.5.2.1.1 Complex I (NADH: ubiquinone oxidoreductase) 
Complex I is responsible for catalysing the oxidation of NADH concomitantly with the 
reduction of CoQ10 to CoQ10H2.  
Reaction: NADH + H+ + CoQ10 + 4H+in→ NAD+ + CoQ10H2 + 4H+out 
Figure 1.9 Schematic diagram of the mitochondrial respiratory chain. The inner mitochondrial 
membrane houses the enzymatic components of the respiratory chain that translocate protons from 
the mitochondrial matrix into the intermembrane (IM) space, thus generating an electrochemical 
gradient (proton motive force, ∆p). ∆p consists of two principle components – the electrical 
component (∆ᴪ, positive in IM space) and a chemical component (∆pH, acidic in IM space). ∆p drives 
protons from the IM space to the matrix through Fo/F1 ATP Synthase (Complex V), generating ATP from 
the phosphorylation of ADP.  
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Number of Protons Translocated to IMS: 4 
Complex I binds NADH, transferring two electrons to the flavin mononucleotide (FMN) 
prosthetic group to produce NAD+ and FMNH2. Electrons are passed through a series of seven 
iron-sulphur (Fe-S) clusters and are finally delivered to the electron acceptor CoQ10. 4H+ are 
pumped into the intermembrane space for every two electrons donated from NADH (Hirst, 
2005).  
1.5.2.1.2 Complex II (succinate dehydrogenase) 
Complex II resides on the matrix side of the IMM, providing the second electron entry point 
into the respiratory chain. In addition to its role in the respiratory chain, complex II is a 
component of the tricarboxylic acid cycle catalysing the oxidation of succinate to fumarate 
in tandem with the reduction of FAD to FADH2. 
Reaction: Succinate + CoQ10 → fumarate + CoQ10H2 
Number of Protons Translocated to IMS: 0 
Two electrons are transferred from FADH2 through three Fe-S clusters before being passed 
onto CoQ10. The transfer of electrons from FADH2 to CoQ10 does not result in the 
translocation of protons from the matrix to the IM space, therefore complex II does not 
directly contribute to ∆p generation (Rutter et al., 2010).  
1.5.2.1.3 Complex III (ubiquinol: cytochrome c oxidoreductase)   
The reaction catalysed by complex III involves the oxidation of one molecule of CoQ10H2 and 
the reduction of two molecules of cytochrome c. Unlike CoQ10, which can accept two 
electrons per molecule, cytochrome c can accept only one thus the reaction mechanism is 
more elaborate than that of the other respiratory enzymes.  
Reaction: CoQ10H2 + 2 cytochrome c (Fe3+) + 2H+in → CoQ10 + 2 cytochrome c (Fe2+) + 4H+out 
Number of Protons Translocated to IMS: 4 
Diffusible CoQ10H2 binds to the QO site on complex III, donating one electron to the 2Fe-2S 
cluster known as the Reiske Iron-Sulphur Protein (ISP). The ISP donates the electron to 
cytochrome c1, allowing for the extrusion of two protons into the IM space whilst CoQ10H2 
(now ubisemiquinone) remains bound to the QO site. The second electron from CoQ10H2 is 
passed to a lower potential chain containing the bL and bH hemes of cytochrome b. This chain 
delivers electrons to a second CoQ10 processing site, the Qi site. At this site, CoQ10 is 
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reduced to CoQ10H2. The reaction requires two electrons, therefore the QO site must turn 
over twice, oxidising two CoQ10H2 molecules and releasing four protons into the IMM. If the 
complex starts with a CoQ10 molecule already bound, the first electron at the Qi is stored on 
a ubisemiquinone which reduced to CoQ10H2 by the second electron (Crofts, 2004). 
1.5.2.1.4 Complex IV (cytochrome c oxidase) 
Complex IV is the terminal oxidase of the respiratory chain, catalysing the transfer of 
electrons from reduced cytochrome c to molecular oxygen forming two molecules of water. 
Reaction: 4 cytochrome c (Fe2+) + 4H+ + 02 → 4 cytochrome c Fe3+ + 2H2O  
Number of Protons Translocated to IMS: 2 
Cytochrome c transfers its electron to the redox centre of subunit II (CuA) then subsequently 
to heme a allowing cytochrome c to dissociate. Heme a then transfers its electron to the 
redox centre CuB associated with heme a3. A second molecule of cytochrome c then binds 
and transfers its electron to heme a3. With two electrons bound, heme a3 binds with 
molecular oxygen. A third molecule of cytochrome c donates its electron to heme a3, this 
electron together with two protons from the matrix leads to the cleavage of the O=O bond 
and the generation of a Fe4+ centre. A fourth molecule of cytochrome c donates its electron 
to the heme a3 CuB centre reducing Fe4+ =O to Fe3+. The free oxygen atom picks up two 
protons simultaneously to produced H2O (Blomberg, 2016). 
1.5.2.2 Mitochondrial ATP Synthase and ATP Production 
Mitochondrial ATP Synthase (Fo/F1 ATPase) is a large protein complex partially embedded 
into matrix side of the inner mitochondrial membrane (Figure 1.10). Although not formally 
part of the respiratory chain, it is often referred to as complex V. Its primary function is to 
synthesise ATP from ADP and Pi using ∆p generated by the proximal respiratory chain. The 
protein is bipartite as indicated by its name and is comprised of a F1 portion (α3, β3, γ, OSCP 
and ε subunits), and a FO portion made up by a, b and c subunits in the stoichiometry 1:2:10-
14. Two stalks, a peripheral one involving the b and OSCP subunits and a central one 
containing the γ and ε subunits link F1 and FO (Capaldi and Aggeler, 2002) . 
 39 
  
 
1.5.2.2.1 Conformational Model of ATP Synthesis  
The most widely accepted mechanistic model of ATP synthesis is the ‘conformational change’ 
or ‘alternating site’ hypothesis proposed by Boyer (Boyer, 1993). The key feature of this 
model is that the catalytic domains housed on the three β-subunits of F1 are in one of three 
different conformational states at any given time. The conformational states act to vary the 
binding affinity of the β-subunits for substrates (ADP+Pi) and products (ATP). Conformation 
‘O’, meaning open, is characterised by a low affinity for ATP; conformation ‘L’ meaning loose, 
loosely binds ADP and Pi; conformation ‘T’, meaning tight, tightly binds ADP and Pi.  
Under physiological conditions, protons flowing from the IM space into the matrix via the 
membrane embedded FO force the γ subunit to rotate whilst subunit b holds the αβ dimers 
stationary. For one complete 360° turn of subunit γ, one proton must return to the matrix 
for every c subunit present (10-14 H+). In simplified terms, rotation of the γ subunit by 120° 
results in a switch from conformation to the next. As depicted in Figure 1.11,  if  a β subunit 
starts at conformation ‘O’, after rotating 120° it will change its conformation to L, after 
rotating another 120° it will now sit in the T conformation. One 360° revolution of the γ 
Figure 1.10 Structure of ATP Synthases (Fo/F1 ATPase). The Fo region of ATP synthase is composed of a 
ring structure embedded into the inner mitochondrial membrane. It acts as a proton pore allowing H+ 
ions to return to the matrix. The F1 region of ATP synthase is responsible for catalysing ATP synthesis. 
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subunit constitutes one full cycle in which three molecules of ATP are synthesised (Wojtczak 
and Zabłocki, 2008; Capaldi and Aggeler, 2002) 
 
1.5.3 Beta-Oxidation of Fatty Acids 
The principle pathway used for the catabolism of fatty acids is mitochondrial fatty acid β-
oxidation (FAO). FAO is of particular importance in organs such as the liver for the production 
of ketone bodies and in the heart and skeletal muscle as a substrate for OXPHOS (Houten 
and Wanders, 2010). Fatty acid transport proteins (FATPs) mediate the uptake of fatty acids 
into the cell. FATPs have acyl-CoA synthetase activity and rapidly convert fatty acids to acyl-
CoAs after translocation across the plasma membrane (Figure 1.12).  Acyl-CoAs are unable 
to cross the outer mitochondrial membrane and require import via the carnitine shuttle. The 
first step, performed by carnitine palmitoyltransferase I (CPT1) converts acyl-CoA to 
acylcarnitine. Carnitine acylcarnitine translocase (CACT) then exchanges acylcarnitines for 
free carnitine molecules at the inner mitochondrial membrane. Once acylcarnitines have 
entered the mitochondrial matrix, carnitine palmitoyltransferase II (CPT2) converts 
acylcarnitines into their CoA esters, which then undergo β-oxidation (Houten and Wanders, 
2010; Bartlett and Eaton, 2004).  
Figure 1.11 Conformational model of ATP synthesis. O, L and T represent the three different 
conformational states of the catalytic domain of the β subunit. The revolution of the γ subunit drives 
the changes in conformational state. ADP and Pi bind loosely (L), followed by tight binding (T) resulting 
in ATP synthesis, before being released (O). From Wojtczak and Zablocki, 2008. 
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Once within the mitochondrial matrix, acyl-CoAs are broken down into acetyl-CoA molecules 
via a four-step series of enzymatic reactions called β-oxidation. The process is cyclic whereby 
acyl-CoA molecules are shortened, releasing two carboxy-terminal carbon atoms after the 
completion of each full cycle. Each cycle begins with an acyl-CoA ester that is 
dehydrogenated by an acyl-CoA dehydrogenase (ACAD) to produce a trans-2-enoyl-CoA. 
Following hydration of the double bond to produce L-3-hydroxy-acyl-CoA, a dehydrogenation 
step generates 3-keto-acyl-CoA. Finally, 3-keto-acyl-CoA undergoes thiolytic cleavage to 
produce a chain-shortened acyl-CoA, an acetyl-CoA, NADH and FADH2. The chain-shortened 
acyl-CoA enters another cycle of β-oxidation whilst the acetyl-CoA enters the TCA cycle and 
NADH/FADH2 donate their electrons to the respiratory chain (Bartlett and Eaton, 2004).  
Directly after import, long chain acyl-CoA molecules undergo 2-3 FAO cycles to produced 
medium chain acyl-CoAs. Metabolism of long chain acyl-CoAs is perfomed by membrane 
bound very long chain acyl-CoA dehydrogenase (VLCAD) and mitochondrial trifunctional 
protein (MTP). Medium and short chain acyl-CoAs are metabolised by a series of matrix-
soluble enzymes. The initial steps are catalysed by medium chain acyl-CoA dehydrogenase 
(MCAD) for 3-4 cycles then subsequently by short chain acyl-CoA dehydrogenase (SCAD) for 
the final 1-2 cycles (Houten and Wanders, 2010).  
Figure 1.12 Overview of the mitochondrial carnitine shuttle and fatty acid β-oxidation pathway in 
humans.  
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Three enzymes perform steps 2-4 of the oxidation of both medium and short chain acyl-
CoAs: enoyl–CoA hydratase (crotonase), medium and short chain hydroxyacyl-CoA 
dehydrogenase (M/SCHAD) and medium chain 3-ketoacyl-CoA thiolase (MCKAT). The 
enzymes have broad substrate specificity to accommodate for acyl-esters with chain lengths 
of up to ten carbon atoms. The oxidation of unsaturated fatty acids such as oleic acid requires 
an additional isomerase step performed by dodecenoyl-CoA delta isomerase (DCI) (Houten 
and Wanders, 2010). 
1.5.4 Reactive Oxygen Species  
The production of reactive oxygen species (ROS) by mammalian mitochondria is an inevitable 
consequence of aerobic metabolism. The proximal respiratory chain produces superoxide 
(O2-.) anions when single electrons leak to O2 as electron pairs are passed from one complex 
to the next. There are seven widely accepted sites of O2-. production in the mitochondria, 
however the two sites with the greatest maximal capacities to produce ROS are situated 
within complexes I and III (Brand, 2010). Though, the relative contribution of each complex 
to ROS production is as yet unresolved and may be tissue or condition specific.  
Under physiological conditions O2-. can readily dismutate to form hydrogen peroxide (H2O2), 
a reaction catalysed by manganese superoxide dismutases (MnSODs) (Brand, 2010; Murphy, 
2009). Glutathione peroxidases (GSPx), peroxiredoxins and catalase (peroxisomes) along 
with a number of low molecular weight antioxidants (e.g. ascorbic acid, β-carotene, α-
tocopherol) constitute the antioxidant defence system, converting H2O2 to H2O thus 
completely scavenging the ROS produced by the mitochondria (Wojtczak and Zabłocki, 
2008).  
Whilst O2-. and H2O2 are not strong oxidants themselves, they are the precursor molecules 
of most reactive oxygen species and are involved in the propagation of oxidative chain 
reactions within the cell. H202 may be partially reduced to a hydroxyl radical (.OH) by 
transition metal ions (Fe2+ or Cu+) whilst O2-. can react with other radicals such as nitric oxide 
(NO) to form reactive nitrogen species (RNS) (Turrens, 2003). 
Imbalance between ROS/RNS production and endogenous antioxidant defences due to 
disease or toxic agents results in oxidative stress and the initiation of cell death. Whilst small 
fluctuations in steady-state ROS concentration is thought to play a role in mitochondrial 
signalling, excessive free radical production can lead to the indiscriminate targeting of 
proteins, lipids, polysaccharides and DNA (Vuda and Kamath, 2016; Turrens, 2003).  
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1.5.5 Regulation of Oxidative Phosphorylation 
The rate of OXPHOS is primarily governed by substrate feedback as electron transport, in 
most cases, is tightly coupled to oxidative phosphorylation. OXPHOS requires a source of 
electrons at high potential (NADH and FADH2), O2, ADP and Pi. However, the most important 
factor determining respiratory rate is the abundance of ADP. Addition of ADP markedly 
increases mitochondrial oxygen consumption which subsequently returns to its initial value 
once converted to ATP. The regulation of OXPHOS by ADP availability is known as respiratory 
control (Hüttemann et al., 2007; Berg et al., 2007). 
In higher organisms, additional mechanisms have evolved in order to ‘fine tune’ aerobic 
metabolism. These regulatory mechanisms include the expression of isoenzyme variants for 
tissue-specific requirements, intracellular allosteric control (e.g. phosphorylation) and 
extracellular cell signalling (e.g. glucagon and insulin). 
1.6 The Mitochondrial Genome  
In mammals the mitochondrial genome represents the only source of essential cellular 
proteins outside of the nucleus. Within the mitochondrion, mitochondrial DNA (mtDNA) is 
arranged as a circular, double-stranded DNA molecule. The two strands are distinguishable 
due to their nucleotide composition, the heavy strand (H-strand) is rich in guanine whilst the 
light strand (L-strand) is rich in cytosine. The length of mtDNA is variable amongst species, 
however in humans it is ~16,569 bp. Depending upon their energetic demands, somatic cells 
can contain anywhere between 100-10,000 copies of mtDNA (Chinnery and Hudson, 2013).  
1.6.1 Basic Structure  
MtDNA encodes a total of 37 genes, 28 of which reside on the H-strand and 9 on the L-strand 
(Figure 1.13). Thirteen of the genes encode for integral structural subunits of the 
mitochondrial respiratory chain, whilst the remaining 24 genes encode 22 tRNA molecules, 
16s ribosomal RNA and 12s ribosomal RNA. Unlike nuclear DNA (nDNA), mtDNA lacks intronic 
regions and some genes, most notably MT-ATP6/MT-ATP8 which code for subunits within 
the Fo complex of ATP synthase, possess overlapping reading frames (Chinnery and Hudson, 
2013). The displacement loop (D-loop), is the only major non-coding region within the 
mtDNA. It also represents the start site of mtDNA replication, containing both the origin of 
H-strand synthesis (OH) and H-strand transcription factors (heavy strand promotors (HSP) 
1/2) (Chinnery and Hudson, 2013).  
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Figure 1.13 Basic structure of a human mitochondrial DNA molecule. Mitochondrial DNA encoded 
subunits of the respiratory chain are colour coded to the corresponding genes. 
Human mtDNA does not strictly adhere to the genetic code of the nuclear genome. MtDNA 
uses only two stop codons ‘AGA’ and ‘AGG’ as opposed to ‘UAA’, ‘UGA and ‘UAG’ used in 
nDNA (Temperley et al., 2010). ‘UGA’ in the mitochondria encodes tryptophan whilst ‘AUA’, 
the codon for isoleucine in nDNA, encodes for methionine in the mtDNA (Chinnery and 
Hudson, 2013).   
1.6.2 Inheritance  
The DNA of cytoplasmic organelle such as the mitochondria are inherited in a non-Mendelian 
manner. It is generally accepted that in most multicellular organsims, mtDNA is inherited 
solely from the maternal germ line. This inheritance pattern is also known as ‘uniparental 
inheritance’.  
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In human spermatozoa the mtDNA copy number is relatively low (50-100 copies), whereas 
in the oocyte it is extremely high (~100,000 copies). Thus maternal inheritance was originally 
thought to be due to dilution of the paternal mtDNA contribution beyond detection. More 
recent studies have unveiled that paternal mitochondria are selectively targeted for 
proteolysis once they enter the cytoplasm of the oocyte due to the presence of 
polyubiquinated prohibitin, an inner mitochondrial membrane protein expressed during 
spermatogenesis (Sutovsky et al., 2004; W. E. Thompson et al., 2003). 
1.6.3 Nucleoid Packaging  
The organisation of mtDNA is consequential of the endosymbiotic origin of the 
mitochondrion. Like bacterial DNA, mtDNA is compacted into ~100 nm DNA-protein 
complexes called nucleoids (Kukat et al., 2011). Without nucleoid packaging, a completely 
relaxed 16.6 kb circular DNA molecule would have a diameter of ~5 µm (Gilkerson et al., 
2013). It has been estimated that each nucleoid houses 1.4 copies of mtDNA in human 
mitochondria and 1.5 copies in murine mitochondria, arguing the point that most 
mammalian nucleoids probably contain only a single copy of mtDNA (Kukat et al., 2011). 
The mitochondrial nucleoid comprises a variety of different proteins with diverse functions 
of which the most abundant are TFAM (mitochondrial transcription factor A). These 
functions range from the packaging, transcription and replication of mtDNA to 
communication and integration with the wider cellular signalling network. The condensation 
of mtDNA into nucleoids ensures distribution of genetic material throughout the 
mitochondrion and responsiveness to the metabolic needs of the cell (Gilkerson et al., 2013). 
Nucleoids are often found in close contact with the inner mitochondrial membrane, an 
attachment which is speculated to serve in the segregation of mtDNA during fission events 
or to aid insertion of mtDNA transcribed proteins into the IMM (Scheffler, 2008). 
1.6.4 MtDNA Maintenance: Replication, Transcription and Translation 
Replication of the mitochondrial genome takes place within the mitochondrial matrix. As 
opposed to the nuclear genome, mtDNA replication can occur in terminally differentiated 
cells which have exited the cell cycle (i.e. neurons and skeletal muscle) as well as proliferating 
cells. The ability of mtDNA to replicate in post mitotic cells highlights the importance of 
continuous mtDNA turnover throughout the life of an organism.  
The mechanistic basis of mitochondrial replication has not yet been fully resolved however 
the ‘traditional’ model describes replication as an asynchronous strand displacement 
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mechanism involving two independent origins. Briefly, mtDNA synthesis begins at the origin 
of H-strand replication (OH), downstream of the light strand promoter (LSP) within the non-
coding D-loop domain. Upon displacement of the L-strand, synthesis proceeds along the 
parental H-strand until it reaches the origin of L-strand replication (OL). Exposure of the L-
strand initiation site allows replication to progress in the opposite direction to generate the 
daughter L-strand (Fernández-silva et al., 2003; Clayton, 1982).  
A second model of mtDNA replication has been suggested in which coupled leading-lagging 
strand replication initiated at the OH is coordinated. In this model, lagging L-strand synthesis 
begins shortly after the initiation of H-strand synthesis and is the result of Okazaki fragment 
generation and subsequent conversion to DNA. (Holt et al., 2000; Yasukawa et al., 2006; 
Pohjoismäki et al., 2010; Tuppen et al., 2010). 
Replication of the mitochondrial genome is accomplished by nuclear encoded proteins. Core 
components of the replisome include mitochondrial DNA polymerase γ (POLG), 
mitochondrial transcription factor A (TFAM) and mitochondrial single stranded binding 
protein (mtSSB) (Tuppen et al., 2010). 
1.6.4.1 Transcription  
In mammalian mitochondria, mtDNA transcription is regulated at the D-loop. The D-loop 
possess two H-strand promoters (HSP1/2) along with the LSP and the OH. Transcription 
initiated from the L-strand promoter is necessary for the generation of the primer for H-
strand replication, therefore mtDNA replication is considered to be inherently linked to 
transcription. Bi-directional transcription gives rise to transcripts which encode several 
proteins (polycistronic transcripts). Transcription of both the L- and H-strand is achieved by 
the mitochondrial transcriptional core (TFAM, mitochondrial RNA polymerase (POLMT) and 
mitochondrial transcription factor B2) (Rebelo et al., 2011).  After transcriptional activation, 
elongation steps are performed by the mitochondrial transcriptional elongation factor 
(TEFM) through interaction with POLMT. MtDNA transcription, when initiated from the HSP1 
promoter is terminated by the specific binding of mitochondrial transcription termination 
factor 1 (MTERF1) (Tuppen et al., 2010).  
1.6.4.2 Translation 
The mitochondrial translation system is responsible for the production of 13 essential 
subunits of the respiratory chain complexes (I-IV) and ATP synthase. Whilst critical for 
respiratory function, the existence and biogenesis of mitochondria is not dependent upon 
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mitochondrial protein synthesis as demonstrated by the generation of rho0 cells which are 
devoid of mtDNA (Kukat et al., 2008; Scheffler, 2008).  
Mitochondrial protein synthesis mechanisms are poorly resolved in comparison to their 
cytoplasmic counterparts. The basic machinery required to perform mitochondrial 
translation includes mtDNA encoded rRNA and tRNAs as well as nuclear encoded factors 
which are imported into the mitochondria. These include two initiation factors (IF2 and IF3), 
four elongation factors (EFG1, EFG2, EFTs and ETFu) and one termination factor (mtRF1a) 
along with mitochondrial ribosomal proteins, aminoacyl-tRNA synthetases, methionyl-tRNA 
transformylase and ribosome recycling factors (mtRRF) (Van Den Heuvel et al., 2010). 
The mitochondrial translation system is distinct from its cytoplasmic counterpart due to the 
presence of polycistronic transcripts, polyadenylated partial stop codons, deviation from the 
standard genetic code and RNA-poor mitoribosomes (Tuppen et al., 2010). 
1.6.5 Heteroplasmy  
Mutations in mtDNA cannot always be linked to phenotypic consequence due to the 
presence of multiple copies of mtDNA within a cell (polyploidy). Whilst in most cases the 
polymorphisms present in mtDNA molecules are homoplasmic (i.e. present in all copies), 
mutations can affect a subset of the mtDNA population, leading to the presence of multiple 
distinct sequences which can be both inter or intra-mitochondrial. This phenomenon is 
known as heteroplasmy (Wallace and Chalkia, 2013).  
The majority of pathogenic mtDNA mutations are recessive and the mutational load can 
differ significantly between tissues of the same individual  (Tam et al., 2008) or may be 
entirely tissue specific. The segregation of mtDNA during cell division is a random process 
resulting in the potential for daughter cells to receive different copies of mtDNA in an event 
called replicative segregation (Diez-Juan and Simón, 2015). Replicative segregation can lead 
to the continuous propagation of bioenergetic defects however, a minimum critical 
proportion of mutant mtDNA is required before a phenotypic consequence is apparent. 
Typically this threshold value can range anywhere between 60-90 % mutant to wild-type 
mtDNA and may be lower in cell types which are particularly reliant on OXPHOS for ATP 
generation (Tuppen et al., 2010). Conversely, mtDNA mutants may be reduced or lost via 
replicative segregation, particularly in highly proliferative cell types (Rahman et al., 2001). 
In post mitotic cells, mtDNA is continuously being turned over in a process referred to as 
relaxed replication. In a heteroplasmic cell, it is plausible that by chance a mutant mtDNA 
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copy may be replicated more frequently than a wild-type molecule. This has the potential to 
change the mutational load of a cell over time (Stewart and Chinnery, 2015). 
1.6.6 MtDNA Mutations 
MtDNA genes have a very high sequence evolution rate, in the order of 10-17 fold greater 
than that of nuclear genes. This is a by-product of an exceptionally high mutational rate and 
a comparatively low endogenous repair capacity (Wallace and Chalkia, 2013). The high 
mutational rate of mtDNA is attributable to errors accrued during genome replication rather 
than oxidative damage as previously assumed (Larsson, 2010).  
Rearrangements (deletions) of the genome are thought to be a result of inherited mutations 
in nuclear genes whose products are involved in mtDNA maintenance (e.g. POLG or 
TWINKLE) (Tuppen et al., 2010). Point mutations may be the result of imbalances in the levels 
of different nucleotides within the mitochondria and not the fidelity of POLG specifically 
(Flintoft, 2005; Song et al., 2005). 
There are three types of clinically relevant mtDNA mutations: functional variants associated 
with ancient mtDNA lineages, recent deleterious mutations that can result in maternally 
inherited disease and somatic mutations which accumulate in tissues over time. The 
phenotypic consequences of mtDNA mutations may be further modulated by interactions 
with the nuclear genome and the environment (Wallace, 2013). 
1.6.7 Mitochondrial Haplogroups 
A mitochondrial ‘haplotype’ is defined as a group of polymorphisms within an organism that 
have been inherited together from a single parent. A mitochondrial haplogroup represents 
Figure 1.14 Simplified phylogenetic tree of major human mitochondrial DNA haplogroups. The tree 
is based upon mtDNA phylotree build 17 (van Oven, 2015). 
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a group of similar haplotypes that share a common ancestor but are distinguishable by the 
addition of functionally significant single nucleotide polymorphisms (SNPs). 
Each mitochondrial haplogroup originates from, and remains a part of a preceding single 
haplogroup. As such, related haplogroups can be modelled as a nested hierarchy, relating to 
the sequential accumulation of mutations since the most recent common ancestor (MRCA) 
(Figure 1.14). Macro-haplogroups are identified by an initial letter of the alphabet with sub-
clade refinements consisting of additional letter and number combinations. As haplogroups 
were named in the order of their discovery, the alphabetical ordering does not pertain to 
any genetic relationships.  
1.6.8 MtDNA Variation and Functional Consequence  
The central role of the mitochondrial genome in OXPHOS and cellular physiology means that 
functional variants in mtDNA genes can have considerable consequences at the tissue or 
systemic level. In the past it has been difficult to evaluate the contribution of mtDNA 
variation to molecular processes. However, with the advent of the cybrid (cytoplasmic 
hybrid) model, questions relating to the functional importance of mtDNA variation and 
mitochondria-nuclear interactions can now be answered. The cybrid model relies on the 
fusion of rho0 zero cells (devoid of mtDNA) with mitochondria rich cytoplasts (anucleate) 
from different donors, creating cells with an identical nuclear background whilst varying the 
mtDNA haplogroup.  
This technique has been instrumental in identifying key functional differences between 
different mitochondrial haplogroups. For example, recent studies have demonstrated 
differences in mtDNA copy number and mtDNA coded respiratory complex expression 
between African haplogroup L and European haplogroup H. Haplogroup L exhibited 
decreased ATP turnover and lower levels of ROS production, attributes which are consistent 
with greater OXPHOS efficiency (Kenney et al., 2014).  
Importantly, work such as this has paved the way for studies into the effects of mitochondrial 
genome variability upon susceptibility to complex diseases such as breast cancer, metabolic 
syndrome and sepsis (Tanaka et al., 2007; Bai et al., 2007; Yang et al., 2008; Jiménez-Sousa 
et al., 2015). Furthermore, several studies have also investigated a causal linkage between 
mitochondrial genome variation and the development of adverse reactions in response to 
certain drugs, particularly antiretroviral agents (Hendrickson et al., 2009; Canter et al., 2010; 
Kampira et al., 2013; Micheloud et al., 2011). 
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1.7 Models to Assess Mitochondrial Dysfunction  
Interrogations of mitochondrial function in vitro are typically performed using isolated 
mitochondria or whole cells. Both approaches are accompanied by their own set of 
advantages and disadvantages; particularly, the use of isolated mitochondria allows for the 
direct delivery of respiratory substrates to the organelle but suffers from limited 
physiological relevance. In contrast, intact cells have greater physiological relevance yet are 
constrained as a model by impermeability to some mitochondrial substrates (Salabei et al., 
2014; Brand and Nicholls, 2011). Therefore, to facilitate the selection of an appropriate 
model, one must first consider both the chemical characteristics of the drug in question and 
the overall aim of the study (Figure 1.15). 
 
1.7.1 Whole Cell Models  
Whole cell models are frequently used to indirectly assess mitochondrial function, via the 
measurement of cellular ATP abundance for example. They also have the additional benefit 
of only requiring a relatively small amount of biological material to perform a plethora of 
plate-based assays, thus improving through-put. Importantly, intact cells provide a more 
physiologically relevant environment from which to study mitochondria in situ. Maintenance 
of the native cellular environment preserves inter-mitochondrial communications, 
mitochondrial dynamics and interactions with other organelle. As such, cell-based systems 
Figure 1.15 Comparison of different models used to assess drug-induced mitochondrial dysfunction, 
ranging from isolated mitochondria to 3D cell models. 
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are more appropriate when examining multi-mechanistic toxicity or indirect mitochondrial 
dysfunction (Brand and Nicholls, 2011) 
1.7.2 Isolated Mitochondria  
The isolation of mitochondria from cells has long been a mainstay in the field of drug-induced 
mitochondrial dysfunction, a technique necessitated by the impermeability of the plasma 
membrane to mitochondrial substrates (Salabei et al., 2014). However, there are practical 
limitations associated with the method, namely the amount of cellular material required to 
generate a sufficient yield of mitochondria for study, structural disruption during isolation, 
and limited functionality of the organelle post-isolation (Kuznetsov et al., 2008).  
The isolation of mitochondria does indeed allow for the study of direct mitochondrial 
interactions with exogenously supplied compounds and substrates; however, these 
interactions are less physiologically relevant due to a lack of competing toxicity or protective 
mechanisms which would otherwise be present in a ‘whole cell’ setting (Perry et al., 2013; 
Kuznetsov et al., 2008). Furthermore, compound screening performed using isolated 
organelle may increase the likelihood that drug-induced dysfunction remains undetected, 
particularly in scenarios whereby multi-mechanistic toxicity is at play or biotransformation 
of a compound is required to see an effect.  
1.7.3 Permeabilised Cells  
The caveats associated with both isolated mitochondria and whole cells can be, in part, 
ameliorated using permeabilised cells. This technique enables the simultaneous delivery of 
mitochondrial substrates past the plasma membrane whilst maintaining the integrity of 
mitochondrial-protein and mitochondrial-organelle contacts in situ (Brand and Nicholls, 
2011). The cellular material requirements are far more conservative than those needed to 
perform comparable studies in isolated mitochondria. Furthermore, the technique avoids 
any bias mediated by the sub-selection of mitochondrial populations during isolation and the 
functional decline of mitochondria removed from their native environment (Kuznetsov et al., 
2008; Brand and Nicholls, 2011). 
1.8 Thesis Aims  
The deleterious effects of statins upon the mitochondrial respiratory chain has been 
implicated as one of several putative mechanism by which myopathic symptoms may be 
potentiated in some statin recipients. Furthermore, inter-individual variation in 
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mitochondrial genotype and by extension, bioenergetic function, may in part underpin 
susceptibility to statin-related myopathy.  
Therefore, the overall aim of this research was to first establish the effects of statin chemical 
species (i.e. inactive lactone pro-drugs versus active β-hydroxy acids) upon the functionality 
of the mitochondrial respiratory chain using high-resolution respirometry. Thereafter, the 
remainder of the thesis focussed upon the development of a three-dimensional, 
bioengineered, micro-tissue model of human skeletal muscle to identify functional 
bioenergetic factors which may confer enhanced or diminished risk of statin-mediated 
mitochondrial dysfunction. Finally, due to the governance of respiratory chain assembly, 
stability and functionality by the mitochondrial genome, next generation sequencing (NGS) 
of patient mitochondrial DNA was performed on a statin myopathy case-control cohort to 
determine if there was an association between mitochondrial genotype and patient status.  
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2.1 Introduction 
The deleterious effect of statins upon muscular energy metabolism appears to represent 
both an important and frequently cited feature of the mechanism through which they impart 
their cytotoxic effects (Apostolopoulou et al., 2015; Golomb and Evans, 2008). However, 
despite continued research within the field, the precise nature of the mitochondrial toxicity 
is still widely debated. To add further complexity, statins are administered as either a lactone 
pro-drug or a pharmacologically active β-hydroxy acid. Both lactones and acids of a given 
statin can be detected in systemic circulation, indicating the interconversion of the chemical 
species in vivo (Prueksaritanont, Subramanian, et al., 2002; Hoffmann and Nowosielski, 
2008). It has been reported, across a limited number of studies, that the lactone species of 
statins have a greater propensity for mediating acute cytotoxicity when directly compared, 
at equimolar concentrations, with their corresponding β-hydroxy acid (Skottheim et al., 
2008; Schirris et al., 2015). However, this has yet to be investigated under extended time 
points or at concentration ranges which are more reflective of the plasma Cmax in patients 
(Table 2.1).  
Table 2.1 Plasma Cmax ranges for each statin in its administered form i.e. lovastatin and simvastatin 
values are calculated for the lactone species whilst all remaining values are calculated for the β-
hydroxy acid species. 
 Statin 
Atorva Ceriva Fluva Lova Pitava Prava Rosuva Simva 
Plasma 
Cmax (nM) 
48-118 15.4-19.5 1000 24 142.3 105.9-129.5 76.8 80-2200 
Based on a 40 mg oral dose, with the exceptions of pitavastatin (2 mg) and cerivastatin (0.8 mg) and 
simvastatin (7.5 mg/kg). Table generated using data compiled from (Stefano et al., 2004; Catapano, 
2010; Jung et al., 2012; Morgan et al., 2012; Corsini et al., 1999; White, 2002; Mück, 2000; Ahmed et 
al., 2013). 
Previous in vitro studies within this area have been typically performed using immortalised, 
cancer-derived cell lines of either human or rodent origin. One of the key aspects by which 
immortalised cells differ from those within living systems or those maintained in primary 
culture is that of their bioenergetic profile. Whilst is it typical of most cells, under 
physiological conditions, to generate ATP preferentially through oxidative phosphorylation 
within the mitochondria, it is characteristic of some cancer cells to undergo extensive 
metabolic adaptations in order to meet the energetic demands imposed by an enhanced 
proliferative capacity (Diaz-Ruiz et al., 2011). Specifically, the repression of oxidative 
metabolism in cancer cells can occur despite the presence of saturating oxygen 
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concentrations and a full complement of functional mitochondria, a phenomenon known as 
‘aerobic glycolysis’ or the ‘Warburg effect’. This change is thought to be a long-term 
compensatory mechanism which allows for cellular proliferation in hypoxic environments, 
such as those found in solid tumours (Diaz-Ruiz et al., 2011; Warburg, 1956). It has also been 
demonstrated that some cell lines are capable of reversibly switching between fermentation 
and oxidative metabolism depending on the exogenous glucose supply, a transient event 
known as the ‘Crabtree effect’ (Diaz-Ruiz et al., 2011, 2009). 
In cells that exhibit an enhanced reliance on aerobic glycolysis, direct mitochondrial toxicants 
have little observable effect on cell viability or ATP content, which in turn diminishes their 
utility as predictors of mitochondrial dysfunction. Resistance to mitochondrial perturbations 
is exacerbated by modern cell culture practice whereby cells are often grown in media 
containing glucose concentrations five-fold greater than physiological levels, thus supressing 
oxidative metabolism via the Crabtree effect (Marroquin et al., 2007; Rodríguez-Enríquez et 
al., 2001) . To circumvent this effect and allow for the identification of mitochondrial toxins 
in an otherwise resistant system, an elegant solution was developed in 2007 by Marroquin 
et al. The culturing of cells in the presence of galactose and L-glutamine, with the 
simultaneous exclusion of glucose, impels anaerobically poised cells to oxidise pyruvate and 
glutamine via oxidative phosphorylation due to insufficient ATP gain from the oxidation of 
galactose to pyruvate (Marroquin et al., 2007; Reitzer et al., 1979). 
This method has been increasingly employed as a means of screening for compound 
associated mitochondrial toxicity in tissue specific systems. Indeed, subsequent studies 
conducted by Dott et al., have demonstrated that the L6 rat skeletal myocyte line exhibits 
increased susceptibility to classic mitochondrial toxicants when supported by galactose and 
L-glutamine supplementation, as opposed to glucose (Dott et al., 2014). Therefore, by 
utilising simvastatin as an archetypical representative of a lipophilic statin which causes 
myopathy in both human and animal models (Kwak et al., 2012), this chapter shall assess the 
differential toxic effects of simvastatin, in both its inactive lactone (SVL) and 
pharmacologically active β-hydroxy acid (SVA) conformations, upon mitochondrial function. 
Initially this shall be assessed by comparing measurements of cytotoxicity and ATP content 
in L6 myotubes which have been metabolically conditioned to media containing either 
glucose or galactose and L-glutamine.  
Assessment of mitochondrial respiratory function in vitro has typically been performed by 
measuring the rate of oxygen consumption in isolated organelles or cells in suspension using 
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an oxygen electrode. Whilst this method has proved extremely effective in delineating 
aspects of mitochondrial physiology, it is not suitable for all cell types. Conversely, the use of 
isolated organelle lacks the cellular regulation of mitochondrial function and may overstate 
drug toxicity (Dranka et al., 2011). In order to bridge this gap, methods have been developed 
to assess the behaviour of mitochondria within a cellular setting using real time extracellular 
flux analysis (XF). XF analysers are capable of simultaneously measuring the oxygen 
consumption rate (OCR) and extracellular acidification rate (ECAR) of adherent cell cultures, 
facilitating the simultaneous assessment of oxidative and glycolytic flux with the capacity to 
sequentially inject a variety of respiratory inhibitors (Hill et al., 2012). 
In this chapter, extracellular flux analyser technology (XFe96) shall be employed so that the 
bioenergetic performance of SVL and SVA treated L6 myocytes may be ascertained. Using 
sequential injections of respiratory inhibitors, whilst monitoring the resultant variations in 
OCR/ECAR in real time, it is possible to determine the efficiency at which oxidative 
phosphorylation is coupled to oxygen consumption whilst concurrently measuring 
parameters such as maximal respiratory capacity, ATP-linked respiration, proton leak and 
spare respiratory capacity. Furthermore, this technology shall be used to examine the 
mechanistic nature of any observed perturbations. This will be achieved by means of in situ 
cell permeabilisation, using recombinant perfringolysin O (rPFO), and controlled substrate 
provision so that the functionality of each independent respiratory complex and the fatty 
acid β-oxidation pathway may be interrogated (Divakaruni et al., 2014).  
Investigations within this chapter have been performed over a range of drug concentrations 
and time courses in order to examine the relationship between the onset of mitochondrial 
dysfunction and the emergence of cell death. It is intended that through these experiments, 
the hypothesis that simvastatin and its active hydroxy acid can exert direct and independent 
deleterious effects on the mitochondrial respiratory chain, may be fully examined. 
2.1.1 Summary of Chapter Aims  
1) To examine the differential impact of simvastatin lactone and β-hydroxy acid upon 
ATP content and cell viability in both acutely and chronically treated L6 myocytes. 
2) To examine the differential impact of simvastatin lactone and β-hydroxy acid 
application upon respiratory functionality in whole and permeabilised L6 cells at 
acute and chronic time points. 
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3) To examine the differential impact of acute simvastatin lactone and β-hydroxy acid 
application upon mitochondrial swelling and inner membrane potential in isolated 
mitochondria.  
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2.2 Materials and Methods   
2.2.1 Materials 
All forms of Dulbecco’s Modified Eagle Medium (DMEM), media supplements and cell culture 
reagents were purchased from Life Technologies (Paisley, UK). L6 myoblasts were obtained 
as a cryopreserved stock (1 x 106 cells) from the American Type Culture Collection (ATCC, VA, 
USA). Anti-actin and anti-VDAC 1 antibodies were purchased from Abcam (Cambridge, UK). 
Anti-Ras antibody was purchased from BD Biosciences (London, UK). Lactate dehydrogenase 
cytotoxicity detection kit was purchased from Roche Diagnostics Ltd (West Sussex, UK). 
Extracellular flux analyser (XFe96) consumables and base medium were purchased from 
Agilent Technologies (CA, USA). Simvastatin hydroxy acid ammonium salt and cerivastatin 
hydroxy acid sodium salt were purchased from Toronto Research Chemicals (LGC 
Promochem, Middlesex, UK). Cerivastatin lactone was purchased from Santa-Cruz 
Biotechnology Inc (TX, USA). All other reagents and chemicals were purchased from Sigma 
Aldrich (Dorset, UK) unless otherwise stated. 
2.2.2 General Cell Culture Maintenance  
L6 rat skeletal myoblasts were routinely maintained in a complete growth medium consisting 
of high glucose DMEM (25 mM), supplemented with 4 mM L-glutamine (1 % v/v), 10 % (v/v) 
foetal bovine serum (FBS), 5 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic 
acid) (1 % v/v) and 1 mM sodium pyruvate (1 % v/v). Cells were cultured in vented T75 flasks 
and incubated in a humidified environment at 37 °C with 5 % (v/v) CO2. In order to prevent 
the decline of cell fusion properties, L6 myoblasts were maintained at sub-70 % confluence 
and were used between passages 3-15 as per the vendor instructions.  Cell populations were 
frozen using a standard cryopreservation mix which consisted of complete growth medium 
supplemented with 10 % DMSO (v/v) and stored at -180 °C under the liquid nitrogen vapour 
phase.  
2.2.3 Differentiation Procedure  
Cells were dissociated using 0.25 % trypsin-EDTA and seeded into collagen coated (50 µg/mL 
in 0.02 M acetic acid) tissue culture plates at the specified densities. Cells were incubated for 
24 hours in complete growth medium to promote adherence (37 °C with 5 % (v/v) CO2). The 
following day, the growth medium was removed and cells were washed twice with 1X HBSS. 
Cells were then cultured in a differentiation medium consisting of high glucose (25mM) 
DMEM supplemented with 4 mM L-glutamine (1 % v/v), 5 mM HEPES (1 % v/v), 1 mM sodium 
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pyruvate (1 % v/v) and 2 % (v/v) horse serum. Thereafter, the differentiation medium was 
changed every 48 hours for 7 days.  
2.2.4 Combined Lactate Dehydrogenase (LDH) and ATP Assays  
2.2.4.1 Acute Metabolic Manipulation using Galactose Media  
Many highly proliferative cell types grown in supra-physiological glucose conditions generate 
the vast majority of their ATP via glycolysis despite being cultured in the presence of oxygen 
and possessing a full complement of functional mitochondria. This process is known as the 
crabtree effect (Marroquin et al., 2007). Therefore, assessment of direct mitochondrial 
dysfunction in some cell types requires the replacement of glucose with galactose as the 
primary carbon source. By substituting glucose, glycolysis must be initiated by the oxidation 
of galactose to pyruvate, resulting in negligible net ATP gain via glycolysis and an increased 
reliance upon oxidative phosphorylation for ATP generation (Figure 2.1) (Reitzer et al., 1979). 
This ultimately enables the detection of compounds which perturb mitochondrial function 
within an in vitro setting. 
This method was later adapted by Kamalian et al., whereby acute conditioning to galactose 
media 2 hours prior to the addition of test compounds, rather than long-term culture,  was 
deemed sufficient to detect mitochondrial liabilities in HepG2 cells (Kamalian et al., 2015) 
and later in HepaRG cells (Kamalian et al., 2018).  
The assessment of ATP content in galactose media is used as an endpoint measure of 
mitochondrial function and is sensitive enough to be detected in the absence of cell death. 
When assessed in parallel to cytotoxicity, it can provide additional information on whether 
the mitochondrial liability is the cause or consequence of cytotoxicity (Kamalian et al., 2015). 
Direct mitochondrial dysfunction can be defined as a significant difference between the ATP 
IC50 values in glucose and galactose media with a ratio ≥ 2 (IC50ATPglu/IC50ATPgal ≥ 2). 
Induction of mitochondrial dysfunction prior to the onset of cell death is defined as 
(IC50LDHgal/ IC50ATPgal ≥ 2) (Kamalian et al., 2015; Swiss et al., 2013). 
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Figure 2.1 The principles behind galactose and L-glutamine supported respiration. There is zero net ATP gain from galactose oxidation until reaction equilibria is reached. At 
steady state, due to inefficiencies in the pathway, the net yield is 0.4 mol ATP per mol galactose i.e. 80 % less than with glucose. 22.5 mol ATP is derived from glutamine 
metabolism, accounting for > 98 % of the total ATP yield. This is sufficient to force cells to become aerobically poised (Reitzer et al., 1979). Abbreviations: ETC, electron 
transport chain; TCA, tricarboxylic acid; CoA, Coenzyme A; UDP, uridine diphosphate; 1/6-P, 1/6-phosphate.  
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2.2.4.2 Experimental Design  
L6 myoblasts were collected by trypsinisation and seeded into collagen coated (50 µg/mL in 
0.02 M acetic acid) flat-bottomed 96-well plates in complete growth media (1.6x104 cells/100 
µL/well) and differentiated for 7 days thereafter (37 °C with 5 % (v/v) CO2). Resultant 
myotubes were washed three times in serum-free glucose or galactose media (DMEM 
supplemented with 25 mM glucose and 4 mM L-glutamine or 10 mM galactose and 6 mM L-
glutamine respectively, plus 5 mM HEPES (1 % v/v) and 1 mM sodium pyruvate (1 % v/v)), 
before the addition of either glucose or galactose media (50 µL) and incubation for 2 hours 
(37 °C with 5 % (v/v) CO2). For drug incubation periods which exceeded 48 hours, 2 % (v/v) 
horse serum was added to the assay medium.  
After 2 hours of media conditioning, 200X drug stock solutions prepared in DMSO were 
diluted 1:100 into either glucose or galactose media before 50 µL was added to the relevant 
wells (final solvent concentration 0.5 %). Drug incubations were carried out for the stipulated 
time period, in the relevant assay media type (37 °C with 5 % (v/v) CO2). Dosing medium was 
refreshed every 24 hours if culture time exceeded this period. All plates included both a 
vehicle control (0.5 % DMSO) and blank wells containing media alone. 
2.2.4.3 ATP Assay  
A bioluminescence assay kit was used for the quantitative determination of ATP content. The 
principle of the assay is based upon the hydrolysis of ATP and the emission of light when 
recombinant firefly luciferase catalyses the oxidation of D-luciferin. When ATP is the limiting 
factor, the light emitted during the assay is directly proportional to the amount of ATP 
present in the sample:  
 
 
ATP content was assessed by the addition of sample lysates (5 µL) and ATP standards to a 
white-walled 96-well plate. The ATP reaction solution was prepared according to 
manufacturer’s instructions by mixing ATP assay mix with ATP dilution buffer in a 1:25 ratio. 
40 µL of the reaction solution was added to both samples and standards then read 
immediately on a Varioskan™ Flash multimode plate reader with SkanIt™ software to 
capture the peak luminescent signal. 
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2.2.4.4 Lactate Dehydrogenase (LDH) Assay 
Detection of cytotoxicity was achieved using a lactate dehydrogenase (LDH) assay kit.  LDH 
is a stable cytoplasmic enzyme present in most cell types. Upon rupture or damage of the 
plasma membrane, LDH is rapidly released into the surrounding supernatant. LDH activity is 
determined in a coupled reaction whereby L-lactate and pyruvate are interconverted 
concomitantly with NADH and NAD+ by LDH. Diaphorase and NADH reduce the tetrazolium 
salt INT (2-(4-iodophenyl)-3-(4-nitrophenyl)-5-phenyl-2H-tetrazolium) to a red, water 
soluable formazan dye which is quantifiable at an absorbance of 492 nm (Figure 2.2).  
LDH retention was determined by extracting 25 µL supernatant and 10 µL cell lysate for each 
sample and incubating them with 50 µL LDH catalyst-dye solution (1:45 ratio), according to 
manufacturer’s instructions. After 30 minutes incubation in the dark, samples were read at 
490 nm on a Varioskan Flash multimode plate reader with SkanIt™ software. LDH retention 
was determined using the following equation:  
𝐋𝐃𝐇 𝐑𝐞𝐭𝐞𝐧𝐭𝐢𝐨𝐧 =  
𝐋𝐲𝐬𝐚𝐭𝐞 
(𝐒𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐚𝐧𝐭 + 𝐋𝐲𝐬𝐚𝐭𝐞)
  
 
2.2.4.5 Bicinchoninic Acid (BCA) Assay  
The bicinchoninic acid (BCA) assay kit was used to normalise ATP data to total protein in 
order to account for potential variances in cell seeding density. The BCA assay works by 
combining the reduction of Cu2+ to Cu1+ by proteins in an alkaline medium, with the 
colorimetric detection of the cuprous oxide cation (Cu1+) by BCA.  
The first step, also known as the biuret reaction, involves the chelation of copper (II) sulphate 
with proteins containing 3 or more amino acid residues in an alkaline environment to 
produce a light blue coloured chelate complex with Cu1+. The second step is a colour 
Figure 2.2 Upon rupture of the cell membrane, release of LDH into the surrounding supernatant can 
be detected using INT tetrazolium salts.  
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development reaction whereby BCA reacts with reduced Cu1+ to produce an intense purple-
coloured copper-BCA complex which exhibits a strong linear absorbance at 562 nm. 
Protein content was determined using cell lysates (10 µL) and a bovine serum albumin (BSA) 
standard curve (10 µL). BCA reagent was prepared according to manufacturer’s instructions 
by mixing BCA with copper (II) sulphate in a ratio of 50:1. 200 µL of the resultant reaction 
mixture was dispensed into each well. The plates were then incubated at 37 ᵒ C for 30 minutes 
before reading at 562 nm on a Varioskan™ Flash multimode plate reader with SkanIt™ 
software.  
2.2.5 Extracellular Flux Analysis  
One of the most commonly used instruments to measure respiratory function is the 
extracellular flux analyser (Agilent Technologies). The instrument uses a 96-well (XFe96) or 
24 well (XF24) cell culture microplate and a sensor cartridge which sits within the microplate 
to execute the assay. Each probe of the cartridge harbours two fluorophores, one of which 
is sensitive to oxygen (O2) and the other to protons (H+) (Figure 2.3). 
Fibre optic bundles are lowered into the sensor probes, creating a transient micro-chamber 
(200 µL) whilst emitting light and exciting the embedded fluorophores. Changes in the 
Figure 2.3 Schematic diagram depicting the detection of analytes (O2 and H+) by extracellular flux 
analysis. Measurement of changes in O2 and H+ within the extracellular medium occurs in real time 
by lowering a sensor cartridge containing fluorophores into a microplate containing a cell monolayer. 
Injection ports allow for the addition of substrates or inhibitors at user-defined intervals.  
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emission of the fluorophores corresponds to changes in the concentration of O2 and H+ in the 
extracellular medium.  
This relates to changes in the oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) of the cells (Ferrick et al., 2008; Perry et al., 2013). In addition, the XF analyser 
cartridges have four injection ports which allow for the sequential incorporation of 
compounds or substrates at user defined intervals to determine various respiratory 
parameters as outlined in Table 2.2. 
Table 2.2 Calculations for mitochondrial stress test respiratory parameters. 
Bioenergetic Parameter  Calculation  
Basal Respiration  Last OCR measurement before injection of 
oligomycin – non-mitochondrial OCR 
ATP-Linked Respiration  Last OCR measurement before injection of 
oligomycin – lowest OCR measurement after 
oligomycin injection  
Proton Leak  Lowest OCR measurement after injection of 
oligoycin- non-mitochondrial OCR   
Maximal Respiratory Capacity  Highest OCR measurement after injection of 
FCCP – non-mitochondrial OCR 
Spare Respiratory Capacity  Maximal respiratory capacity – basal 
respiration  
Non-Mitochondrial OCR Lowest OCR measurement after injection of 
rotenone and antimycin A  
% Coupling Efficiency  ATP-linked respiration/basal respiration *100 
Abbreviations: OCR, oxygen consumption rate; FCCP, carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone. 
2.2.5.1 Assay Preparation and Normalisation  
L6 myoblasts were collected by trypsinisation and seeded into collagen coated (50 µg/mL in 
0.02 M acetic acid) XFe96 cell culture microplates in complete growth media (1x104 
cells/well/100 µL) and differentiated for 7 days (37 °C with 5 % (v/v) CO2). Following the 
completion of XF assays, cells were lysed in somatic cell ATP releasing agent (20 µL). Lysates 
(10 µL) were transferred to a 96-well plate for quantification of protein content by BCA assay. 
Protein content per well was used as a means to normalise raw OCR and ECAR values.  
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2.2.5.2 Mitochondrial Stress Test  
L6 myotubes were incubated for 1 hour (37 ᵒ C, 0 % CO2) prior to the start of the assay. Culture 
medium was replaced with 175 µL unbuffered XF base medium supplemented with glucose 
(25 mM), L-glutamine (2 mM), sodium pyruvate (1 mM), pre-warmed to 37 ᵒC (pH 7.4).  
2.2.5.3 Compound Preparation 
For the acute injection of test compounds (Table 2.3), serial dilutions of 200X drug stocks 
were prepared in DMSO. Each 200X stock was further diluted to 8X the final well 
concentration in unbuffered assay media. Injection solutions were buffered to pH 7.4 using 
0.03 M HCl and/or NaOH before being loaded into injection port A of the sensor cartridge. 
Table 2.3 Acute mitochondrial stress test injection port locations, compound stock concentrations, 
dilution factors and final well concentrations. 
Injection 
Port 
Compound Stock 
Concentration 
Well 
Dilution 
Factor 
Final well 
concentration 
A Test Compound (x) 200X final 
concentration 
8 0-300 µM 
B Oligomycin 2.5 mM 9 1 µM 
C FCCP 2.5 mM 10 0.75 µM 
D Rotenone/Antimycin A 2.5 mM 11 1 µM 
Abbreviations: FCCP, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone. 
For the pre-treatment strategy (Table 2.4), serial dilutions of 200X drug stocks were 
performed in DMSO. Each 200X stock was further diluted 1:200 into L6 differentiation media 
and incubated with the cells in XFe96 microplates for the stipulated time period. The dosing 
medium was refreshed every 24 hours where applicable. 
Table 2.4 Pre-treatment mitochondrial stress test injection port locations, compound stock 
concentrations, dilution factors and final well concentrations. 
Injection 
Port 
Compound Stock 
Concentration 
Well 
Dilution 
Factor 
Final well 
concentration 
A Oligomycin 2.5 mM 8 1 µM 
B FCCP 2.5 mM 9 0.75 µM 
C Rotenone/Antimycin A 2.5 mM 10 1 µM 
Abbreviations: FCCP, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone. 
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Each run included a pre-programmed calibration, an equilibration step and 3 cycles of 
mix/measure/wait (3 mins/3 mins/0 mins) to establish a baseline OCR/ECAR prior to the 
injection of any compounds. Where applicable, test compounds were acutely injected and 
ten OCR measurement cycles (54 minutes) were performed. Following this, a mitochondrial 
stress test was conducted, consisting of sequential injections of oligomycin (ATP synthase 
inhibitor), carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (ionophore) and 
rotenone/antimycin A (complex I/III inhibitors respectively) (Figure 2.4).  
2.2.5.4 Respiratory Complex Assays (I-IV) 
The cell culture medium was replaced with mitochondrial assay solution (MAS) buffer (5 mM 
MgCl2, 220 mM mannitol, 70 mM sucrose, 10 mM KH2PO4, 2 mM HEPES, 1 mM ethylene 
glycol-bis(β- aminoethyl ether)-N,N,N′,N′-tetraacetic acid (EGTA) and 0.4 % (w/v) fatty acid 
free bovine serum albumin (BSA), pH 7.2), supplemented with constituents to stimulate 
oxygen consumption via complex I (4.6 mM ADP, 30 mM malic acid, 22 mM glutamic acid, 
0.2 % (w/v) BSA and 1 nM recombinant perfringolysin O (rPFO)), complex II (4.6 mM ADP, 20 
mM succinic acid, 1 µM rotenone, 0.2 % (w/v) BSA and 1 nM rPFO), complex III (4.6 mM ADP, 
500 µM duroquinol, 1 µM rotenone, 40 µM malonic acid, 0.2 % (w/v) BSA and 1 nM rPFO) or 
Figure 2.4 Fundamentals of the mitochondrial stress test. (A) Sites of action of the respiratory 
inhibitors used in the mitochondrial stress test. (B) Representative mitochondrial stress test trace 
including derived bioenergetic parameters: basal respiration, ATP-linked respiration, proton leak, 
maximal respiratory capacity and spare respiratory capacity. Abbreviations: FCCP, carbonyl cyanide 4-
(trifluoromethoxy) phenylhydrazone; IM, intermembrane space; IMM, inner mitochondrial 
membrane. 
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complex IV (4.6 mM ADP, 20 mM ascorbic acid, 0.5 mM TMPD (N,N,N’,N’-tetramethyl-p-
phenylenediamine, 2 µM antimycin A, 0.2 % (w/v) BSA and 1 nM rPFO).  
Each run included a pre-programmed calibration and 3 cycles of mix/measure/wait (30 
secs/2 mins/ 30 secs) to establish a baseline OCR prior to the injection of any compounds. 
Where applicable, test compounds were acutely injected and three measurement cycles 
were performed. Following this, a mitochondrial stress test was conducted as previously 
described. The sites of action of complex specific substrate and inhibitors are illustrated in 
Figure 2.5.  
For the assessment of complex IV driven respiration, the final injection of 
rotenone/antimycin A was substituted with potassium azide (50 µM) (complex IV inhibitor), 
allowing for the calculation of non-mitochondrial OCR. This was of importance as 
TMPD/ascorbate undergoes redox cycling which ‘consumes’ oxygen within the medium, 
producing notable background signal which could be falsely interpreted as complex IV 
activity (Morgan and Wikstrom, 1991). Individual complex activities were defined as maximal 
respiratory capacity (as a % of basal respiration), normalised to the respective vehicle 
control.  
2.2.5.5 Fatty Acid Oxidation Assays  
The cell culture medium was replaced with mitochondrial assay solution (MAS) buffer (pH 
7.2).  Substrate injections were prepared by combining 36.8 mM ADP, 4 mM malic acid, 400 
µM palmitoyl-L-carnitine or octanyl-L-carnitine and 8 nM rPFO in MAS buffer before loading 
into injection port A. Ports B and C contained oligomycin (final well concentration 1 µM) and 
rotenone/antimycin A (final well concentration 2 µM) respectively (Salabei et al., 2014).  
Figure 2.5 Sites of action of substrates (green) and inhibitors (red) used within the mitochondrial 
complex assays. Abbreviations: TMPD, N,N,N’,N’-tetramethyl-p-phenylenediamine; IM, 
intermembrane space; IMM, inner mitochondrial membrane. 
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Following three cycles of mix/measure/wait (2 mins/ 3 mins/ 2 mins) to establish a baseline 
OCR, substrate solutions containing either palmitoyl-L-carnitine or octanyl-L-carnitine were 
injected and measured for two cycles. Subsequent injections were measured over two cycles. 
Respiratory activity supported by fatty acid oxidation was determined by deducting non-
mitochondrial OCR from substrate driven OCR and normalising to the vehicle control.   
2.2.6 Semi-Automated Pump Controlled Cell (PCC) Rupture System for the Isolation 
of Mitochondria from Cultured Cells 
Functionally intact mitochondria were isolated from cultured cells using methods obtained 
from the laboratory of Professor Hans Zischka (Helmholtz Centre, Munich, Germany) and 
optimised for the L6 cell line (Schmitt et al., 2013).  
2.2.6.1 Assay Preparation  
L6 myoblasts were seeded into T175 culture flasks (1.2x106 cells/flasks) in complete growth 
media before being differentiated for 7 days (37 °C with 5 % (v/v) CO2). Cells were collected 
by trypsinisation before resuspension in mitochondrial isolation buffer (300 mM sucrose, 5 
mM N-[Tris (hydroxymethyl) methyl]-2-aminoethanesulfonic acid (TES), 200 µM EGTA) at a 
density of 6x106 cells/mL and chilled for 20 minutes on ice.  
2.2.6.2 Semi-Automated Pump Controlled Cell Rupture  
A Balch homogeniser containing a tungsten carbide ball (8 µm clearance) and 1 mL luer lock, 
gas-tight syringes (4.608 mm diameter) were pre-chilled to 4 °C. A high precision pump 
(Pump 11, Harvard apparatus, USA) was set with a flow rate of 700 µL/min. The syringes and 
homogeniser were primed with isolation buffer to flush air pockets from the system.  
Homogenisation was achieved by taking up 1 mL of cell suspension in a syringe and attaching 
it to the first inlet of the homogeniser. The second inlet was occupied by an empty syringe. 
The pump was used to depress the plunger of the first syringe and ‘pass’ the cells through 
the homogeniser into the empty syringe at a constant rate (Figure 2.6).  
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The process was repeated 4 times before collecting the homogenate and centrifuging at 800 
x g (4 °C) for 5 minutes to pellet the cell debris. The resultant supernatant was transferred 
to fresh tubes before centrifuging again at 9000 x g (4 °C) for 10 minutes to pellet the 
mitochondrial fraction. Total protein content of the mitochondrial fraction was determined 
by Bradford assay. Briefly, 20 µL BSA protein standards and mitochondria (diluted 1:20 in 
isolation buffer) were loaded into a plate in duplicate. Bradford reagent was diluted 1:5 in 
water and 200 µL of the reaction mix was added to each well. Plates were read immediately 
at 595 nm on a Varioskan™ Flash multimode plate reader with SkanIt™ software.  
 
Figure 2.6 Schematic diagram of the pump controlled cell (PCC) rupture system. A high precision pump 
(1) was connected to gas tight syringes (2) to ensure the continuous delivery of sample (3) at a 
constant rate to the Balch homogeniser (4). Rupture of cells occurred upon passage through a defined 
clearance (8 µm) which was dictated by the diameter of a tungsten carbide ball (5). Homogenates 
were collected in a second syringe (6) and were subject to further ‘passes’ through the homogeniser 
(Schmitt et al., 2013). 
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2.2.7 Simultaneous Assessment of Membrane Potential and Swelling in Isolated 
Mitochondria  
Integrity of the mitochondrial membrane potential (MMP) was assessed using the cationic 
fluorescent dye, rhodamine 123 (Rho123) under quenching conditions. In polarised 
mitochondria, high concentrations of Rho123 (>100 nM) accumulate within the matrix and 
form aggregates, quenching the fluorescent signal. Depolarisation of the inner mitochondrial 
membrane by chemical uncouplers (e.g. FCCP) releases the dye from the matrix, thus 
resulting in a relative increase in fluorescent signal. This probe is preferentially used for its 
poor ability to interact with mitochondrial structures and inhibit electron transport 
compared with other lipophilic, cationic dyes (Perry et al., 2011; Scaduto and Grotyohann, 
1999). 
The induction of the mitochondrial permeability transition pore (MPTP) under pathological 
conditions (e.g. Ca2+ overloading) promotes a non-specific increase in membrane 
permeability. The resultant influx of solutes to the matrix increases mitochondrial volume 
which can be detected by monitoring changes in the mitochondrial suspension pseudo-
absorbance. Decreases in optical density correlate with increased matrix swelling and vice 
versa. Changes to optical density are monitored at 540 nm which falls within the range of 
mitochondrial isosbestic point (Fulda et al., 2010).  
2.2.7.1 Assay preparation  
Freshly isolated mitochondria were diluted in chilled isolation buffer (2 µg/µL) before being 
dispensed (25 µL/well) into a black-walled 96-well plate with a transparent bottom. Neutral 
swelling buffer (200 mM sucrose, 10 mM MOPS (3-(N-morpholino)propanesulfonic acid) – 
Tris, 1 mM phosphoric acid, 10 µM EGTA) was supplemented with 5 mM succinate and 2 µM 
rotenone and chilled on ice. Test compounds (200X stocks in DMSO) were diluted 1:50 into 
succinate swelling buffer before being added to the plate (50 µL/well). Wells containing FCCP 
(500 nM) were used as a positive control for depolarisation of the MMP and Ca2+ (100-600 
µM) for induction of mitochondrial swelling. Mitochondria (0.5 % DMSO) were used as a 
negative control.  
Finally, 25 µL succinate swelling buffer and 50 µL rhodamine 123 (500 nM) were added to all 
wells (200 µL final well volume) before the plate was briefly agitated and placed on a 
Varioskan™ Flash multimode plate reader. Alternating photometric (540 nm) and 
fluorometric (500/20 nm excitation; 528/20 nm emission) reads were performed every 30 
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seconds for 1 hour, after which 1 µM FCCP was added to all wells to dissipate the MMP of 
any remaining functional mitochondria, serving as an internal control.  
2.2.8 Western Blots  
L6 myotubes were treated with SVL or SVA for the stipulated time periods and drug 
concentrations before being rinsed with 1X PBS (-/-) and lysed with RIPA buffer. All lysates 
were centrifuged at 13,000 rpm for 20 minutes (4 °C) to remove aggregates and insoluble 
components. Total protein quantification was performed by BCA assay. 
Briefly, 20 µg of protein lysate was mixed with 5 µL of sample loading dye. Samples were 
heat denatured at 95 ᵒC for 5 minutes before loading into NuPAGE® 4-12 % Bis-Tris pre-cast 
gels alongside 5 µL of Precisions Plus Protein™ molecular weight marker. Loaded samples 
were subject to electrophoretic separation by molecular weight under reducing conditions 
in 1X MOPS-SDS (50 mM MOPS, 50 mM Tris-base, 0.1 % (w/v) SDS, 1 mM EDTA) running 
buffer supplemented with 500 µL NuPAGE® antioxidant for 1 hour (170 V).  
Separated proteins were transferred onto nitrocellulose membranes using an XCell II blotting 
module for 1 hour (220 V). The transfer stack was submerged in 1X transfer buffer (25 mM 
Tris-base, 192 mM glycine, 20 % (v/v) methanol). Resultant membranes were stained with 
ponceau red dye to ensure transfer uniformity before blocking for 1 hour in 10 % (w/v) non-
fat milk 1X TBS-T (137 mM NaCl, 2.7 mM KCl, 19 mM Tris-base, 0.01 % (v/v) Tween 20, pH 
7.4). Primary antibodies were diluted in 5 % (w/v) non-fat milk 1X TBS-T in accordance with 
Table 2.5 and incubated with membranes for 16 hours (4 ᵒC). 
Table 2.5 Summary of primary antibodies, dilution factors and complimentary secondary antibodies.  
Primary Antibodies  Dilution Factor  HRP-Conjugated Secondary 
Antibodies 
Anti- Ras  1: 500 Rabbit anti-mouse  
Anti- β actin  1: 10,000 Rabbit anti-mouse  
Anti- VDAC1 1: 1,000 Goat anti-rabbit   
 
Following washes in 1X TBS-T, appropriate HRP-conjugated secondary antibodies were 
diluted 1:10,000 in 5 % (w/v) non-fat milk 1X TBS-T and incubated with membranes for 2 
hours at room temperature. Band signals were detected using enhanced chemiluminescent 
reagent (ECL) and developed on film. Densitometry analyses were performed using ImageJ 
1.48 software.    
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2.2.9 Statistical Analyses  
Data are representative of at least three independent experiments (n=3) and all values are 
expressed as mean ± standard deviation (S.D.) as appropriate. Statistical analyses were 
performed using GraphPad Prism® 7 software (GraphPad Software, Inc, CA, USA). Data were 
tested for Guassian distribution using the Shapiro-Wilk normality test before statistical 
significance was determined using a student’s t-test with Welch’s correction, one-way 
Analysis of Variance (ANOVA) with Dunnett’s correction for multiple comparisons or two-
way ANOVA with Dunnett’s or Sidak’s correction for multiple comparisons. The non-
parametric equivalents for each test were used where applicable. IC50 values for dose 
response curves were determined using non-linear regression analysis. A p value ≤ 0.05 was 
accepted as the significance threshold.  
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2.3 Results 
2.3.1 Acute Metabolic Manipulation of L6 Myocytes Using Galactose Media. 
The effects of simvastatin lactone and its pharmacologically active β-hydroxy acid on cellular 
ATP content and LDH retention were examined in L6 myotubes acutely conditioned to 
glucose or galactose media (Figure 2.7).  
Figure 2.7 The effect of acute simvastatin lactone (0-300 µM), simvastatin β-hydroxy acid (0-300 µM) 
and rotenone (0-10 µM) exposure on ATP content and LDH retention in L6 myotubes compared with 
the vehicle control in glucose and galactose media. Results are expressed as a percentage of the 
corresponding media vehicle control and graphical values are displayed as mean ± S.D (n=3). Statistical 
significance compared to the vehicle control was determined by one-way ANOVA with Dunnett’s 
correction for multiple comparisons. LDH glucose *p value < 0.05 **p value < 0.01 ***p value < 0.001, 
LDH galactose #p value < 0.05 ##p value < 0.01 ###p value < 0.001, ATP glucose ^p value < 0.05 ^^p value 
< 0.01 ^^^p value < 0.001, ATP galactose +p value < 0.05 ++p value < 0.01 +++p value < 0.001. 
Abbreviations: SVL, simvastatin lactone; SVA, simvastatin β-hydroxy acid. 
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Rotenone, a potent NADH dehydrogenase (complex I) inhibitor, was used as a positive 
control (Figure 2.7 (F)). Exposure of L6 myocytes to simvastatin lactone (SVL) for 2 and 24 
hours at a supra-physiological concentration range (0-300 µM) reduced both cellular ATP 
content and LDH retention in glucose and galactose media (Figure 2.7 (A-B)). Conversely, 
exposure of cells to simvastatin β-hydroxy acid (SVA) for 2 and 24 hours did not induce any 
appreciable loss in ATP content or LDH retention in either media condition at equimolar 
concentrations (Figure 2.7 (C-D)). After an extended 48 hour incubation period, 300 µM SVA 
induced a significant reduction (94.3 %) in ATP content in the galactose media condition 
specifically, with an accompanying 27.2 % reduction in LDH retention (Figure 2.7 (E)).  
Mitochondrial toxicity was defined by calculating the ratio between the IC50 values for ATPglu 
versus ATPgal, whereby a ratio ≥ 2 indicated that the test compound was a respiratory 
toxicant, thus had a more pronounced effect in galactose media. An IC50 ratio ≥ 2 for LDHgal 
versus ATPgal indicated that mitochondrial dysfunction preceded cell death, in line with 
previous definitions (Swiss et al., 2013; Kamalian et al., 2015). As indicated in Table 2.6, 
rotenone exceeded the threshold for a respiratory toxicant and induced mitochondrial 
dysfunction in the absence of cell death as expected.  
Table 2.6 Summary of accompanying IC50 values for each compound as determined by non-linear 
regression analysis. Results are displayed as mean ± S.D (n=3). Statistical significance was determined 
by un-paired t-test with Welch’s correction. *p value < 0.05, **p value < 0.01, ***p value < 0.001. 
  ATP  IC
50
 (μM) ± S.D LDH IC
50 
(μM) ± S.D   
Compound 
Incubation 
(Hours) 
Glucose Galactose Glucose Galactose 
IC
50
 ATP 
glu/ IC
50
 
ATP gal 
IC
50
 LDH 
gal/ IC
50
 
ATP gal 
SVL 
2 
34.81 ± 
2.02 
29.28 ± 
1.42 
90.62 ± 
6.13 
39.60 ± 
0.53 
1.18 
(*) 
1.35 
(*) 
24 
29.62 ± 
7.64 
20.25 ± 
1.99 
48.82 ± 
2.57 
31.45 ± 
2.46 
1.48 
(*) 
1.55 
(**) 
SVA 
2 >300 >300 >300 >300 
~1 
(n/d) 
~1 
(n/d) 
24 >300 >300 >300 >300 
~1 
(n/d) 
~1 
(n/d) 
48 >300 
176.16 ± 
22.69 
>300 >300 
>1.70 
(n/d) 
>1.70 
(n/d) 
Rotenone  2 >10  
0.0094 ± 
0.0018 
>10 >10  
>1059.45 
(n/d) 
>1059.45 
(n/d) 
Abbreviations: SVL, simvastatin lactone; SVA, simvastatin β-hydroxy acid; n/d, value not determined.  
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In contrast, neither SVL nor SVA met the screening threshold over the 2 or 24 hour incubation 
periods. After 48 hours, SVA displayed hallmarks of a positive mitochondrial toxicant, 
showing a dramatic loss of ATP content in galactose media which preceded loss of viability.  
In order to assess whether the outcomes of the acute mitochondrial toxicity screening were 
specific to simvastatin, the same assay conditions were applied to cerivastatin lactone (CVL) 
and cerivastatin β-hydroxy acid (CVA) (Figure 2.8). 
Incubation of L6 myocytes with CVL for 2 and 24 hours, at the same concentration range (0-
300 µM), induced concomitant loss of ATP content and LDH retention more potently than 
SVL in both media conditions (Figure 2.8 (A-B)). Unlike SVA, reduced ATP content was evident 
after 2 hours of exposure to CVA (300 µM), which was accompanied by loss of LDH retention 
Figure 2.8 Examining the effect of acute cerivastatin lactone (0-300 µM) and cerivastatin β-hydroxy 
acid (0-300 µM) exposure on ATP content and LDH retention in L6 myotubes compared with the 
vehicle control in glucose and galactose media. Results are expressed as a percentage of the 
corresponding media vehicle control and graphical values are displayed as mean ± S.D (n=3). Statistical 
significance compared to the vehicle control was determined by one-way ANOVA with Dunnett’s 
correction for multiple comparisons. LDH glucose *p value < 0.05 **p value < 0.01 ***p value < 0.001, 
LDH galactose #p value < 0.05 ##p value < 0.01 ###p value < 0.001, ATP glucose ^p value < 0.05 ^ ^p value 
< 0.01 ^^^p value < 0.001, ATP galactose +p value < 0.05 ++p value < 0.01 +++p value < 0.001. 
Abbreviations: CVL, cerivastatin lactone; CVA, cerivastatin β-hydroxy acid. 
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after 24 hours (Figure 2.8 (C-D)). There was no differential toxicity between glucose and 
galactose.  
In support of these observations, the ratios between IC
50
 ATP glu/ IC
50
 ATP gal for each of the 
compounds and time points did not breach the screening threshold of ≥ 2. However, a 
reduction in ATPgal preceded a reduction in LDHgal for CVL at the 2 hour time point as 
indicated by a ratio of 4.15 (Table 2.7). 
Table 2.7 Summary of accompanying IC50 values for each compound as determined by non-linear 
regression analysis. Results are displayed as mean ± S.D. (n=3). Statistical significance was determined 
by un-paired t-test with Welch’s correction. *p value < 0.05, **p value < 0.01, ***p value < 0.001. 
Abbreviations: CVL, cerivastatin lactone; CVA, cerivastatin β-hydroxy acid; n/d, value not determined; 
NS, not significant.  
2.3.2 Examining the Post-Translational Farnesylation of RAS GTPase in L6 Myocytes 
via Western Blot.  
Alterations in the post-translational farnesylation state of RAS GTPase were determined via 
western blot after simvastatin lactone and β-hydroxy acid treatment (10 µM) to detect 
modulation of the mevalonate pathway. Unfarnesylated RAS has a higher molecular weight 
than its farnesylated counterpart due to the cleavage of the last three carboxy terminal 
residues. The difference can be visualised as a band split using a single antibody (Mullen et 
al., 2010).  
After treatment, the higher molecular weight band was detected at the 24 hour time point 
for both compounds (Figure 2.9). As only the active β-hydroxy acid can inhibit HMG-CoAR, 
thus modulating the mevalonate pathway, the presence of a band split after exposure to SVL 
  ATP  IC
50
 (μM) ± S.D LDH IC
50 
(μM) ± S.D   
Compound  
Incubation 
(Hours) 
Glucose Galactose Glucose Galactose 
IC
50
 ATP 
glu/ IC
50
 
ATP gal 
IC
50
 LDH 
gal/ IC
50
 
ATP gal  
CVL 
2 13.59 ± 
0.62 
10.51 ± 
 0.40 
34.77 ± 
0.27 
43.69 ±  
3.26 
1.29 
(*) 
4.15 
(***) 
24 12.93 ± 
0.30 
12.98 ± 
 0.33 
15.19 ± 
2.20 
21.33 ± 
 4.79 
0.99 
(NS) 
1.64 
(**) 
CVA 
2 187.50 ± 
5.52 
234.55 ± 
44.63 >300 >300 
0.79 
(NS) 
>1.27 
(n/d) 
24 171.99 ± 
6.30 
152.34 ± 
18.04 
194.71 ± 
3.01 
192.74 ± 
0.93 
1.13 
(NS) 
1.27 
(NS) 
 79 
  
is suggestive of the lactone ring undergoing either enzymatic or non-enzymatic hydrolysis in 
vitro during the 24 hour incubation period.  
 
2.3.3 Extracellular Flux Analysis of Acute Statin-Induced Changes in Mitochondrial 
Function  
An extracellular flux analyser instrument (XFe96) was utilised to specifically interrogate 
mitochondrial respiratory chain functionality via a mitochondrial stress test, a representative 
trace for the L6 cell line is displayed in Figure 2.10. Acute injection of SVA demonstrated 
respiratory uncoupling, promoting a non-significant increase in basal respiration paired with 
a significant decrease in coupling efficiency at the highest concentration (300 µM) (Figure 
2.11, Figure 2.12 (A-C)). 300 µM SVA however, significantly increased proton leak in tandem 
with a decrease in ATP-linked respiration and spare respiratory capacity as standalone values 
and also as a proportion of the maximal respiratory capacity (Figure 2.11 (E & G)). In contrast, 
acute injection of SVL showed marginal changes in basal respiration, maximal respiration and 
coupling efficiency (Figure 2.11, Figure 2.12 (A-C)). However, when examining further 
respiratory parameters, there was a significant increase in proton leak at 30 µM (Figure 2.11 
(D & F)) and 100 µM (Figure 2.11 (F)) when plotted alone or reported as a proportion of 
maximal respiratory capacity.  
Figure 2.9 Representative blots demonstrating the effect of 10 µM simvastatin lactone and 
simvastatin β-hydroxy acid on the farnesylation state of RAS GTPase. β-actin was used as a loading 
control. Abbreviations: SVL, simvastatin lactone; SVA, simvastatin β-hydroxy acid. 
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Figure 2.10 Representative control mitochondrial stress test trace for L6 myocytes. The mitochondrial 
stress test assay consisted of sequential injections of test compounds and respiratory inhibitors into 
the cell culture microplate to determine various respiratory parameters. After three basal 
measurement cycles, either a test compound or vehicle control was injected, followed by ten 
measurement cycles. The remaining injections of oligomycin, FCCP and rotenone/antimycin A were 
followed by three measurement cycles. Abbreviations: OCR, oxygen consumption rate; FCCP, carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone. 
 
Figure 2.11 Representative mitochondrial stress test trace of vehicle control, simvastatin lactone and 
simvastatin β-hydroxy acid treated L6 myocytes. Following compound incubation, a mitochondrial 
stress test was performed via the sequential injection of respiratory inhibitors oligomycin (1 µM), 
carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP) (0.75 µM) and rotenone/antimycin A 
(1 µM) whilst monitoring changes in oxygen consumption rate (OCR). Abbreviations: SVL, simvastatin 
lactone; SVA, simvastatin β-hydroxy acid. 
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Figure 2.12 Examining the effect of acute simvastatin lactone (SVL) and β-hydroxy acid (SVA) (0-300 
µM) exposure upon mitochondrial function in L6 myocytes compared with the vehicle control. (A) 
basal respiration, (B) maximal respiration, (C) coupling efficiency, (D-E) bioenergetic parameters as 
standalone values, (F-G) bioenergetic parameters as a percentage of maximal respiratory capacity. 
Graphical values are displayed as mean ± S.D. (n=3) and were normalised to µg protein per well. 
Statistical significance compared to the vehicle control and between drug treatments was determined 
by two-way ANOVA with Dunnett’s or Sidak’s correction for multiple comparisons *p value < 0.05 **p 
value < 0.01 ***p value < 0.001. Abbreviations: PL, proton leak; ALR, ATP-linked respiration; SRC, spare 
respiratory capacity; OCR, oxygen consumption rate. 
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2.3.4 Assessing Acute Simvastatin-Induced Respiratory Complex Dysfunction 
For the assessment of individual respiratory complex driven respiration (I-IV), L6 myocytes 
were permeabilised in situ using recombinant perfringolysin O (rPFO) and assayed using 
solutions which contained specific substrate-inhibitor mixtures to support the function of 
the complex of interest. Cells were acutely treated with either SVL (0-300 µM) or SVA (0-300 
µM) before conducting a mitochondrial stress test (Figure 2.13). A significant reduction in 
complex I driven respiration was observed in response to SVL (300 µM) and SVA (100-300 
µM) with notable differential toxicity between the two compounds (Figure 2.13 (A)). A 
similar trend was observed for complex II, however considerable dysfunction was evident 
after only 30 µM SVA (Figure 2.13 (B)). 
 
Figure 2.13 The effect of acute simvastatin lactone (SVL) and simvastatin β-hydroxy acid (SVA) 
exposure upon the activity of the mitochondrial respiratory complexes (I-IV). Permeablised L6 
myocytes were treated with SVL or SVA (0-300 µM) before conducting a mitochondrial stress test 
using an extracellular flux analyser (XFe96) instrument. Complex driven respiration (activity) was 
defined as maximal respiration (as a % of basal respiration) normalised to the vehicle control. 
Graphical values are displayed as mean ± S.D. (n=3) and results were normalised to µg protein per 
well. Statistical significance compared to the vehicle control and between drug treatments was 
determined by two-way ANOVA with Dunnett’s or Sidak’s correction for multiple comparisons *p 
value < 0.05 **p value < 0.01 ***p value < 0.001. 
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In addition, both SVL and SVA exerted inhibitory effects upon complex III driven respiration 
(25.4 % and 15.6 % respectively) starting at 30 µM (Figure 2.13 (C)). However, there were no 
significant changes to complex IV activity after SVL application at any concentration tested 
(Figure 2.13 (D)).  
2.3.5 Assessment of Mitochondrial Membrane Potential and Swelling in Isolated 
Mitochondria  
The integrity of the inner mitochondrial membrane potential was assessed using the cationic 
fluorescent dye, rhodamine 123 (Rho123) under quenching conditions in isolated 
mitochondria (Figure 2.14). Introduction of compounds that depolarise the inner 
mitochondrial membrane (e.g. FCCP) results in a relative increase in fluorescent signal due 
to the release of Rho123 from the mitochondrial matrix (Figure 2.14 (A)).  Additionally, 
induction of the mitochondrial permeability transition pore (MPTP) (e.g. in the presence of 
high Ca2+ concentrations) perpetuates a large, non-specific increase in membrane 
permeability. The consequential influx of solutes into the mitochondrial matrix results in 
swelling of the organelle, which may be detected as a relative decrease in optical density at 
540 nm (Figure 2.14 (B)). 
Exposure of isolated mitochondria to SVL (100 and 300 µM) caused a significant increase in 
fluorescent signal compared with the negative control, an observation consistent with 
membrane depolarisation (Figure 2.15 (A & C)). In addition, both the 30 µM and 100 µM 
conditions demonstrated a decrease in optical density, suggestive of mitochondrial swelling. 
This was not, however, recapitulated at 300 µM where there was a marked increase in the 
Figure 2.14 Representative kinetic traces for the assessment of mitochondrial membrane potential 
and swelling. Mitochondria isolated from L6 myocytes (50 µg/well) were incubated with a series of 
Ca2+ concentrations (100-600 µM) and FCCP (500 nM) in a succinate swelling buffer before assessing 
mitochondrial membrane integrity using rhodamine 123. Mitochondrial swelling was measured 
photometrically by monitoring changes in optical density at 540 nm. Abbreviations: FCCP carbonyl 
cyanide 4-(trifluoromethoxy) phenylhydrazone. 
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optical density reading at 540 nm. Increased optical density compared with the negative 
control is considered to be characteristic of either mitochondrial shrinkage or rupture (Figure 
2.15 (B & D). As illustrated in Figure 2.15 (B), time to onset of mitochondrial swelling was 
delayed for the 30 µM (~30 minutes) and 100 µM (~20 minutes) conditions, exemplifying the 
need to sample from an appropriately ‘stable’ time point.  
Conversely, simvastatin β-hydroxy acid caused significant membrane depolarisation at 300 
µM (Figure 2.16 (A & C)), this was preceded by mitochondrial swelling which reached 
statistical significance at 30 µM (Figure 2.16 (B & D)).  
Figure 2.15 Representative kinetic traces for the assessment of mitochondrial membrane potential 
and swelling in response to simvastatin lactone treatment (A-B). Mitochondria isolated from L6 
myocytes (50 µg/well) were treated with the test compound (0-300 µM) in a succinate swelling buffer 
before assessing mitochondrial membrane integrity using rhodamine 123 dye under quenching 
conditions (C). Mitochondrial swelling was measured by monitoring changes in optical density (D). 
Calculation of percentage change compared to mitochondria alone was performed at kinetic read 20 
(46 minutes). Graphical values are displayed as mean ± S.D. (n=3). Statistical significance was 
determined by one-way AVOVA with Dunnet’s correction for multiple comparisons *p value < 0.05 
**p value < 0.01 ***p value < 0.001. Abbreviations: SVL, simvastatin lactone; FCCP carbonyl cyanide 
4-(trifluoromethoxy) phenylhydrazone. 
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Figure 2.16 Representative kinetic traces for the assessment of mitochondrial membrane potential 
and swelling in response to simvastatin β-hydroxy acid treatment (A-B). Mitochondria isolated from 
L6 myocytes (50 µg/well) were treated with the test compound (0-300 µM) in a succinate swelling 
buffer before assessing mitochondrial membrane integrity using rhodamine 123 (C). Mitochondrial 
swelling was measured by monitoring changes in optical density (D). Calculation of percentage change 
compared to mitochondria alone was performed at kinetic read 20 (46 minutes). Graphical values are 
displayed as mean ± S.D. (n=3). Statistical significance was determined by one-way AVOVA with 
Dunnet’s correction for multiple comparisons *p value < 0.05 **p value < 0.01 ***p value < 0.001. 
Abbreviations: SVA, simvastatin β-hydroxy acid; FCCP carbonyl cyanide 4-(trifluoromethoxy) 
phenylhydrazone. 
2.3.6 Chronic Metabolic Manipulation of L6 Myocytes Using Galactose Media 
To address the chronic effects of SVL and SVA upon mitochondrial function at a 
concentration range which better reflected the plasma Cmax in patients (0-1000 nM), 
differentiated L6 myocytes were dosed every 24 hours for 120 hours in either glucose or 
galactose media before simultaneously assessing ATP content and LDH retention (Figure 
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2.17). These investigations were performed with the intention to detect changes in 
mitochondrial function (ATP content) which occur independently of significant cytotoxicity.  
 
In response to long-term SVL treatment (Figure 2.17 (A)), there were no significant losses to 
cell viability in the glucose or galactose media conditions compared with the respective 
media controls. At 100 nM and above, ATP content declined in galactose media, followed by 
glucose at 300 nM. Simvastatin β-hydroxy acid exhibited a significant decline in ATP content 
in both media conditions starting from 30 nM (Figure 2.17 (B)). 
 
2.3.7 Extracellular Flux Analysis of Chronic Statin-Induced Changes in 
Mitochondrial Function  
Chronic exposure of L6 myocytes to both SVL and SVA at a physiological concentration range 
induced a dose dependent decline in basal respiration and maximal respiration with no 
notable differential toxicity between the two compounds (Figure 2.18 (A-B)). 
 
Figure 2.17 The effect of chronic (120 hours) simvastatin lactone (0-1000 nM) and simvastatin β-
hydroxy acid (0-1000 nM) exposure on ATP content and LDH retention in L6 myotubes compared with 
the vehicle control in glucose and galactose media. Results are expressed as a percentage of the 
corresponding media vehicle control and graphical values are displayed as mean ± S.D (n=3). Statistical 
significance compared to the vehicle control was determined by one-way ANOVA with Dunnett’s 
correction for multiple comparisons. LDH glucose *p value < 0.05 **p value < 0.01 ***p value < 0.001, 
LDH galactose #p value < 0.05 ##p value < 0.01 ###p value < 0.001, ATP glucose ^p value < 0.05 ^^p value 
< 0.01 ^^^p value < 0.001, ATP galactose +p value < 0.05 ++p value < 0.01 +++p value < 0.001. 
Abbreviations: SVL, simvastatin lactone; SVA, simvastatin β-hydroxy acid. 
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Figure 2.18 Examining the effect of chronic (120 hours) simvastatin lactone (SVL) and β-hydroxy acid 
(SVA) (0-1000 nM) exposure upon mitochondrial function in L6 myocytes compared with the vehicle 
control. (A) basal respiration, (B) maximal respiration, (C) coupling efficiency, (D-E) bioenergetic 
parameters as standalone values, (F-G) bioenergetic parameters as a percentage of maximal 
respiratory capacity. Graphical values are displayed as mean ± S.D. (n=3) and were normalised to µg 
protein per well. Statistical significance compared to the vehicle control and between drug treatments 
was determined by two-way ANOVA with Dunnett’s or Sidak’s correction for multiple comparisons *p 
value < 0.05 **p value < 0.01 ***p value < 0.001. Abbreviations: PL, proton leak; ALR, ATP-linked 
respiration; SRC, spare respiratory capacity; OCR, oxygen consumption rate. 
 88 
  
When examining further metabolic parameters, the data illustrated a marked reduction in 
spare respiratory capacity and ATP-linked respiration as standalone values for both SVL and 
SVA at 300 and 1000 nM (Figure 2.18 (D & E)). However, when metabolic parameters were 
reported as a percentage of their respective maximal respiratory capacities, proton leak 
values increased dose dependently (Figure 2.18 (F & G)).  
2.3.8 Assessing Chronic Simvastatin-Induced Respiratory Complex Dysfunction 
As described in section 2.3.4, assessment of individual respiratory complex (I-IV) driven 
respiration was performed in permeabilised L6 myocytes using substrate-inhibitor mixtures 
specific to the complex of interest. Cells were chronically treated (120 Hours) with either 
simvastatin lactone or β-hydroxy acid (0- 1000 nM) before conducting a mitochondrial stress 
test (Figure 2.19). 
 
Figure 2.19 The effect of chronic (120 hours) simvastatin lactone (SVL) and simvastatin β-hydroxy acid 
(SVA) exposure upon the activity of the mitochondrial respiratory complexes (I-IV). L6 myocytes were 
pre-treated with SVL or SVA (0-1000 nM) before cell permeabilisation and delivery of complex specific 
substrate mixtures using an extracellular flux analyser (XFe96) instrument. Complex driven respiration 
was defined as maximal respiration (as a % of basal respiration) normalised to the vehicle control. 
Graphical values are displayed as mean ± S.D. (n=3) and results were normalised to µg protein per 
well. Statistical significance compared to the vehicle control and between drug treatments was 
determined by two-way ANOVA with Dunnett’s or Sidak’s correction for multiple comparisons *p 
value < 0.05 **p value < 0.01 ***p value < 0.001.  
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The most significant change to respiratory complex function in response to prolonged 
simvastatin exposure was observed at complex II (Figure 2.19 (B)), an observation which was 
consistent with the acute toxicity screening results (section 2.3.4). At the highest 
concentration tested (1000 nM) both simvastatin lactone and β-hydroxy acid showed an 
almost equipotent inhibitory capacity, reducing complex II driven respiration by 42.7 % and 
44.1 % respectively.  Dose dependent decreases in substrate supported respiration were also 
noted at complexes III and IV to a lesser extent (Figure 2.19 (C-D)). Whilst there were no 
changes to complex I supported respiration compared with vehicle, with the exception of 
1000 nM SVA, there were differential effects between the two compounds at 300 nM and 
1000 nM (Figure 2.19 (A)). 
To ensure that the changes in respiratory complex function after statin exposure were not 
due to a decrease in mitochondrial mass, mitochondrial voltage-dependent anion channel 1 
(VDAC1) abundance was measured in whole cell lysates via western blot (Figure 2.20). 
Figure 2.20 Examining the abundance of voltage-gated anion channel 1 (VDAC1) present in whole cell 
lysates pre-treated with simvastatin lactone (A) or simvastatin β-hydroxy acid (B) for 120 hours. 
Integrated band intensities were determined via densitometry using ImageJ 1.48 software and 
normalised to the loading control β-actin before presenting as fold change relative to the vehicle 
control. Graphical values are displayed as mean ± S.D. (n=3). Statistical significance compared to the 
vehicle control was determined by one-way ANOVA with Dunnett’s correction for multiple 
comparisons *p value < 0.05 **p value < 0.01 ***p value < 0.001. Abbreviations: SVL, simvastatin 
lactone; SVA, simvastatin β-hydroxy acid. 
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There were no significant changes to mitochondrial mass in response to SVL (Figure 2.20 (A)) 
or SVA (Figure 2.20 (B)) treatment. 
2.3.9 Investigating the Impact of Chronic Simvastatin Treatment upon Acyl-
Carnitine Driven Respiration  
Medium- (octanyl-L-carnitine; C8) and long- (palmitoyl-L-carnitine; C16) chain acyl-carnitine 
stimulated respiration was assessed using permeabilised L6 myocytes pre-treated with 
either SVL or SVA for 120 hours (Figure 2.21).   
Simvastatin lactone and β-hydroxy acid promoted a dose dependent decrease in long-chain 
(Figure 2.21 (A)) and medium-chain (Figure 2.21 (B)) acyl-carnitine oxidation, exhibiting an 
almost equipotent reduction (~40 %) in substrate driven respiration at 1000 nM in both 
cases. In regard to palmitoyl-L-carnitine specifically, significant inhibitory effects to 
substrate-driven respiration were noted from 10 nM, though a similar trend was observed 
for octanyl-L-carnitine.  
 
 
 
Figure 2.21 Examining the effect of chronic (120 hours) simvastatin lactone (SVL) and simvastatin β-
hydroxy acid (SVA) exposure upon long- (A) and medium- (B) chain acyl-carnitine driven respiration. 
L6 myocytes were pre-treated with SVL or SVA (0-1000 nM) before cell permeablisation and delivery 
of specific substrate mixtures using an extracellular flux analyser instrument (XFe96). Respiratory 
activity supported by acyl-carnitine oxidation was determined by deducting non-mitochondrial OCR 
from substrate driven OCR and normalising to the vehicle control. Graphical values are displayed as 
mean ± S.D. (n=3) and results were normalised to µg protein per well. Statistical significance compared 
to the vehicle control and between drug treatments was determined by two-way ANOVA with 
Dunnett’s or Sidak’s correction for multiple comparisons *p value < 0.05 **p value < 0.01 ***p value 
< 0.001. Abbreviations: SVL, simvastatin lactone; SVA, simvastatin β-hydroxy acid. 
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2.4 Discussion 
Mitochondrial dysfunction is increasingly implicated as a contributing factor in many 
xenobiotic-induced organ toxicities, particularly in aerobically poised tissues. The ability to 
detect drug mediated mitochondrial liabilities pre-clinically has been propelled by the 
introduction of the glucose-galactose metabolic screening assay. However, whilst much work 
has been conducted using hepatocarcinoma (HepG2) and myocardiocyte (H9c2) cell lines, 
until recently this model had not been evaluated in a skeletal muscle cell line (Marroquin et 
al., 2007; Rana et al., 2011; Dykens et al., 2008). Therefore to fill an unmet need, studies 
have since demonstrated that the L6 myogenic cell line is not only amenable to long-term 
culture supported by galactose and L-glutamine supplementation but also shows enhanced 
susceptibility to classic mitochondrial toxicants when compared to its glucose-conditioned 
counterpart (Dott et al., 2014). However, no studies to date have assessed the long-term 
proteomic implications of culturing L6 cells in galactose versus glucose media. 
Acute manipulation of L6 bioenergetics via the substitution of 25 mM glucose with 10 mM 
galactose and 6 mM L-glutamine in the culture medium increased cellular reliance upon 
oxidative metabolism for ATP generation. This was evidenced by a significant decrease in 
ATP content following rotenone treatment, a potent NADH dehydrogenase (complex I) 
inhibitor, in galactose-conditioned cells versus glucose-conditioned cells. Comparisons of the 
resultant IC50 values in both media types further confirmed that rotenone mediated direct 
mitochondrial dysfunction (IC50 ATPglu/IC50 ATPgal ratio ≥2) which preceded the induction of 
cytotoxic effects (IC50 LDHgal/ IC50 ATPgal ≥2) as expected (Kamalian et al., 2015; Dott et al., 
2014).  
Upon challenge with simvastatin lactone over a 2 and 24 hour time period, ATP depletion 
was observed in both media types accompanied by a loss of cellular LDH retention. Based 
upon the IC50 values, simvastatin lactone had a more pronounced effect upon galactose-
conditioned cells. However, despite this difference reaching statistical significance, the 
resultant ratios were indicative of a multifactorial toxicity mechanism rather than 
mitochondrial dysfunction alone (Swiss et al., 2013; Hynes et al., 2013). Though it should be 
acknowledged that there are several examples of drugs (e.g. troglitazone, chlorpromazine 
and sertraline) which have known mitochondrial liabilities yet fall under the umbrella of 
multifactorial toxicity (Swiss et al., 2013; Li et al., 2012; Bullough et al., 1985).  
When examining an equimolar range of simvastatin β-hydroxy acid over a 2 and 24 hour 
period, there were no appreciable effects on ATP content or cell viability. Though this was 
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followed by a 94.34 % reduction in ATP content (300 µM) after 48 hours in galactose-
conditioned cells. At the shorter incubation periods, it could be assumed that the compound 
harboured no mitochondrial liability, however extended modelling revealed that there was 
indeed considerable differential toxicity between the two media types. Importantly, these 
findings are in firm agreement with previous reports that statin lactones are more potent 
mediators of acute cytotoxicity than their β-hydroxy acid counterparts. This observation was 
replicated when examining the two chemical species of cerivastatin within this chapter and 
amongst several other statins in C2C12 myocytes and primary human myocytes (Schirris et 
al., 2015; Skottheim et al., 2008). 
Although glucose-galactose assays are extremely useful as a first-line screening tool, a major 
caveat of the model is that it cannot be used to detect all forms of mitochondrial dysfunction 
and is often confounded by multifactorial toxicity mechanisms or insufficient incubation 
periods. For example, compounds with documented mitochondrial liabilities e.g. perhexilline 
can be incorrectly defined as negative for mitochondrial toxicity based upon the defined 
screening thresholds (Kamalian et al., 2015; Swiss et al., 2013; Deschamps et al., 1994). In 
addition, the use of total ATP content as a surrogate measure of overall mitochondrial 
functionality is extremely simplistic, providing no deeper mechanistic insight to the nature 
of the perturbations taking place. Furthermore, it does not take into account depletion of 
ATP reserves due to the activation of cellular defence mechanisms or compensatory 
mechanisms which may maintain ATP levels despite the presence of respiratory dysfunction 
(Espinosa-Diez et al., 2015). Crucially, it exemplifies the need to use supplementary 
techniques to determine the contribution of mitochondrial dysfunction to the overall 
cytotoxic effect of a compound. As such, extracellular flux analysis was used to provide 
further mechanistic information as monitoring changes to cellular oxygen consumption is 
known to be a more sensitive measure of mitochondrial function (Brand and Nicholls, 2011; 
Wu et al., 2007). 
Both simvastatin lactone and β-hydroxy acid differed considerably in their effects upon 
mitochondrial respiration in an acute setting; simvastatin lactone induced marginal, dose-
dependent reductions in basal and maximal respiration, whereas the β-hydroxy acid 
increased basal respiration at 300 µM. These observations are consistent with mild ETC 
inhibition by the lactone and respiratory uncoupling by the β-hydroxy acid. The uncoupling 
of oxidative phosphorylation, particularly in the presence of weak acids, increases basal 
respiration as the rate-limiting step of ATP synthesis is no longer coupled to oxygen 
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consumption, enabling OCR to increase (Terada, 1990). This was substantiated by the 
concurrent increase in proton leak and decrease in coupling efficiency, ATP-linked 
respiration and spare respiratory capacity mediated by simvastatin β-hydroxy acid. 
Furthermore, acute respiratory uncoupling by simvastatin β-hydroxy warrants further 
investigation to determine the specific mechanism by which it disrupts the mitochondrial 
membrane potential.  
In line with previous reports, extracellular flux analysis of permeabilised L6 myocytes in the 
presence of respiratory complex-specific substrates identified SVL as an inhibitor of complex 
I, and to a greater extent, complex II and III supported respiration (Sirvent et al., 2005; Schirris 
et al., 2015; Larsen et al., 2013; Paiva et al., 2005; Nadanaciva et al., 2007; La Guardia et al., 
2013). However, simvastatin β-hydroxy acid caused global reductions in substrate driven 
respiration, particularly at complex II, demonstrating differential inhibitory potency when 
compared to the lactone species at equimolar concentrations. Whilst, reductions in complex 
I and II supported respiration have been noted in response to the β-hydroxy acid species in 
C2C12 myocytes, the precise concentrations used to see this effect were not fully disclosed 
(2-8 times IC50 of the corresponding lactone) (Schirris et al., 2015). Encouragingly, a 
significant reduction in complex III driven respiration by SVL was seen at a 30 µM which is 
consistent with predictive in silico modelling and experimental data suggesting that 
simvastatin lactone is capable of reversibly binding to the QO site of complex III, the effects 
of which may be mitigated by enriching the reduced ubiquinol pool to compete with SVL for 
the binding site (Schirris et al., 2015).  
When examining the effect of both chemical species upon isolated mitochondria, in 
agreement with the respirometry data, 300 µM SVA increased rhodamine123 fluorescence 
indicating depolarisation of the inner mitochondrial membrane. In addition, an increase in 
mitochondrial volume was also detected starting from 100 µM as signified by a relative 
decrease in optical density. In contrast, the highest concentration of SVL (300 µM) promoted 
an increase in optical density compared with the vehicle, eluding to mitochondrial shrinkage 
or rupture with the simultaneous loss of membrane potential. These results are consistent 
with the effects of acute simvastatin application upon permeabilised human skeletal muscle 
fibers. Concentrations greater than 100 µM have been shown to cause mitochondrial 
membrane depolarisation and Ca2+ efflux into the cytoplasm via induction of the MPTP. The 
consequential increase in cytosolic Ca2+ promotes further Ca2+ release from the sarcoplasmic 
reticulum, precipitating the myotoxic effects of simvastatin. The initiation of this ‘chain 
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reaction’ was later linked to complex I inhibition in human and rat skinned skeletal muscle 
samples (Sirvent et al., 2005a; Sirvent et al., 2012; Sirvent et al., 2005b).  
Whilst experiments have illustrated acute differential effects mediated by the two chemical 
species of simvastatin upon respiratory function, it is important to acknowledge that the 
concentrations used in this setting are well in excess of the plasma Cmax for each compound 
(0.08-2.2 µM SVL and 0.03-0.6 µM SVA), thus limiting the translational utility of the data 
(Björkhem-Bergman et al., 2011; Ahmed et al., 2013). However, it is documented that the 
doses of statin required to produce myopathic effects in rodents are high compared with 
therapeutic doses in humans, possibly due to differences in drug-biotransformation, basal 
metabolic rate, lipid metabolism or greater spare respiratory capacity (Sidaway et al., 2009; 
Sanuki et al., 2017).  
To address this, further investigations endeavoured to define if simvastatin, in both its 
lactone and β-hydroxy acid conformation, when administered using a chronic and 
therapeutically relevant dosing regime in vitro, can have a similar negative impact upon 
mitochondrial respiratory function. In contrast to previous studies using acute high dose 
statin application in murine cell lines, reductions in cellular ATP content (SVL (1 µM) 
galactose: 40.9 %, SVA (1 µM) galactose: 24.51 %) were observed over a 120 hour dosing 
period which preceded the induction of cell death.  
When assessing mitochondrial respiratory chain functionality using extracellular flux 
analyser technology in whole cells, significant decreases in basal respiration, maximal 
respiration and coupling efficiency were observed for both SVL and SVA (1 µM). When 
compared to the respective vehicle controls there was no significant difference between the 
two drug treatments at equimolar concentrations. Respiratory uncoupling (i.e. an increase 
in basal respiration) as seen when acutely injecting SVA (300 µM) was not recapitulated in 
this model suggesting that this is a phenomenon only observed when ‘overloading’ the 
mitochondria with high concentrations of compound.  
When examining the effect of simvastatin on the individual respiratory complexes in 
permeabilised cells, both SVL and SVA (1 µM) had the most profound effect on succinate 
dehydrogenase (complex II) function (41.7 % and 44.1 % reductions in complex activity 
respectively), which paralleled with the results garnered from the acute injection studies. 
Significant reductions in function were also observed for complexes I, III and IV to a lesser 
extent. Importantly, these changes were independent of changes to mitochondrial mass. 
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However, this could be further supported by examining citrate synthase activity or mtDNA 
copy number especially as these parameters have been reported to be perturbed by long-
term statin treatment in human subjects (Stringer et al., 2013; Larsen et al., 2013; Schick et 
al., 2007; Paiva et al., 2005) 
Interrogation of the mitochondrial β-oxidation pathway was also examined under the 
chronic modelling system. Consistent with reports that statins can exert inhibitory effects 
upon carnitine palmitoyl transferase II (CPT2) activity, the enzymatic mediator of medium- 
and long-chain fatty acid oxidation in the mitochondrion, significant reductions in acyl-
carnitine driven respiration were observed in response to both SVL and SVA exposure 
(Vladutiu et al., 2006; Hur et al., 2014; Schirris et al., 2015). This effect was particularly 
prominent in the presence of long-chain palmitoyl-L-carnitine (SVL >100 nM, SVA >10 nM), 
possibly due to the reliance upon the carnitine shuttle for mitochondrial entry (Vladutiu et 
al., 2006). Medium-chain fatty acids, on the other hand, are only partially reliant upon 
facilitated transport due to the ability of molecules with ≤ 8 carbon atoms to permeate the 
inner mitochondrial membrane (Schönfeld and Wojtczak, 2016). Thus, there may be less of 
a substrate feeding ‘bottle-neck’ in the presence of octanyl-L-carnitine, delaying the onset of 
dysfunctional substrate-driven respiration under these conditions.  
Lack of substantial differential toxicity between the two chemical conformations in most 
cases is likely reflective of the hydrolysis of the lactone ring in vitro over each 24 hour re-
dosing period as evidenced by the modulation of RAS GTPase farnesylation by SVL. Indeed, 
it has been demonstrated, using liquid chromatography-mass spectrometry, that 
atorvastatin β-hydroxy acid is relatively stable in myocyte culture medium (< 10 % conversion 
to lactone) over a 72 hour period. In contrast, the majority of atorvastatin lactone is 
converted to the β-hydroxy acid species after 24 hours (Hermann et al., 2005; Skottheim et 
al., 2008). Therefore, it would be of merit to investigate if the same outcomes can be 
replicated with simvastatin. 
Whilst beyond the scope of this thesis, aside from the induction of respiratory dysfunction, 
it is important to consider the implications that therapeutically relevant statin exposure may 
have upon the wider mitochondrial signalling network, particularly Ca2+ mediated cross-talk 
with the sarco/endoplasmic reticulum as the primary location of HMG-CoAR, attenuation of 
the Akt/mTOR/ULK1 signalling pathway, redox signalling, the homeostatic role of mitophagy 
and the induction of cell death pathways (Sirvent et al., 2005b; Mullen et al., 2011; du Souich 
et al., 2017; Kwak et al., 2012; Andres et al., 2017). Further work should begin to integrate 
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the aforementioned themes to build a more holistic picture of the causes and consequences 
of statin-mediated mitochondrial dysfunction in skeletal muscle.  
2.5 Conclusions  
The data presented within this chapter demonstrate that simvastatin can mediate 
deleterious effects upon several pathways of mitochondrial energy metabolism which may, 
in turn, perpetuate the manifestation of myopathic symptoms in some patients receiving 
statin therapy. At supra-physiological concentrations and acute time points these 
perturbations appear to be discrete between the two chemical species, however the same 
outcomes are not recapitulated using chronic modelling at concentrations which reflect the 
plasma Cmax. This is likely due to the hydrolysis of simvastatin lactone over extended culture 
periods, resulting in an inability to distinguish a significant differential impact upon 
mitochondrial function between the two chemical species. Though, this situation is perhaps 
more reflective of the behaviour of the compounds in vivo. Based upon these findings, the 
remainder of this thesis will focus upon the development of advanced in vitro models of 
human skeletal muscle and the identification of both functional and genetic (mtDNA) patient 
factors which may confer an enhanced or diminished risk of statin mediated mitochondrial 
perturbations and by extension, development of myopathic symptoms.  
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3.1 Introduction 
Cell based assays have long been the backbone of the drug development process. They 
provide a simple, fast and economically viable tool to alleviate the ethical considerations 
demanding a reduction in the use of animals in biomedical research. Cultured cells represent 
the fundamental building blocks of such techniques, since the results of the assays are based 
upon the cellular responses to exogenously supplied compounds or stimuli. The vast majority 
of cell based assays are performed using a conventional monolayer of primary or 
immortalised cells grown on a flat, rigid substrate. Whilst two-dimensional (2D) culture has 
proven to be an extremely valuable tool for cell-based research, the limitations of the 
platform have been increasingly recognised as fields have advanced (Breslin and O’Driscoll, 
2013; Edmondson et al., 2014; Anton et al., 2015).  
In an in vivo setting, almost all cells are surrounded by, and interact with, an extracellular 
matrix (ECM) and cells from neighbouring tissues in a three-dimensional (3D) fashion. As 
such, monoculture cannot adequately reconstruct the environment from which these cells 
are originally derived. There are a number of reasons that this may occur, including but not 
limited to, differences in cellular morphology, receptor expression, polarity, ECM 
interactions, cell-cell signalling and lack of tissue architecture (Breslin and O’Driscoll, 2013; 
Edmondson et al., 2014). When taken together, this may result in the generation of 
misleading or non-predictive data for in vivo or clinical responses.  
Recently there has been a drive for the development of more sophisticated in vitro models 
which can accurately reflect the physiology and function of native tissues. There has been 
considerable progress made in the areas of liver and cardiac tissue modelling (Mathur et al., 
2016; Underhill and Khetani, 2018). However, functional skeletal muscle models are still in 
their infancy which, until recently, has posed a significant barrier to musculoskeletal 
research. This is particularly important as there exists a wide range of muscular diseases 
encompassing metabolic, neuromuscular and dystrophic disorders that are currently under 
investigation and lack effective therapeutic intervention strategies (Madden et al., 2015; 
Truskey et al., 2013). Tissue-engineered human skeletal muscle presents a promising 
candidate platform from which to study both the fundamentals of muscle physiology and 
perform high content screening of muscle-active compounds (Vandenburgh et al., 2008). 
The present chapter aims to utilise established tissue-engineering techniques to generate 
myobundles, a biomimetic and three-dimensional human skeletal micro-tissue model with 
improved physiological relevance and culture lifespan over conventional primary myocyte 
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culture (Madden et al., 2015; Juhas and Bursac, 2014). The study will expand upon previous 
iterations of the model by taking a ‘scaled-down’ approach, producing myobundles which 
are 6.7x smaller in volume than the originally published design (Juhas and Bursac, 2014). This 
approach will be taken for two purposes; firstly to reduce the amount of cellular material 
required to make each myobundle and secondly to make the model amenable to a standard 
96-well plate format, improving throughput and utility for drug screening applications. 
Myobundles will be generated using myogenic cells isolated from surgical waste tissue 
derived from two donors with an additional sample of primary human skeletal myoblasts 
purchased from a commercial source (Cook Myosite Ltd, PA, USA).  
A recent study demonstrated the amenability of the myobundle model to interrogations of 
mitochondrial oxygen consumption polarographically in conjunction with measurements of 
contractile function (Davis et al., 2017). Therefore, the aim of this chapter is to define the 
utility of the myobundles as a platform for detecting drug-induced mitochondrial dysfunction 
in skeletal muscle using compounds with known mitochondrial liabilities. This will be 
investigated using standard mitochondrial toxicity screening assays, including the acute 
glucose-galactose metabolic conditioning model (Kamalian et al., 2015) and extracellular flux 
analyser technology (XF24), the principles of which are described in detail in Chapter 2.  
3.1.1 Summary of Chapter Aims  
1) To generate a down-scaled, tissue-engineered myobundle model amenable to a 96-
well plate format, using primary proliferative myocytes derived from both 
commercial sources and donor tissue. 
2) To characterise the structure and cellular composition of the myobundles.  
3) To assess the predictive utility of the myobundle model for identifying known 
mitochondrial toxicants using glucose-galactose metabolic conditioning and 
extracellular flux analyser (XF24) technology.  
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3.2 Materials and Methods 
3.2.1 Materials 
3.2.1.1 Commercially Sourced Primary Cells 
Human primary skeletal muscle derived cells (HSKMDC) (catalogue #SK-1111, Lot 
#P0100750F) were purchased from Cook Myosite Ltd, PA, USA as a cryopreserved stock of 
myoblasts (5x105 cells/ mL). 
3.2.1.2 Human Skeletal Muscle Samples  
Surgical waste tissue (500 mg - 2 g) was obtained from the quadriceps femoris of patients 
undergoing orthopaedic surgeries at the Royal Liverpool and Broadgreen University Hospital 
NHS Trust (RLBUHT). Tissue samples were collected by the Liverpool Musculoskeletal 
Biobank (LMB) in accordance with LMB approved standard operating procedures (SOPs) and 
covered by LMB study sponsorship (UoL001361) and ethical approval (Ref 15/NW/0661). All 
participants gave written, informed consent. Further details of patient inclusion/exclusion 
criteria are outlined in the LMB study sponsorship protocol (Appendix I). 
3.2.1.3 Reagents and Consumables  
All forms of DMEM, media supplements, Hoechst Fluoropure™, AlexaFluor® Phalloidin (568 
nm), AlexaFluor® conjugated secondary antibodies and ProLong® Gold antifade mountant 
were purchased from Life Technologies (Paisley, UK). Matrigel and growth factor reduced 
(GFR) matrigel were purchased from Corning GmBH (Wiesbaden, Germany). Epidermal 
growth factor (10 µg/mL) was purchased from PeproTech (London, UK). Anti-sarcomeric α-
actinin, anti-desmin, anti-vimentin and anti-β-actin antibodies were purchased from Abcam 
(Cambridge, UK). Anti-myogenin (MyoG) primary antibody was purchased from the 
Developmental Studies Hybridoma Bank (Iowa, USA). Lactate dehydrogenase cytotoxicity 
detection kit was purchased from Roche Diagnostics Ltd (West Sussex, UK). Extracellular flux 
analyser (XF24/XFe96) consumables and base medium were purchased from Agilent 
Technologies (CA, USA). All other reagents and chemicals were purchased from Sigma Aldrich 
(Dorset, UK) unless otherwise stated.  
3.2.1.4 Specialist Equipment  
Precision milled polytetrafluoroethylene (PTFE) masters for the casting of 
polydimethylsiloxane (PDMS) moulds and laser cut Cerex® frames were kindly provided by 
Dr George Truskey, Department of Biomedical Engineering, Duke University, North Carolina. 
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Dow Corning Sylgard 184 PDMS kit was obtained from Ellsworth Adhesives Limited (East 
Kilbride, Scotland). 
3.2.2 Isolation of Satellite Cells from Surgical Waste Tissue  
Satellite cells were isolated from surgical waste tissue and expanded by outgrowth using 
methods similar to those described by Blau and Webster with amendments (Blau and 
Webster, 1981; Madden et al., 2015). Upon receipt, tissue samples were washed with 1X PBS 
(-/-) supplemented with 2X gentamycin and amphotericin B (0.2% v/v) and weighed. The 
muscle tissue was carefully dissected to remove fat and connective tissue before being gently 
separated into smaller tissue fragments. Tissue fragments were enzymatically digested for 
30 minutes in 0.05 % trypsin-EDTA (37 °C) under periodic agitation.  
Following digestion, the trypsin was neutralised with an equal volume of complete growth 
medium and the tissue collected. Digested tissue fragments were pre-plated into uncoated 
T75 flasks for 2 hours to promote the adherence and subsequent disposal of remnant dermal 
fibroblasts. After two hours, the tissue fragments and media were transferred to growth 
factor reduced (GFR) matrigel coated flasks (5 µL/mL). Myogenic cell populations were 
observed daily to monitor cell outgrowth and expanded over a period of two weeks before 
bulk stocks were cryopreserved at passage 3 (1x106 cells/mL).  
3.2.3 General Cell Culture Maintenance  
Both commercial HSKMDC and isolated myocytes were routinely maintained in complete 
growth medium containing physiological glucose (5 mM) DMEM with sodium pyruvate (1 
mM) and L-glutamine (4 mM), supplemented with 8 % (v/v) FBS, 0.4 μg/mL dexamethasone, 
10 ng/mL epidermal growth factor, 50 μg/mL fetuin, 0.1 % (v/v) gentamycin and 
amphotericin B. Cells were kept in vented T75 flasks coated in GFR matrigel (5 μL/mL) and 
incubated in a humidified environment (37 ᵒC with 5 % (v/v) CO2), media changes were 
performed every 48 hours. All stock cultures were maintained at sub-60 % confluence and 
used between passages 3-5 (≤10 population doublings) to prevent the decline of cell fusion 
properties. Cell populations were frozen using a standard cryopreservation mix which 
consisted of complete growth medium supplemented with 10 % DMSO (v/v). All 
cryopreserved cell stocks were stored at -180 °C under the liquid nitrogen vapour phase. 
3.2.4 Differentiation Procedure for Monolayers  
Cells were dissociated using 0.05 % trypsin-EDTA and seeded into GFR-matrigel (5 μL/mL) 
coated tissue culture plates at specified densities before incubating in complete growth 
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media for 24 hours (37 ᵒC, 5 % (v/v) CO2). The following day, the growth media was removed 
and the cells were washed twice with 1X PBS (-/-). Cells were then cultured in a 
differentiation medium consisting of physiological glucose (5 mM) DMEM with sodium 
pyruvate and L-glutamine, supplemented with 2 % (v/v) horse serum, 10 nM human insulin, 
0.1 % (v/v) gentamycin and amphotericin B. Thereafter, the differentiation media was 
changed every 48 hours for 5 days. Differentiation of cultures was confirmed through visual 
inspection under a light microscope. 
3.2.5 Fabrication of Myobundles  
Expanded myogenic cell populations maintained in complete growth medium were 
dissociated from T75 flasks in 0.05 % trypsin-EDTA to a single cell suspension and 
encapsulated in a fibrin hydrogel solution on to laser cut Cerex® frames (3.8 mm x 3.6 mm 
outer dimensions, 2.6 mm x 2.0 mm inner dimensions) within PDMS moulds (cast from 
machine milled PTFE masters and pre-treated with 0.2 % (w/v) pluronic® F127) at a density 
of 1x105 cells/myobundle (Figure 3.1). 
Figure 3.1 Schematic diagram depicting the dimensions of the Cerex® frames and PTFE masters used 
for casting PDMS moulds. All designs provided by the Truskey laboratory, Duke University, NC, USA. 
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Specifically, a cell solution (1x105 cells in 3.35 µL growth media per myobundle with 0.4 µL of 
50 units/ mL thrombin (reconstituted in 1X PBS supplemented with 0.1 % fatty acid free BSA) 
and a hydrogel solution (0.75 µL growth medium, 1.5 µL fibrinogen (25 mg/mL) and 1.5 µL 
matrigel) were prepared in separate vials on ice for up to four myobundles per vial. The 
hydrogel solution was combined with the cell solution and pipetted vigorously on ice to mix. 
7.5 µL of the cell/hydrogel mixture was individually pipetted into PDMS moulds ensuring end-
to-end contact with the Cerex® frames (Figure 3.2). 
The cell/hydrogel mixture was polymerised at 37 ᵒC for 25 minutes followed by incubation 
in complete growth media supplemented with 1.5 mg/mL 6-aminocaproic acid (ACA) for 5 
days to allow the hydrogel structure to compact. After 5 days, the myobundles (attached to 
Cerex® frames) were ‘shifted’ from their PDMS moulds and placed into differentiation media 
supplemented with 2 mg/mL ACA and cultured dynamically on a fixed-angle platform rocker 
in suspension for a further 5 days (37 ᵒC, 5 % (v/v) CO2). 
Figure 3.2 Schematic representation of the myobundle generation process (Madden et al., 2015). 
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3.2.6 Fluorescent Imaging  
3.2.6.1 Monolayers  
Myoblasts were seeded on top of GFR-matrigel (5 μL/mL) coated 13 mm coverslips in 24 well 
plates at a density of 4500 cells/well. Cells were allowed to adhere and proliferate for 2-3 
days after which they were either processed or differentiated (section 3.2.4). 
Cells were rinsed with 1X PBS (-/-) before being fixed with either cold methanol for 5 minutes 
or 4 % (w/v) paraformaldehyde for 30 minutes. Samples were then incubated with 
permeabilisation buffer (1X PBS (-/-) with 0.2 % (v/v) Tween-20 and 0.5 % (v/v) Triton-X) for 
30 minutes at 4 ᵒC and blocked with 5 % (w/v) BSA reconstituted in permeabilisation buffer 
for a further 30 minutes at room temperature. 
Primary antibodies, mouse anti-myogenin (1:50), rabbit anti-desmin (1:100) and mouse anti-
vimentin (1:200) were diluted in 5 % (w/v) BSA permeabilisation buffer and incubated with 
the samples overnight at 4 ᵒ C. After washing, appropriate Alexa Fluor® conjugated secondary 
antibodies (488 nm /568 nm) were diluted 1:1000 and co-incubated with Hoechst (nuclear) 
and phalloidin (filamentous-actin) dyes (1:5000) for 2 hours, in the dark at room 
temperature. 
Samples were mounted onto glass slides for imaging. 10 µL Pro-Long Gold anti-fade reagent 
was added to each of the samples before sealing and allowing to dry overnight at 4 ᵒC. All 
images were captured using a Zeiss Axio Observer.Z1 (apotome) widefield florescent 
microscope and processed with Zen Blue software. 
3.2.6.2 Myobundles  
Differentiated myobundles were rinsed with 1X PBS (-/-) and fixed in their frames overnight 
with 2 % (w/v) paraformaldehyde. Myobundles were then washed and incubated with 
blocking/permeabilisation buffer (1X PBS (-/-) with 3 % (w/v) BSA, 0.2 % (v/v) Tween-20 and 
0.5 % (v/v) Triton-X) overnight (4 ᵒC).  
Primary antibodies, mouse anti-myogenin (1:50), mouse anti-vimentin (1:200) and rabbit 
anti-sarcomeric alpha actinin (1:200) were diluted in 3 % BSA blocking/permeabilisation 
buffer and incubated with the samples overnight at 4 ᵒC under gentle agitation. Post 
incubation, samples were washed before the appropriate Alexa Fluor® conjugated secondary 
antibodies (488 nm/568 nm) were diluted (1:1000) in 3 % BSA block/permeabilisation and 
co-incubated with Hoechst and phalloidin dyes (1:5000) for 2 hours, in the dark at room 
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temperature.  All images were captured using a Zeiss Axio Observer.Z1 (Apotome) widefield 
florescent microscope and processed with Zen Blue Software. 
3.2.7 Western Blots 
Western blots were performed as previously described in Chapter 2 (section 2.2.8). 
Undifferentiated myobundles (day 5) and differentiated myobundles (day 12) were rinsed 
with 1X PBS (-/-) and lysed in 100 µL RIPA buffer via pulse sonication for 10 seconds (Soniprep 
150, MSE, UK).  Protein quantification was performed by BCA assay.  
Briefly, 10 µg of protein lysate was mixed with 5 µL of sample loading dye. Samples were 
heat denatured at 95 ᵒC for 5 minutes before loading into NuPAGE® 4-12 % Bis-Tris pre-cast 
gels alongside 5 µL of Precisions Plus Protein™ molecular weight marker. Loaded samples 
were subject to electrophoretic separation by molecular weight under reducing conditions 
in 1X MOPS-SDS (50 mM MOPS, 50 mM Tris-base, 0.1 % (w/v) SDS, 1 mM EDTA) running 
buffer supplemented with 500 µL NuPAGE® antioxidant for 1 hour (170 V).  
Separated proteins were transferred onto nitrocellulose membranes using an XCell II blotting 
module for 1 hour (220 V). The transfer stack was submerged in 1X transfer buffer (25 mM 
Tris-base, 192 mM glycine, 20 % (v/v) methanol). Resultant membranes were stained with 
ponceau red dye to ensure transfer uniformity before blocking for 1 hour in 10 % (w/v) non-
fat milk 1X TBS-T (137 mM NaCl, 2.7 mM KCl, 19 mM Tris-base, 0.01 % (v/v) Tween 20, pH 
7.4). 
Primary antibodies were diluted in 5 % (w/v) non-fat milk 1X TBS-T (rabbit anti-sarcomeric 
α-actinin (1:1000), mouse anti-myogenin (1:50) and mouse anti-actin (1:10,000)) then 
incubated with membranes for 16 hours (4 ᵒC). Following washes in 1X TBS-T, appropriate 
HRP-conjugated secondary antibodies were diluted 1:10,000 in 5 % (w/v) non-fat milk 1X 
TBS-T and incubated with membranes for 2 hours at room temperature. Band signals were 
detected using enhanced chemiluminescent reagent (ECL) and developed on film.  
3.2.8 Acute Metabolic Manipulation using Galactose Media  
Myogenic cells from each donor were collected by trypsinisation and seeded into GFR-
matrigel coated (5 µL/mL), flat bottomed 96-well plates in complete growth medium (20,000 
cells/100 µL/well) and incubated for 24 hours (37 ᵒC, 5 % (v/v) CO2). Differentiation of 
myogenic cell cultures grown in 2D were performed as described in section 3.2.4 for 5 days. 
Myobundles were fabricated and differentiated as described in section 3.2.5.  
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Cells and myobundles were washed three times in either serum-free high-glucose (DMEM, 
25 mM glucose, 4 mM L-glutamine, 1 mM sodium pyruvate and 5 mM HEPES) or galactose 
(DMEM, 10 mM galactose, 6 mM L-glutamine, 1 mM sodium pyruvate and 5 mM HEPES) 
media. Cells and myobundles were pre-incubated in glucose or galactose media (50 µL) for 2 
hours (37 ᵒC, 5 % (v/v) CO2). 
Rotenone stock solutions were prepared in DMSO and diluted further in the appropriate 
media to produce a dose range between 0-10 µM for both the glucose and galactose media 
conditions. Diluted stock compounds were then added to each well (50 µL) for a final well 
volume of 100 µL and incubated for 2 hours (37 ᵒC, 5 % (v/v) CO2). The final solvent 
concentration for all conditions was 0.5 % DMSO.  
3.2.9 Combined Lactate Dehydrogenase (LDH) and ATP assays 
Cells and myobundles conditioned to glucose or galactose media were incubated with 
rotenone for 2 hours. Supernatants were collected and cells/myobundles were lysed using 
50 µL or 100 µL of somatic cell ATP releasing agent respectively. Myobundles required an 
additional pulse sonication for 10s to fully dissociate the micro-tissue from the Cerex® frame 
before commencing with the simultaneous assessment of ATP content, cell viability and 
protein content. Detailed assay descriptions can be found in Chapter 2 (section 2.2.4).  
3.2.9.1 ATP Assay 
Quantitative determination of ATP content was assessed by the addition of sample lysates 
(5 µL) and ATP standards to a white-walled 96-well plate. ATP reaction solution was prepared 
according to manufacturer’s instructions by mixing ATP assay mix with ATP dilution buffer in 
a 1:25 ratio. 40µL of the reaction solution was added to both samples and standards then 
read immediately on a Varioskan™ Flash multimode plate reader with SkanIt™ software to 
capture the peak luminescent signal. 
3.2.9.2 LDH Assay 
Detection of cytotoxicity was achieved using a colorimetric LDH assay kit. LDH retention was 
determined by extracting 25 µL supernatant and 10 µL cell lysate for each sample and 
incubating them with 50 µL LDH catalyst-dye solution (1:45 ratio), according to 
manufacturer’s instructions. After 30 minutes incubation in the dark, samples were read at 
490 nm on a Varioskan Flash multimode plate reader. LDH retention was determined as:  
𝐋𝐃𝐇 𝐑𝐞𝐭𝐞𝐧𝐭𝐢𝐨𝐧 =  
𝐋𝐲𝐬𝐚𝐭𝐞 
(𝐒𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐚𝐧𝐭 + 𝐋𝐲𝐬𝐚𝐭𝐞)
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3.2.9.3 BCA Assay  
In order to correct for potential variance in cell number, the BCA assay was used to normalise 
ATP assay results. Quantification of sample protein content was determined using 10 µL 
sample lysate and protein standards. Assay products were read at 562 nm after 30 minutes 
incubation at 37 ᵒC. 
3.2.10 Extracellular Flux Analyser (XF24/XFe96) Assays  
Myogenic cells from each donor were collected by trypsinisation and seeded into GFR-
matrigel coated (5 µL/mL), XFe96 cell culture microplates in complete growth medium 
(25,000 cells/100 µL/well) and incubated for 24 hours (37 ᵒC, 5 % (v/v) CO2). Differentiation 
of myogenic cell cultures grown in 2D were performed as described in section 3.2.4. 
Myobundles were fabricated and differentiated as described in section 3.2.5. On the day of 
the assay, myobundles were moved to XF24 cell culture microplates coated with neat GFR-
matrigel and orientated horizontally within the wells to align with the XF24 sensor cartridge 
probes.  
Following the completion of XF assays, cells and myobundles were lysed in somatic cell ATP 
releasing agent (20 µL and 100 µL respectively). Lysates (10 µL) were transferred to a 96-well 
plate for quantification of protein content by BCA assay. Protein content per well was used 
as a means to normalise raw OCR and ECAR data.  
3.2.10.1 Mitochondrial Stress Test 
Myogenic cells and myobundles were incubated for 1 hour (37 ᵒC, 0 % CO2) prior to the start 
of the assay. Culture medium was replaced with 175 µL (XFe96) or 450 µL (XF24) unbuffered 
XF base medium supplemented with glucose (25 mM), L-glutamine (2 mM), sodium pyruvate 
(1 mM), pre-warmed to 37 ᵒC (pH 7.4).  
3.2.10.1.1 Stress Test Compound Preparation 
Stock mitochondrial stress test compounds were prepared and loaded into XF sensor 
cartridges in accordance to Table 3.1 for monolayers on the XFe96 and Table 3.2 for 
myobundles on the XF24. Optimal stress test compound concentrations were determined 
empirically for each system.  
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Table 3.1 Mitochondrial stress test injection port locations, compound stock concentrations, dilution 
factors and final well concentrations for the XFe96. 
Injection 
Port 
Compound Port 
Dilution 
Factor 
Final Well 
Concentration 
Port Loading 
Volume 
A Oligomycin 8 1 µM 25 µL 
B FCCP 9 0.75 µM 25 µL 
C Rotenone/Antimycin A 10 1 µM 25 µL 
 
Table 3.2 Mitochondrial stress test injection port locations, compound stock concentrations, dilution 
factors and final well concentrations for the XF24. 
Injection 
Port 
Compound Port 
Dilution 
Factor 
Final Well 
concentration 
Port Loading 
Volume  
A Oligomycin 10 10 µM 50 µL 
B FCCP 10 6 µM 55 µL 
C FCCP 10 4 µM 62 µL 
D Rotenone/Antimycin A 10 10 µM 68 µL 
 
Each run included a pre-programmed calibration, an equilibration step and 3 cycles of 
mix/measure/wait (3 mins/3 mins/0 mins) to establish a baseline OCR/ECAR prior to the 
injection of any compounds. Following this, a stress test was performed via the sequential 
injection of mitochondrial toxicants. This enabled the calculation of basal respiration (BR), 
maximal respiratory capacity (MRC), ATP-linked respiration (ALR), proton leak (PL) and spare 
respiratory capacity (SRC).  
3.2.10.2 Calculation of the Proton Pumping Rate Attributable to Glycolysis (PPRgly) 
Baseline measurements of oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) were performed in the absence of any compounds for monolayers and 
myobundles. The OCR and ECAR measurements were then used to calculate the proton 
pumping rate (PPR) attributable to glycolysis (PPRgly) as per the formula below: 
PPRgly= ECARtot/BP – (10 (pH-pK1)/(1+10 (pH-pK1))(max H+/02)(OCRtot – OCRrot/AA) 
Where tot = total, ECAR units = (mpH/min/µg), BP = buffering power (mpH/pmol H+ in 2 µL 
(XFe96) or 7 µL (XF24)), K1 = combined equilibrium constant of CO2 hydration and dissociation 
to HCO3- + H+, max H+/O2 = the CO2-derived acidification for the complete oxidation of 
glucose, OCR units = (pmol O2/min/µg) and OCRrot/AA = non-mitochondrial OCR (Mookerjee 
and Brand, 2015). 
 111 
  
3.2.11 Statistical Analysis  
Data are representative of at least three independent experiments (n=3) and all values are 
expressed as mean ± standard deviation (S.D.) as appropriate. Statistical analyses were 
performed using GraphPad Prism® 7 software (GraphPad Software, Inc, CA, USA). Data were 
tested for Guassian distribution using the Shapiro-Wilk normality test before statistical 
significance was determined using a student’s t-test with Welch’s correction, one-way 
Analysis of Variance (ANOVA) with Dunnett’s correction for multiple comparisons or two-
way ANOVA with Dunnett’s or Sidak’s correction. Non-parametric equivalents were used as 
appropriate. IC50 values were determined using non-linear regression analysis. A p value ≤ 
0.05 was regarded as the significance threshold. 
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3.3 Results 
3.3.1 Participant Characteristics  
A summary of clinical data for study participants and commercially sourced primary myocytes are outlined in Table 3.3. Participants and commercial myocytes 
were selected for the study due to their advanced age (> 45 years), statin-naïve status, lack of inherited metabolic disorders and no history of diabetes.  
Table 3.3 Clinical information for recruited study participants and commercially sourced primary myocytes.  
Sample ID Age  Gender  Ethnicity  BMI (kg/m2) Smoking Status  Alcohol 
(Units/Week) 
Inherited 
Metabolic 
Disorders 
Medication  Biopsy Location  
LMB-HI-229 85 M Caribbean  22.7 Non-smoker <1 No Zemtard 
Betahistine 
Cetirizine  
Omeprazole 
Quadriceps Femoris  
LMB-PP-231 59 F Caucasian  33.5 Previous 1-5 No Codeine 
Paracetamol  
Ibuprofen  
Quadriceps Femoris 
HSKMDC 50 F Caucasian  23 Previous  NK No Sertraline  Abdominal Rectus 
Abbreviations: M, male; F, female; NK, not known. 
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3.3.2 Characterisation of Isolated and Commercial Myocytes  
Proliferative cell populations from each participant were co-stained for vimentin (type III 
intermediate filament) and desmin (muscle specific type III intermediate filament) (Figure 
3.3).  
The proportion of myocytes (desmin and vimentin +ve) to fibroblasts (vimentin +ve only) 
were quantified for each of the cellular sources to ensure that an enriched myocyte 
population (>60 %) was present (Figure 3.4). In each case, the percentage of myocytes 
Figure 3.3 Representative image of desmin/vimentin co-staining for donor LMB-HI-229 at passage 3. 
Image taken on 60X oil immersion lens. Scale bar = 50 µm. 
Figure 3.4 Proportion of myocytes to fibroblasts in each source culture at passage 3. Four random 
images per slide were taken for each slide (n=4). Average counts were performed using ImageJ 1.48 
software. 
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exceeded the threshold, with the commercial HSKMDC culture exhibiting the least enriched 
stock population (83.1 %) of the sources examined.  
3.3.3 Assessment of Myoblast Fusion Potential 
Differentiation of myocyte cultures was assessed via visual inspection for cell fusion after the 
substitution of growth for differentiation medium. Commitment of cells to a myogenic fate 
was confirmed by probing for the expression of the myogenic regulatory factor (MRF) 
myogenin (MyoG). As shown in Figure 3.5 (A), before initiation of differentiation myocytes 
were discrete, mononuclear and did not express MyoG. After differentiation (Figure 3.5 (B)), 
myocytes fused to form polynucleated myotubes and MyoG expression was present and 
localised to the nuclei. 
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Figure 3.5 Representative images of HSKMDC MyoG staining. (A) Myoblasts 24 hours after seeding. (B) Myotubes after 5 days in differentiation media. Images taken on 40X 
oil immersion lens. Scale bar = 50 µm. 
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3.3.4 Assessment of Myobundle Architecture and Composition  
Engineered skeletal ‘myobundles’ were generated using a fibrin hydrogel moulding 
technique and anchored to nylon fabric frames as previously described (Hinds et al., 2011; 
Juhas and Bursac, 2014; Madden et al., 2015) with amendments. After compaction and 
differentiation in dynamic suspension, myobundle constructs assumed a characteristic ‘dog 
bone’ shape, bowing due to the contraction of the seeded myocytes (Figure 3.6) (Qazi et al., 
2015). 
Differentiated myobundles exhibited extensive MyoG expression (Figure 3.7 (A)), showed 
focal accumulation of vimentin positive cells (fibroblasts) at the peripheral edge of the 
myobundle (Figure 3.7 (B)) and expressed the mature muscle protein sarcomeric α-actinin 
(SAA) (Figure 3.7 (C)). Additionally, comparisons of the expression of MyoG and SAA between 
pre-differentiated and differentiated myobundles showed clear differences in abundance 
between the two time points (Figure 3.7 (D)). 
Figure 3.6 Representative images of 7.5 µL myobundles produced from each cellular source. Images 
taken on Nikon Digital Sight (DS-L2) imaging unit, 4X objective lens. Scale bar = 100 µm. 
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Figure 3.7 Representative HSKMDC myobundle images for (A) MyoG, (B) vimentin and (C) SAA staining after 7 days differentiation. Maximum intensity projection (MIP), Z-
stack images (apotome) were taken using the 5X objective lens. Scale bar = 500 µm. (D) Differential expression of MyoG and SAA at day 5 (pre-differentiation) and day 7 (post 
differentiation) in HSKMDC myobundles (n=3). 
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3.3.5 Longitudinal Assessment of Myobundle Stability 
To ensure that the cell and hydrogel components of the myobundles were not subject to 
degradation over time, both ATP and protein content were measured at 5 day intervals. As 
shown in Figure 3.8, despite small fluctuations, there was no significant change in either 
parameter tested, suggesting that the constructs remained stable over a 15 day period.  
3.3.6 Acute Metabolic Modification of Monolayers with Galactose Media  
Differentiated myotubes, metabolically conditioned to either glucose or galactose media 
were exposed to rotenone, a classic mitochondrial toxin with a well-defined molecular target 
(complex I), for two hours as previously described (Ball et al., 2016; Kamalian et al., 2015). 
To identify compound-induced mitochondrial dysfunction in the context of cell death, 
cellular ATP content and LDH retention were measured simultaneously. 
Exposure to rotenone for two hours did not significantly reduced the LDH retention values 
for any donor, in either media condition. However, ATP content values varied. Donor LMB-
HI-229 (Figure 3.9 (A)) and the HSKMDC (Figure 3.9 (C)) both showed significant reductions 
in ATP content in glucose media, whilst LMB-PP-231 (Figure 3.9 (B)) appeared to be less 
sensitive in that respect. In all cases, there was a dramatic reduction in ATP content in 
myotubes conditions to galactose media. A summary of IC50 values for each cellular source 
are displayed in Table 3.4.  
Figure 3.8 Longitudinal study of the ATP and protein content of myobundles over a 15 day period. 
Graphical values are displayed as mean ± S.D. and are representative of n=2 donors and n=3 
myobundles per time point. Statistical significance was determined by one-way ANOVA with 
Dunnett’s test for multiple comparisons.  
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Table 3.4 Summary of corresponding IC50 values for each cellular source in response to rotenone 
exposure (2 hours). Results are displayed as mean ± S.D. (n=3). Statistical significance was determined 
by un-paired t-test with Welch’s correction. *p value < 0.05, **p value < 0.01, ***p value < 0.001, n/d 
p value not determined. 
 
 IC50 ATP (µM) ± S.D. IC50 LDH (µM) ± S.D. IC50 ATPglu/ 
IC50 ATPgal 
IC50 LDHgal/  
IC50 ATPgal 
 Glucose Galactose Glucose Galactose 
LMB-HI-229 >10 
 
0.0094  
±  
0.0018 
>10 
 
>10 
 
>1059.45 
(n/d) 
 
>1059.45 
(n/d) 
LMB-PP-231 >10 0.0096 
±  
0.0018 
>10 
 
>10 
 
>1039.65 
(n/d) 
 
>1039.65 
(n/d) 
HSKMDC >10 0.0093 
±  
0.0015 
>10 >10 >1075.79  
(n/d) 
 
>1075.79  
(n/d) 
 
Figure 3.9 Examining the effect of rotenone (0-10 µM) exposure on ATP content and LDH retention in 
primary myocytes (2 Hours) compared with the vehicle control in glucose and galactose media. Results 
are expressed as a percentage of the corresponding media vehicle control and graphical values are 
displayed as mean ± S.D. (n=3).  (A): LMB-HI-229, (B): LMB-PP-231, (C): HSKMDC. Statistical 
significance was determined by one-way ANOVA with Dunnett’s test for multiple comparisons. *p 
value < 0.05 **p value < 0.01 ***p value < 0.001. 
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Mitochondrial toxicity was defined by calculating the ratio between the IC50 values for ATPglu 
versus ATPgal, whereby a ratio ≥ 2 indicated that the tested compound was a mitochondrial 
toxin, thus had a more pronounced effect in galactose media due to a lack of compensatory 
ATP generation from glycolysis. An IC50 ratio ≥ 2 for LDHgal versus ATPgal indicated that 
mitochondrial dysfunction preceded cell death, in line with previous definitions (Swiss et al., 
2013). In all three examples provided, both criteria were met.   
3.3.7 Acute Metabolic Modification of Myobundles with Galactose Media  
The assays were next performed using myobundles from each respective cellular source. In 
this instance, mitochondrial toxicity was defined as the lowest concentration at which the 
ATP level declined significantly more in galactose media than in glucose (Figure 3.10). 
The HSKMDC myobundles (Figure 3.10 (C)) were the most sensitive to rotenone exposure in 
galactose media, displaying a 46.9 % reduction in ATP content compare to vehicle at 0.013 
µM, LMB-HI-229 (Figure 3.10 (A)) and LMB-PP-231 (Figure 3.10 (B)), required higher doses 
Figure 3.10 Examining the effect of rotenone exposure on ATP content and LDH retention in 
myobundles (2 Hours) compared with the vehicle control in glucose and galactose media. Results are 
expressed as a percentage of the corresponding media vehicle control and graphical values are 
displayed as mean ± S.D. (n=3). (A): LMB-HI-229, (B): LMB-PP-231, (C): HSKMDC. Statistical 
significance was determined by unpaired t-test with Welch’s correction. *p value < 0.05 **p value < 
0.01 ***p value < 0.001. 
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(0.123 µM) in order to see significant reductions in ATPgal at the same time point. 
Nevertheless, each set of myobundles displayed differential toxicity in galactose media only 
without notable reductions in LDH retention compared to vehicle.  
3.3.8 Examining the Oxidative and Glycolytic Profiles of Monolayers 
Baseline measurements of oxygen consumption rate (OCR) and extracellular acidification 
rate (ECAR) in differentiated monolayers were performed in the absence of any compounds. 
The OCR and ECAR measurements were then used to calculate the proton pumping rate 
(PPR) attributable to glycolysis (PPRgly). After the establishment of baseline rates, oligomycin, 
an ATP synthase inhibitor was acutely injected into the plates and OCR/ECAR measurements 
were performed again. The resultant bioenergetic profiles of each participant were plotted 
as phenograms and displayed in Figure 3.11. Phenograms represent the cross-points of OCR 
and PPRgly values to describe energy derivation before and after the application of a 
compound (Kamalian et al., 2018). 
 
Figure 3.11 Bioenergetic phenograms for study participants in monolayer (A) LMB-HI-229, (B) LMB-
PP-231, (C) HSKMDC before treatment (open circles) and after acute application of oligomycin (closed 
squares). Graphical values are displayed as mean ± S.D. (n=3). Statistical significance was determined 
by unpaired t-test with Welch’s correction. *p value < 0.05 **p value < 0.01 ***p value < 0.001. 
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The triggering of energetic dysfunction through the application of a respiratory inhibitor 
instigated a significant decrease in mitochondrial oxygen consumption and a rapid increase 
in compensatory glycolytic flux for each participant.  
3.3.9 Examining the Oxidative and Glycolytic Profiles of Myobundles 
The bioenergetic profile of myobundles was assessed on a XF24 instrument. PPRgly was 
calculated using the same formula as described in section 3.2.10.2, with volumetric 
adjustments for buffering power (mpH/pmol H+ in 7 µL) to account for the larger plate size.  
As shown in Figure 3.12, myobundles produced from the same participants exhibited higher 
basal OCR values than their monolayer counterparts. For example, the OCR values for LMB-
PP-231 (Figure 3.12 (B)) were 16.85 ± 5.48 pmol/min/µg for myobundles versus 6.75 ± 0.24 
pmol/min/µg for monolayer (Figure 3.11 (B)). Conversely, basal PPRgly values were greater 
for monolayers e.g. LMB-PP-231 were 6.64 ± 0.45 pmol H+/min/µg versus -1.97 ± 7.58 pmol 
H+/min/µg for myobundles. However, significant compensatory glycolytic flux upon 
administration of oligomycin was evident for each set of myobundles.  
Figure 3.12 Bioenergetic phenograms for study participant myobundles (A) LMB-HI-229, (B) LMB-PP-
231, (C) HSKMDC before treatment (open circles) and after acute application of oligomycin (closed 
squares). Graphical values are displayed as mean ± S.D. (n=10). Statistical significance was determined 
by unpaired t-test with Welch’s correction *p value < 0.05 **p value < 0.01 ***p value < 0.001. 
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3.3.10 Assessing Respiratory Parameters between Monolayers and Myobundles 
Respiratory parameters were defined for each participant in monolayer alongside their 
myobundle counterparts. OCR values (pmol/min/µg) corresponding to basal respiration (BR), 
maximal respiratory capacity (MRC), proton leak (PL), ATP-linked respiration (ALR) and spare 
respiratory capacity (SRC) were calculated. Figure 3.13 depicts PL, ALR and SRC expressed as 
a proportion of the MRC (%) for each participant. A significant decrease in SRC for 
myobundles versus monolayers was observed in all cases (e.g. Figure 3.13 (C) HSKMDC 
myobundles SRC 17.72 ± 11.11 % versus HSKMDC monolayer SRC 72.54 ± 0.49 % p value 
<0.0001). In addition, both PL and ALR tended to occupy a greater proportion of the MRC for 
myobundles in comparison to monolayer. 
Figure 3.14 shows PL and ALR expressed as proportions of BR (%) for each participant. 
Myobundles exhibited a greater proportion of PL compared to that of their complimentary 
monolayers (LMB-HI-229 (A) 32.16 ± 7.46 %, LMB-PP-231 (B) 39.47 ± 13.98 % and HSKMDC 
(C) 32.11 ± 6.37 % respectively). Conversely, at baseline, monolayers dedicated more OCR to 
Figure 3.13 Comparison between respiratory parameters in monolayer and myobundles (A) LMB-HI-
229, (B) LMB-PP-231, (C) HSKMDC, expressed as percentage of the maximal respiratory capacity. 
Graphical values are displayed as mean ± S.D. (n=3 monolayers, n=10 myobundles). Statistical 
significance between parameters was determined by unpaired t-test with Welch’s correction *p value 
< 0.05 **p value < 0.01 ***p value < 0.001. 
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ALR, implying a more efficient coupling of substrate oxidation (i.e. the proximal respiratory 
chain) to ATP synthesis than that observed with the myobundles.  
 
 
 
 
 
 
 
 
 
Figure 3.14 Comparison between respiratory parameters in monolayer and myobundles (A) LMB-HI-
229, (B) LMB-PP-231 and (C) HSKMDC, expressed as a percentage of basal respiration. Graphical 
values are displayed as mean ± S.D. (n=3 monolayers, n=10 myobundles). Statistical significance 
between parameters was determined by unpaired t-test with Welch’s correction *p value < 0.05 **p 
value < 0.01 ***p value < 0.001. 
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3.4 Discussion 
The research described in this chapter aimed to validate a micro-physiological platform from 
which to measure drug-induced mitochondrial dysfunction in human skeletal muscle, with 
improved throughput compared to existing iterations of the model. Structural and cellular 
characterisation of the model showed conformity with previously published data, 
demonstrating that the smaller myobundles not only assumed the characteristic ‘bowed’ 
shape but also expressed key myogenic regulatory factors (MyoG) and mature structural 
proteins (SAA) upon serum reduction as expected (Madden et al., 2015; Juhas and Bursac, 
2014). Furthermore, the myobundles contained densely packed myofibers which aligned 
end-to-end with the Cerex® anchorage points and were surrounded at the periphery by 
vimentin positive fibroblasts. The presence of fibroblasts within the culture population has 
been reported to be pivotal for the synthesis of extracellular matrix proteins and promotion 
of overall myobundle integrity (Truskey, 2018). Longitudinal stability data demonstrated that 
the myobundle protein content did not significantly degrade over a 15 day culture period, 
however fluctuations in ATP content at day 10 may be explained, in part, by the changing 
energy demands associated with the exiting of myocytes from a state of proliferation to 
terminal differentiation (Davis et al., 2017). 
Preclinical compound screening for mitochondrial liabilities has been widely popularised due 
to the realisation that mitochondrial dysfunction was increasingly implicated in the aetiology 
of drug-induced liver injury (DILI). However, this situation can extend to other organ systems 
which are heavily reliant on oxidative metabolism for ATP production (Dykens and Will, 
2007). Current mitochondrial toxicity screening platforms predominantly focus upon 
measuring alterations in the OCR or respiratory complex activities of cells grown in 
monoculture or in isolated mitochondria (Dott et al., 2014; Hynes et al., 2013; Nadanaciva et 
al., 2007a). Whilst these methodologies have been successful in identifying compounds 
which possess mitochondrial liabilities, little work has been performed using micro-
physiological models of skeletal muscle to date (Davis et al., 2017).  
Maintenance of myocytes in nutrient-limiting media has previously been proposed as a 
means to increase pressure for metabolic remodelling, specifically to increase basal OCR and 
to mediate oxidative fiber type transition in vitro owing to the glycolytic nature of myocytes 
kept under artificial culture conditions (Aguer et al., 2011; Aas et al., 2013; Kase et al., 2013). 
This chapter presents the first study, to our knowledge, which utilises galactose metabolic 
manipulation specifically to assess compound-induced mitochondrial dysfunction in skeletal 
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myobundle constructs. Myobundles which had been acutely conditioned to galactose media 
displayed a significant reduction in ATP content, concomitantly with maintenance of LDH 
retention after acute (2 hours) exposure to the classic mitochondrial toxicant, rotenone. This 
confirmed that the myobundles were indeed capable of acute metabolic adaptation and 
responded appropriately when challenged with a compound that perturbed respiratory 
function. Furthermore, studies using primary myocytes have demonstrated their amenability 
to both propagation and differentiation in galactose media, this opens up the possibility of 
using myobundles cultured in galactose media for chronic dosing studies (Aguer et al., 2011). 
However, it must be noted that the HSKMDC myobundles displayed enhanced susceptibility 
to rotenone-mediated ATP depletion in galactose media (0.013 µM) compared to the biopsy 
derived myocytes (0.123 µM). One of the limitations associated with using commercially 
derived primary myocytes to generate myobundles is that the initial population must first be 
expanded to ensure sufficient cellular material for successive experiments. Consequently, 
the resultant cells will be of an advanced passage compared to those isolated ‘in house’ and 
may undergo phenotypic changes during the expansion phase. There is evidence to suggest 
that cells of an increased passage number exhibit altered mitochondrial dynamics, which in 
turn may confer greater susceptibility to compound-induced mitochondrial liabilities 
(Katajisto et al., 2015). This may, in part, explain the enhanced sensitivity of the HSKMDC to 
rotenone. Therefore, it is of importance to use cells of the same passage number to eliminate 
the influence of mitochondrial aging or cellular senescence upon susceptibility to drug 
toxicity.  
The research within this chapter aimed to define the bioenergetic profiles of primary 
myocytes grown in 2D vs 3D using XF analyser technology. Studies performed by Davies et 
al., first demonstrated that myobundles could be used to perform measurements of 
mitochondrial oxygen consumption polarographically using the Oxygraph-2k (O2k) system. 
It was highlighted that the myobundle model vastly improved upon the physiological 
relevance of the respirometry measurements being made due to enhanced in vitro 
complexity which, in turn, had profound effects upon the bioenergetic profile of the cells 
within the engineered constructs (Davis et al., 2017). However, the O2k instrument does not 
have the capability to assess glycolytic flux and lacks the throughput of the plate-based XF 
assays, thus limiting its use for larger scale drug-screening efforts (TeSlaa and Teitell, 2014; 
Zhang et al., 2012). 
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Therefore, to assess the utility of XF respirometry and gain further insight into the metabolic 
phenotype of the myobundles, bioenergetic parameters for OCR and PPRgly were 
determined. At baseline, the pooled average OCR values were 2.2 times greater in the 
myobundles (14.43 ± 1.74 pmol/min/µg) than that of the monolayers (6.44 ± 0.30 
pmol/min/µg). This is in contrast to the observations made by Davies et al., who reported 
that baseline respiratory rates were 2.5 times higher in myocytes assayed in solution than in 
myobundles. However, it’s important to note that measurement of oxygen consumption 
using Clark-type electrodes, such as the O2k, requires the removal of cells from their growth 
substrate and addition to a continuously stirred solution. In many adherent cell types, such 
as myocytes, this may result in anoikis, oxidative stress or altered oxygen consumption due 
to oscillatory shear, therefore the XF platform provides a physiologically more suitable 
environment from which to assess myocyte bioenergetics (Dranka et al., 2011; Davis et al., 
2017). Interestingly, measurement of intrinsic NADH and FAD auto-fluorescence using label-
free, non-linear optical molecular imaging (OMI) suggests that myotubes grown in 3D 
constructs may be more metabolically active than myotubes grown in 2D monoculture, thus 
supporting the data presented within this chapter (Syverud et al., 2017). 
In vitro myotube metabolism has been reported to be heavily reliant on glycolysis due to a 
combination of high glucose abundance in the culture medium and poor mitochondrial 
maturation (Aas et al., 2013; Cheng et al., 2014). Primary myotubes in monolayer exhibited 
higher baseline PPRgly, which significantly increased upon challenge with the ATP synthase 
inhibitor oligomycin. Basal PPRgly values were negative for the myobundles, representing no 
or extremely low background glycolytic activity, however myobundles demonstrated 
substantial PPRgly reserve capacity when exposed to oligomycin. The lower baseline PPRgly 
may be due to a change in cellular conformation from a 2D growth substrate to a 3D micro-
tissue with enhanced maturation, cell-cell and cell-matrix interactions. Additionally, it has 
been noted that tissue-engineered skeletal muscle constructs predominantly express slow 
oxidative (type I) myosin heavy chain isoforms, which may support the oxidative metabolic 
phenotype of the myobundles (Cheng et al., 2014; Martin et al., 2013). Characterisation of 
the relative expression of MHC isoforms for each set of myobundles would, in part, address 
these assumptions (Vandenburgh et al., 2008).  
Bioenergetic parameters derived from mitochondrial interrogation on the XF instrument also 
showed that myobundles allocated a substantially lower proportion of their maximal 
respiratory capacity to SRC compared to their monolayer equivalents. This may be a by-
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product of the mechanical stimulation associated with maintaining cells under passive 
tension on Cerex® frames. However, these observations were not in complete agreement 
with those made by Davies et al., who stated that the maximal respiratory rates of their 
myobundles were more than double that of the basal respiratory rates. Whilst the SRC was 
not explicitly calculated, it can be inferred from their data that the myobundles had a 
substantial reserve capacity (Davis et al., 2017). Alternatively, the differences observed 
between studies may be a result of donor specific variation in respiratory parameters due 
characteristics such as age, genetic background or environmental factors. In particular, the 
myobundles generated for this study were produced from participants of an advanced age 
(> 45 years). It has been suggested that various aspects of mitochondrial function decline 
with age in aerobically poised tissues such as skeletal muscle (Short et al., 2005; Chabi et al., 
2008). 
Proton leak and ATP-linked respiration were calculated as proportions of the basal metabolic 
rate. Both PL and ALR differed significantly between monolayer and myobundles. In 
myobundles, ALR made up a pooled average of 65.42 ± 3.45 % basal respiration whilst PL 
made up 34.58 ± 3.45 %.  The higher proportion of leak respiration is in agreement with 
previous literature showing that basal leak can account for up to ~50 % of the basal metabolic 
rate of mammalian skeletal muscle at thermoneutrality (Rolfe et al., 1999; Brand et al., 1999; 
Jastroch et al., 2010).  
When considering the limitations of this work, the normalisation of myobundle XF data to 
total protein may not be the most suitable method due to the presence of artificially 
supplemented extracellular protein sources (i.e. fibrinogen, thrombin and matrigel). It is 
difficult to quantify the precise contributions of extracellular protein to the final readings, 
therefore the normalised OCR and PPRgly values are likely to be greater than those stated. 
This impacts particularly upon direct comparisons between monolayer and myobundle 
respirometry data, especially when you consider the potential changes to the cellular 
proteomic profile promoted by growth within a 3D versus a 2D environment. However, 
previous studies performed using whole tissue sections or isolated fibers from biopsy have 
employed total protein normalisation as a mean for correcting skeletal muscle OCR values 
(Shintaku and Guttridge, 2016; Allard et al., 2018).  
Therefore, further work should endeavour to investigate standardised methodologies which 
can be used to normalise data generated from 3D cell constructs as these models become 
more common place in biomedical research, potentially by dissociating cells from the fibrin 
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construct using plasmin prior to protein quantification. Despite these potential limitations, 
this work represents significant advancement from the use of 2D monoculture to assess 
drug-induced mitochondrial dysfunction in skeletal muscle.  
3.5  Conclusions  
The work presented in this chapter has demonstrated the utility of the myobundle model as 
a novel, more physiologically relevant platform from which to assess drug-induced 
mitochondrial perturbations in skeletal muscle. The scaled down system, has allowed for the 
use of XF respirometry to assess the bioenergetic profiles of myobundles and improve 
throughput for the screening of muscle active-compounds. Whilst beyond the scope of this 
study, plasma membrane permeabiliser (PMP) could also be used to interrogate the activities 
of the mitochondrial respiratory complexes in situ by delivering complex-specific substrate 
mixtures to the myobundles (Divakaruni et al., 2017). Furthermore, assessment of 
myobundle bioenergetic parameters enables a personalised approach to determining the 
effects of pharmaceuticals upon mitochondrial function. This may be a useful predictive tool 
to determine an individual’s compatibility with prescribed medications to prevent adverse 
outcomes.  
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4.1 Introduction 
The investigations detailed in the previous chapter have demonstrated the suitability of the 
myobundle model as a physiologically relevant platform from which to assess drug-induced 
mitochondrial perturbations in skeletal muscle. Furthermore, the application of the 
myobundle platform, using cells from specific patients or patient populations, presents an 
opportunity to identify functional deficits or underlying variation which may confer 
enhanced susceptibility to drug-mediated adverse events. This is especially relevant as inter-
individual variation in response to drug treatment remains a significant clinical and public 
health burden, affecting both treatment efficacy and toxicity outcomes (Turner et al., 2015).  
Previous research has indicated that functional variation in mitochondrial respiratory 
parameters, as a downstream consequence of mitochondrial genome variation, can result in 
differential susceptibility to both complex diseases (Tanaka et al., 2007; Bai et al., 2007) and 
adverse drug reactions, as evidenced by trans-mitochondrial cybrid modelling (Canter et al., 
2010; Micheloud et al., 2011; Kampira et al., 2013). Due to the intimate link between 
oxidative metabolism and the physiological functioning of skeletal muscle in vivo, differences 
in baseline bioenergetic parameters between individuals may result in either enhanced 
resistance or susceptibility to compounds which are capable of disturbing muscular 
metabolic homeostasis. Proof-of-pharmacology modelling has demonstrated that 
simvastatin can induce subclinical mitochondrial perturbations in healthy volunteer groups 
with no prior metabolic defects (van Diemen et al., 2017). Therefore, it could be postulated 
that patients with subclinical mitochondrial insufficiencies or conditions which are 
exacerbated by exercise are more likely to experience myopathic symptoms following statin 
therapy (Herbert et al., 2018).  
These inferences have been substantiated by Schirris et al., whereby muscle biopsy samples 
taken from symptomatic patients showed a significant decrease in respiratory complex III 
enzyme activity accompanied with a decrease in mitochondrial ATP production. 
Furthermore, there was a correlation observed between complex III activity and 
symptomatic severity, with patients presenting proximal weakness exhibiting the smallest 
reduction in CIII activity and those with rhabdomyolysis displaying the greatest (Schirris et 
al., 2015). Although, it could be argued that reductions in CIII activity may have been, to a 
certain extent, due to pre-operative statin exposure rather than underlying susceptibility 
specifically.  
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Therefore, this chapter aimed to conduct a pilot study to investigate patient susceptibility to 
statin-mediated mitochondrial dysfunction by taking skeletal muscle samples from statin-
naïve and statin tolerant control groups alongside statin-intolerance cases. Isolated 
proliferative myocytes derived from the tissue samples will be used to generate myobundles 
from which baseline respiratory measures will be made in the absence of any compounds. 
Lastly, the study will investigate the effects of chronic statin treatment (atorvastatin, 
simvastatin and cerivastatin) upon ATP content and cell viability in galactose media 
concomitantly with assessments of respiratory function on the XF24 instrument. 
4.1.1 Summary of Chapter Aims 
1) To conduct a pilot study to determine whether differences exist in baseline 
mitochondrial function between myobundles produced from statin-intolerant, 
statin-tolerant and statin-naïve patients.  
2) To determine if there is differential susceptibility to statin-induced mitochondrial 
dysfunction between the three patient groups. 
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4.2 Materials and methods 
4.2.1 Materials 
4.2.1.1 Human Skeletal Muscle Samples  
A total of five statin-naïve, five statin-tolerant and two statin-intolerant participants were 
recruited to the study. Surgical waste tissue (500mg-2g) was obtained from either the 
quadriceps femoris or gluteal muscles of participants whilst they underwent orthopaedic 
surgeries at the Royal Liverpool and Broadgreen University Hospital NHS Trust (RLBUHT). 
Tissue samples were collected by the Liverpool Musculoskeletal Biobank (LMB) in accordance 
with LMB approved standard operating procedures (SOPs) and covered by LMB study 
sponsorship (UoL001361) and ethical approval (Ref 15/NW/0661). All participants gave 
written informed consent. Further details of inclusion/exclusion criteria are outlined in the 
LMB study sponsorship protocol (Appendix I). 
4.2.1.2 Reagents  
All forms of DMEM, media supplements, Hoechst Fluoropure™ and AlexaFluor® conjugated 
secondary antibodies were purchased from Life technologies (Paisley, UK). Matrigel and 
growth factor reduced (GFR) matrigel were purchased from Corning GmBH (Wiesbaden, 
Germany). Epidermal growth factor (10 µg/mL) was purchased from PeproTech (London, 
UK). Anti-desmin and anti-vimentin antibodies were purchased from Abcam (Cambridge, 
UK). Lactate dehydrogenase cytotoxicity detection kit was purchased from Roche Diagnostics 
Ltd (West Sussex, UK). Extracellular flux analyser (XF24) consumables and base medium were 
purchased from Agilent Technologies (CA, USA). All other reagents and chemicals were 
purchased from Sigma Aldrich (Dorset, UK) unless otherwise stated. 
4.2.1.3 Specialist Equipment  
Precision milled polytetrafluoroethylene (PTFE) masters for the casting of 
polydimethylsiloxane (PDMS) moulds and laser cut Cerex® frames were kindly provided by 
Dr George Truskey, Department of Biomedical Engineering, Duke University, North Carolina. 
Dow Corning Sylgard 184 PDMS kit was obtained from Ellsworth Adhesives Limited (East 
Kilbride, Scotland). 
4.2.2 Satellite Cell Isolation and General Culture Maintenance 
Satellite cells were isolated from surgical waste tissue and expanded by outgrowth as 
described in Chapter 3 (section 3.2.2) using methods similar to those described by Blau and 
Webster with amendments (Blau and Webster, 1981; Madden et al., 2015).  
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Briefly, tissue samples were collected, washed and dissected before enzymatic digestion in 
0.05 % trypsin-EDTA (37 °C) for 30 minutes.  Digested tissue fragments were pre-plated for 
two hours to dispose of remnant dermal fibroblasts prior to transfer to GFR-matrigel coated 
flasks (5 µL/mL). Myocyte populations were observed daily and expanded by outgrowth over 
a two week period. Bulk stocks were frozen using a standard cryopreservation mix which 
consisted of complete growth medium supplemented with 10% (v/v) DMSO at passage 3 
(1x106 cells/mL).  
Isolated myocytes were routinely maintained in complete growth media containing 
physiological glucose (5 mM) DMEM with sodium pyruvate and L-glutamine, supplemented 
with 8 % (v/v) FBS, 0.4 μg/mL dexamethasone, 10 ng/mL epidermal growth factor, 50 μg/mL 
fetuin, 0.1 % (v/v) gentamycin and amphotericin B. Cells were kept in vented T75 flasks 
coated in GFR-matrigel and incubated in a humidified environment (37 ᵒ C with 5 % (v/v) CO2), 
media changes were performed every 48 hours. All stock cultures were maintained at sub-
60% confluence and used at passage 4. 
4.2.3 Fluorescent Imaging 
Isolated myocytes were seeded on top of GFR-matrigel (5 μL/mL) coated 13 mm coverslips 
in 24 well plates at a density of 4500 cells/well. Cells were allowed to adhere and proliferate 
for 2-3 days before processing. The cells were rinsed with 1X PBS (-/-) before being fixed with 
cold methanol for 5 minutes. Samples were then incubated with permeabilisation buffer (1X 
PBS (-/-) with 0.2 % (v/v) Tween-20 and 0.5 % (v/v) Triton-X) for 30 minutes at 4 ᵒC and 
blocked with 5 % (w/v) BSA reconstituted in permeabilisation buffer for a further 30 minutes 
at room temperature. 
Primary antibodies, rabbit anti-desmin (1:100) and mouse anti-vimentin (1:200) were diluted 
in 5 % (w/v) BSA permeabilisation buffer and incubated with the samples overnight at 4 ᵒC. 
After thoroughly washing, appropriate Alexa Fluor® conjugated secondary antibodies (488 
nm /568 nm) were diluted 1:1000 and co-incubated with Hoechst dye (1:5000) for 2 hours, 
in the dark at room temperature. 
Samples were mounted onto glass slides for imaging. 10 µL Pro-Long Gold anti-fade reagent 
was added to each of the samples before sealing and allowing to dry overnight at 4 ᵒC. All 
images were captured using a Zeiss Axio Observer.Z1 (apotome) widefield florescent 
microscope and processed with Zen Blue software. 
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4.2.4 Fabrication of Myobundles 
Myobundles were produced from each donor using methods described fully in Chapter 3 
(section 3.2.5). Briefly, a cell solution (1x105 myocytes in 3.35 µL growth media per 
myobundle with 0.4 µL of 50 unit/ mL thrombin (reconstituted in 1X PBS supplemented with 
0.1 % fatty acid free BSA) and a hydrogel solution (0.75 µL growth medium, 1.5 µL fibrinogen 
(25 mg/mL) and 1.5 µL matrigel) were prepared in separate vials on ice for up to four 
myobundles per vial. The two solutions were combined and pipetted vigorously on ice to 
mix. 7.5 µL of the resultant cell/hydrogel mixture were individually pipetted into PDMS 
moulds, ensuring end-to-end contact with the Cerex® frames before polymerisation at 37 ᵒC 
for 25 minutes. Myobundles were maintained in complete growth media supplemented with 
1.5 mg/mL ACA for 5 days before being shifted out of their moulds and incubated in 
differentiation media supplemented with 2 mg/mL ACA for a further 5 days in dynamic 
suspension (37 ᵒC, 5 % (v/v) CO2).  
4.2.5 Acute Metabolic Manipulation using Galactose Media  
Myobundles were washed three times in glucose free DMEM supplemented with 10 mM 
galactose, 6 mM L-glutamine, 1 mM sodium pyruvate, 5 mM HEPES, 10 nM human insulin, 
0.1 % gentamycin and amphotericin B, 2 % horse serum and 2 mg/mL ACA. Myobundles were 
then pre-incubated in galactose media (50 µL) for 2 hours (37 ᵒC, 5 % (v/v) CO2) to induced 
metabolic adaptation. 
Stock solutions for atorvastatin acid (AVA), cerivastatin acid (CVA) and simvastatin lactone 
(SVL) were prepared in DMSO and diluted in galactose assay media to produce final well 
concentrations of 0.5 µM. Diluted stock compounds were then added to each respective well 
(50 µL) for a final well volume of 100 µL. The solvent concentration for all conditions was 0.5 
% DMSO. Myobundles were incubated with compounds for a total of 120 hours in dynamic 
suspension (37 ᵒC, 5 % (v/v) CO2), the dosing medium was refreshed every 24 hours.  
4.2.6 Combined Lactate Dehydrogenase (LDH) and ATP assays 
Myobundles conditioned to galactose media were incubated with their respective drug 
solutions for 120 hours. Supernatant samples were collected at each 24 hour time point and 
myobundles were sonicated in 100 µL of somatic cell ATP releasing agent at the end of the 
120 hour period. ATP content, cell viability and protein content were simultaneously 
assessed.  
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4.2.6.1 ATP Assay 
Quantitative determination of ATP content was assessed by the addition of lysates (5 µL) and 
ATP standards to a white-walled 96-well plate. ATP reaction solution was prepared according 
to manufacturer’s instructions by mixing ATP assay mix with ATP dilution buffer in a 1:25 
ratio. 40 µL of the reaction solution was added to both samples and standards then read 
immediately on a Varioskan™ Flash multimode plate reader with SkanIt™ software to 
capture the peak luminescent signal. 
4.2.6.2 LDH Assay 
Detection of cytotoxicity was achieved using a colorimetric LDH assay kit. LDH retention was 
determined by extracting 25 µL supernatant at each 24 hour time point and 10 µL lysate for 
each sample and incubating them with 50 µL LDH catalyst-dye solution (1:45 ratio), according 
to manufacturer’s instructions. After 30 minutes incubation in the dark, samples were read 
at 490 nm on a Varioskan Flash multimode plate reader. LDH retention was determined as:  
𝐋𝐃𝐇 𝐑𝐞𝐭𝐞𝐧𝐭𝐢𝐨𝐧 =  
𝐋𝐲𝐬𝐚𝐭𝐞 
(𝐒𝐮𝐩𝐞𝐫𝐧𝐚𝐭𝐚𝐧𝐭 + 𝐋𝐲𝐬𝐚𝐭𝐞)
  
4.2.6.3 BCA Assay  
In order to correct for potential variance in cell number, the BCA assay was used to normalise 
ATP assay results. Quantification of protein content was determined using 10 µL lysate and 
protein standards. The BCA reagent was prepared according to manufacturer’s instructions 
by mixing bicinchoninic acid with copper (II) sulphate in a ratio of 50:1. Assay products were 
read at 562 nm after 30 minutes incubation at 37 ᵒC. 
4.2.7 Extracellular Flux Analyser Assays (XF24)  
Myobundles were fabricated and differentiated as described in section 4.2.4, baseline 
metabolic parameters were determined for each donor in the absence of any compounds in 
accordance with Chapter 3 (section 3.2.10). In addition, myobundles produced from each 
donor were treated with a panel of statins. Stock solutions for AVA, CVA and SVL were 
prepared in DMSO and diluted in differentiation medium supplemented with 2 mg/mL ACA 
to produce a final concentration of 0.5 µM. Diluted compounds were added to their 
respective wells (100 µL). The solvent concentration for all conditions was 0.5 % DMSO. 
Myobundles were incubated with compounds for a total of 120 hours in dynamic suspension 
(37 ᵒC, 5 % (v/v) CO2), the dosing medium was refreshed every 24 hours. On the day of the 
assay, myobundles were moved to XF24 cell culture microplates coated with neat GFR-
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matrigel and orientated horizontally within the wells to align with the XF24 sensor cartridge 
probes.  
Following the completion of XF assays, myobundles were pulse sonicated (10s) in 100 µL 
somatic cell ATP releasing agent. Lysates (10 µL) were transferred to a 96-well plate for 
quantification of protein content by BCA assay. Protein content per myobundle was used as 
a means to normalise raw OCR and ECAR data.  
4.2.7.1 Mitochondrial Stress Test 
Myobundles were incubated for 1 hour (37 ᵒ C, 0 % CO2) prior to the start of the assay. Culture 
medium was replaced with 450 µL unbuffered XF base medium supplemented with glucose 
(25 mM), L-glutamine (2 mM), sodium pyruvate 1 mM) and pre-warmed to 37 ᵒC (pH 7.4).  
4.2.7.1.1 Stress Test Compound Preparation 
Stock mitochondrial stress test compounds were prepared and loaded into XF sensor 
cartridges in accordance with Table 4.1. Optimal stress test compound concentrations were 
determined empirically.  
Table 4.1 Mitochondrial stress test injection port locations, compound stock concentrations, dilution 
factors and final well concentrations for the XF24. 
 
Each run included a pre-programmed calibration, an equilibration step and 3 cycles of 
mix/measure/wait (3 mins/3 mins/0 mins) to establish a baseline OCR/ECAR rate prior to the 
injection of any compounds. Following this, a stress test was performed via the sequential 
injection of mitochondrial toxicants. This enabled the calculation of basal respiration, 
maximal respiratory capacity, ATP-linked respiration, proton leak and spare respiratory 
capacity.  
4.2.8 Statistical Analysis  
Data are representative of at least three myobundles (n=3) per donor for each condition. All 
values are expressed as mean ± standard deviation (S.D.). Statistical analyses were 
performed using GraphPad Prism® 7 software (GraphPad Software, Inc, CA, USA).  
Injection 
Port 
Compound Port 
Dilution 
Factor 
Final well 
concentration 
Port Loading 
Volume  
A Oligomycin 10 10 µM 50 µL 
B FCCP 10 6 µM 55 µL 
C FCCP 10 4 µM 62 µL 
D Rotenone/Antimycin 
A 
10 10 µM 68 µL 
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4.3  Results 
4.3.1 Participant Characteristics  
A summary of patient characteristics are presented in Table 4.2. A total of 12 patients were 
recruited to the study, with an even distribution of male and female participants. The 
majority of participants (83.3 %) were of a white British ethnic background with the 
remainder being of African (8.35 %) or Caribbean (8.35 %) descent respectively. There were 
no significant differences in the mean age, height, weight or BMI between the study groups 
(naïve, tolerant and intolerant). Patients within the statin intolerant group were classified as 
SRM 1,  tolerable myalgia without CK elevation, in line with the Phenotype Standardization 
for Statin-Induced Myotoxicity definitions (Alfirevic et al., 2014). In both cases, statin 
treatment had been withdrawn, however one participant was still experiencing muscle pain 
at the time of sampling. None of the participants recruited to the study had any prior history 
of diabetes or known underlying metabolic disorders, with the exception of one statin 
intolerant donor who suffered from hypothyroidism.  
Table 4.2 Summary of study participant characteristics. Statistical significance was determined by one-
way ANOVA with Dunnett’s test for multiple comparisons. 
 Statin Naïve 
(n=5) 
Statin Tolerant 
(n=5) 
Statin Intolerant 
(n=2) 
Gender 
Male  
Female  
   
4 2 0 
1 3 2 
Ethnicity 
White British 
African 
Caribbean 
   
3 5 2 
1 - - 
1 - - 
Age (y), mean ± S.D. 67.2 ± 12.75 
(NS) 
71.8 ± 4.26 
(NS) 
64.5 ± 8.50 
(NS) 
Height (m), mean ± S.D. 1.708 ± 0.06 
(NS) 
1.634 ± 0.09 
(NS) 
1.585 ± 0.065 
(NS) 
Weight (kg), mean ± S.D. 
 
80.54 ± 13.31 
(NS) 
80.66 ± 6.18 
(NS) 
81.65 ± 14.35 
(NS) 
BMI (kg/m2), mean ± S.D. 27.65 ± 4.62 
(NS) 
30.49 ± 4.12 
(NS) 
32.19 ± 3.06 
(NS) 
Statins  
Atorvastatin  
Simvastatin  
   
- 3 1 
- 2 1 
Dose (mg/d) 
20 
40 
80 
   
- 4 1a 
- - 2 
- 1 - 
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SRM Classificationb 
SRM 1c 
   
- - 2 
Exercise Intolerance  
Yes  
No  
   
- - - 
- - 2 
Statin Withdrawal  - - 2 
Symptom Resolution 
Yes  
No  
   
- - 1 
- - 1 
Smoking Status  
Non-Smoker  
Current  
Previous  
   
4 3 1 
- - 1 
1 2 - 
Alcohol (Units/Week) 
<1 
1-5 
6-14 
22-49 
   
2 2 1 
2 1 - 
1 - 1 
- 2 - 
Co-medication  
Antihypertensivesd 
Analgesics  
Proton Pump Inhibitors 
Laxatives  
Antihistamines  
Vertigo Medication 
NSAIDS 
Antidepressants  
Nutritional Supplements  
Antimuscarinics  
Corticosteroids  
β2 adrenergic agonists 
Anti-gout  
Hormone Replacement  
Anti-malarial  
Steroid Medication   
Hypothyroidism Medication 
   
2 5 1 
2 2 1 
2 5 1 
- 3 - 
1 - - 
1 - - 
2 3 1 
- 2 - 
1 1 1 
- 1 - 
- 1 - 
- 1 - 
- 1 - 
- - 1 
- - 1 
- - 1 
- - 1 
Biopsy Location  
Quadriceps Femoris  
Gluteal Muscles   
   
3 3 2 
2 2 0 
a Statin dosage was dropped from 40 mg/day to 20 mg/day. b SRM definitions are in line with 
Phenotype Standardization for Statin-Induced Myotoxicity (Alfirevic et al., 2014). c SRM 1 is defined as 
tolerable myalgia without creatine kinase (CK) elevation. d Composite drug class including angiotensin 
converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta blockers, calcium channel 
blockers, diuretics and vitamin K antagonists. Abbreviations: NS, not significant; SRM, statin-related 
myopathy; NSAIDS, nonsteroidal anti-inflammatory drugs. 
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In addition, the proportion of myocytes and fibroblasts isolated from the tissue samples of 
each participant were determined by fluorescent imaging to ensure that there was an 
enriched myocyte population for the generation of myobundles (Table 4.3).  
Table 4.3 Proportion of myocytes and fibroblasts present in cultures isolated from each participant at 
passage 3. Four random images per slide were taken for each slide (n=4). Average counts were 
performed using ImageJ 1.48 software. 
 
 
 
Patient Group  Participant ID  Vimentin only (%) 
 
Desmin & vimentin (%) 
 
Statin Naïve  
LMB-HI-229 10.8 89.2 
LMB-PP-231 4.4 95.6 
LMB-JB-232 7.6 92.4 
LMB-TA-237 4.1 95.9 
LMB-MH-241 3.7 96.3 
Statin Tolerant  LMB-JB-228 2.4 97.6 
LMB-GD-230 8.4 91.6 
LMB-DJ- 233 6.9 93.1 
LMB-DR-234 38.4 61.6 
LMB-AS-236 3.9 96.1 
Statin Intolerant  LMB-RS-238  1.5 98.5 
LMB-BM-239 4.5 95.5 
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4.3.2 The Effect of Chronic Statin Application upon ATP Content and Viability 
 Patient derived myobundles conditioned to galactose media were exposed to a panel of 
statins for 120 hours (Figure 4.1). Exposure to atorvastatin and cerivastatin caused a 
significant decrease in ATP content and LDH retention in each patient group when compared 
with their respective vehicle controls. However, there were no significant differences 
between the patient groups in either of the tested parameters, an observation which was 
consistent across each of the statins. The statin tolerant group tended to remain marginally, 
albeit non-significantly, more viable than the naïve and the intolerant groups when 
challenged with equimolar concentrations of atorvastatin and cerivastatin. Interestingly 
within the statin intolerant group, ATP depletion appeared to precede loss of LDH retention, 
a trend which was more pronounced in the presence of cerivastatin (46.5 % LDHgal vs 25.5 
% ATPgal) (Figure 4.1 (C)).  
Figure 4.1 Examining the effect of chronic statin exposure upon ATP content and LDH retention in 
patient derived myobundles (120 hours) compared with the vehicle control in galactose media. (A) 0.5 
µM atorvastatin hydroxy acid, (B) 0.5 µM simvastatin lactone and (C) 0.5 µM cerivastatin hydroxy acid. 
Results are expressed as a percentage of the vehicle control and graphical values are displayed as 
mean ± S.D. (n=4 myobundles per condition, per donor). Statistical significance between patient 
groups was determined by two-way ANOVA with Dunnett’s test for multiple comparisons or t-test 
with Welch’s correction to compare within groups back to the vehicle control (on top of bars) *p value 
< 0.05 **p value < 0.01 ***p value < 0.001. 
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4.3.3 Functional Assessment of Patient Baseline Bioenergetic Parameters 
Assessment of baseline mitochondrial respiratory function using extracellular flux analysis 
and a mitochondrial stress test showed no significant differences between the myobundles 
of statin naïve, statin tolerant or statin intolerant patients in multiple bioenergetic 
parameters (Figure 4.2 (A-F)). However, the statin tolerant patients appeared to dedicate a 
significantly greater proportion of their maximal respiratory capacity to spare respiratory 
capacity when compared to the statin naïve and statin intolerant groups (23.73 % and 25.17 
% difference respectively) (Figure 4.2 (G)). No such differences were observed for proton 
leak or ATP-linked respiration as proportions of maximal respiratory capacity or basal 
respiration (Figure 4.2 (G-H)). 
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Figure 4.2 Untreated myobundles produced from the primary myocytes of statin naïve, statin tolerant 
and statin intolerant patients were assessed using a XF24 analyser and a mitochondrial stress test to 
determine: basal respiration (A), maximal respiration (B), proton leak (C), ATP-linked respiration (D), 
spare respiratory capacity (E) and % coupling efficiency (F). Respiratory parameters expressed as a 
proportion of maximal respiratory capacity (G), parameters expressed as a proportion of basal 
respiration (H). All values are displayed as mean ± S.D. (minimum of n=5 myobundles per donor). 
Statistical significance was determined by one-way ANOVA with Dunnett’s test for multiple 
comparisons *p value < 0.05 **p value < 0.01 ***p value < 0.001.  
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4.3.4 The Effect of Atorvastatin upon Myobundle Bioenergetic Parameters 
Assessment of the respiratory integrity of patient derived myobundles was performed using 
XF analysis after atorvastatin exposure (Figure 4.3).  There were no significant differences 
between the patient groups in any of the tested metabolic parameters in control or 
atorvastatin treated myobundles, however the statin intolerant group were the most 
sensitive to atorvastatin exposure.  
Although atorvastatin caused a ubiquitous decrease in OCR values for each metabolic 
parameter when compared back to the respective group controls, this only reached 
Figure 4.3 Examining the effect of chronic atorvastatin exposure upon mitochondrial function in 
patient derived myobundles (120 hours) compared with vehicle. (A) basal respiration, (B) maximal 
respiration, (C) proton leak, (D) ATP-linked respiration and (E) spare respiratory capacity. Graphical 
values are displayed as mean ± S.D. (n=5 myobundles per condition, per donor). Statistical significance 
was determined between patient groups by one-way ANOVA with Dunnett’s test for multiple 
comparisons or unpaired t-test with Welch’s correction within groups *p value < 0.05 **p value < 0.01 
***p value < 0.001. Abbreviations: AVA, atorvastatin hydroxy acid. 
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statistical significance for ATP-linked respiration in the statin-naïve myobundles (Figure 4.3 
(D)).  
4.3.5 The Effect of Simvastatin upon Myobundle Bioenergetic Parameters 
Parameters assessed during XF analysis did not significantly differ between the three patient 
groups in response to simvastatin exposure (Figure 4.4). Similarly, there were no significant 
differences observed between control and simvastatin treated myobundles within each of 
the groups despite marginal reductions in OCR values.  
  
Figure 4.4 Examining the effect of chronic simvastatin exposure upon mitochondrial function in 
patient derived myobundles (120 hours) compared with vehicle control. (A) basal respiration, (B) 
maximal respiration, (C) proton leak, (D) ATP-linked respiration and (E) spare respiratory capacity. 
Graphical values are displayed as mean ± S.D. (n=5 myobundles per condition, per donor). Statistical 
significance was determined between patient groups by one-way ANOVA with Dunnett’s test for 
multiple comparisons or unpaired t-test with Welch’s correction within groups. Abbreviations: SVL, 
simvastatin lactone. 
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4.3.6 The Effect of Cerivastatin upon Myobundle Bioenergetic Parameters 
Cerivastatin treated myobundles from each patient group exhibited a decline in bioenergetic 
function when compared with their controls, an effect which was particularly prominent 
within basal and ATP-linked respiration (Figure 4.5 (A-D)). There was no significant difference 
in spare respiratory capacity compared with control for any group (Figure 4.5 (E)).  
Despite the obvious effect of cerivastatin upon respiratory function, there was no statistically 
significant differential toxicity observed between the three patient groups in any of the 
assessed parameters. 
Figure 4.5 Examining the effect of chronic cerivastatin exposure upon mitochondrial function in 
patient derived myobundles (120 hours) compared with vehicle control. (A) basal respiration, (B) 
maximal respiration, (C) proton leak, (D) ATP-linked respiration and (E) spare respiratory capacity. 
Graphical values are displayed as mean ± S.D. (n=5 myobundles per condition, per donor). Statistical 
significance was determined between patient groups by one-way ANOVA with Dunnett’s test for 
multiple comparisons or unpaired t-test with Welch’s correction within groups *p value < 0.05 **p 
value < 0.01 ***p value < 0.001. Abbreviations: CVA, cerivastatin hydroxy acid. 
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4.4 Discussion 
The aim of this chapter was to generate myobundles, a biomimetic skeletal micro-tissue 
model, using myocytes derived from five statin naïve, five statin tolerant and two statin 
intolerant patients using methods described in chapter 3. As previous literature had 
indicated a role for subclinical mitochondrial insufficiencies in the aetiology of statin-induced 
myopathy, myobundles were utilised, for the first time,  to conduct a small-scale pilot study 
to determine if variance(s) in baseline mitochondrial function exist between the three 
patient groups (Schirris et al., 2015; Allard et al., 2018; van Diemen et al., 2017; Sirvent et 
al., 2012). In addition, parallel investigations were conducted to determine if functional 
variation(s) in mitochondrial respiratory parameters between groups correlated with 
enhanced or diminished susceptibility to statin-mediated mitochondrial impairment.  
All patients recruited to the study were of a similar mean age, height, weight and body mass 
index (BMI). In accordance with National Health Service (NHS) definitions, the mean BMI for 
the statin naïve group was within the overweight range (27.65) whereas the mean BMI for 
the statin tolerant and intolerant groups fell into the obese range (30.41 and 32.19 
respectively). There is evidence to suggest that excessive nutrient consumption adversely 
affects skeletal muscle mitochondrial dynamics, increases ROS generation and impairs 
insulin-dependent glucose transport (de Mello et al., 2018). Therefore, it was of importance 
to use patients of a similar BMI, within the statin naïve group particularly, to ensure that any 
phenotypic differences observed were not due to the presence of inherent pathological 
processes in some groups and not others (Herbert et al., 2018). In order to address any 
further confounding effects upon mitochondrial functionality, patients receiving co-
medications with known mitochondrial liabilities or patients with diagnosed metabolic 
disorders were excluded from the study. This was with the exception of one statin intolerant 
donor owing to the low number of suitable candidates encountered during the recruitment 
period. 
In addition, due to the practicalities of recruiting patients through the Liverpool 
Musculoskeletal Biobank (LMB), it was not possible to collect venous blood samples to gather 
data on serological markers such as serum lipids (total, HDL-C, LDL-C and triglycerides), CK, 
and alanine aminotransferase (ALT) at the time of sampling. Any supplemental data gathered 
via the patient case report forms (CRF), including co-morbidities, are outlined in the 
appendices (Appendix II). 
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Initial extracellular flux analyses identified marginal differences in most baseline metabolic 
parameters between the patient groups, however none of these variations reached 
statistical significance. Concordantly, coupling efficiency, the proportion of OCR dedicated to 
driving ATP synthesis, did not differ between groups. When examining proton leak, ATP-
linked respiration and spare respiratory capacity as proportions of the maximal respiratory 
capacity, the statin tolerant group dedicated a greater percentage of maximal OCR to spare 
capacity compared with the statin naïve and statin intolerant patients. Spare respiratory 
capacity has been linked to a regulated increase in substrate flux into the TCA cycle 
concomitantly with elevated succinate dehydrogenase (complex II) activity in response to 
stressors or increased functional demand. Moreover, reserve capacity, via complex II, has 
been shown to promote cellular survival through sirtuin-3 (SIRT3) dependent mechanisms in 
several cell types (Nickens et al., 2013; Dhingra and Kirshenbaum, 2015; Yadava and Nicholls, 
2007; Pfleger et al., 2015).  
Therefore, it would be of merit to investigate the putative link between statin tolerance, 
succinate dehydrogenase activity and spare respiratory capacity, particularly as it has been 
shown that complex II activity is significantly reduced in symptomatic statin users  (Allard et 
al., 2018) and sub-groups of healthy volunteers treated with high dose (80 mg/kg) 
simvastatin (Galtier et al., 2012). Furthermore, succinate-driven respiration was impaired by 
simvastatin administration in L6 myocytes as evidenced in Chapter 2, providing the impetus 
to determine whether increased complex II activity confers enhanced resistance to statin-
mediated mitochondrial dysfunction. 
The effect of chronic statin application upon ATP content and LDH retention was examined 
in patient-derived myobundles conditioned to galactose media. This was performed to 
determine drug response in the absence of compensatory ATP generation from glycolysis 
(Marroquin et al., 2007; Kamalian et al., 2015). Whilst myobundle ATP content reduced, most 
notably with atorvastatin and cerivastatin exposure, the simultaneous loss of LDH retention 
was more indicative of cytotoxicity rather than mitochondrial dysfunction specifically (Swiss 
et al., 2013). In addition, there was no significant differential toxicity observed between the 
patient groups when exposed to any of the test compounds. However, myobundles 
produced from statin tolerant patients appeared to remain slightly more viable, particularly 
those treated with atorvastatin. 
Interestingly, within the statin intolerant group, there was a greater decline in ATP content 
than LDH retention. Loss of ATP before the induction of cell death in galactose media is one 
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of the hallmarks of mitochondrial dysfunction and aligns with the idea that changes in 
mitochondrial function may be an early event in the pathophysiology of statin-induced 
myotoxicity (Sirvent et al., 2012; Allard et al., 2018). This could be substantiated by 
performing dose responses for each statin and comparing IC50 values across several time 
points to pin point the induction of mitochondrial changes. 
Whilst not considered within the present chapter, longitudinal interrogation of inter-
mitochondrial dynamics (i.e. fusion and fission of mitochondrial networks) and intra-
mitochondrial dynamics (i.e. the assembly of respiratory super-complexes) warrants 
investigation. It has been suggested that respiratory super-complex assembly modulates 
mitochondrial fuel utilisation and may be essential for overcoming the impact of drug-
mediated perturbations upon the respiratory chain (Acin-Perez and Enriquez, 2014). 
Furthermore, striated muscle mitochondria establish themselves within a highly convoluted 
network or ‘power grid’ known as the mitochondrial reticulum. The reticulum is thought to 
mediate both proactive and reactive functions, such as the distribution of potential energy 
or the physical separation of malfunctioning mitochondria to limit the impact of local 
dysfunction (Glancy et al., 2015, 2017). Indeed, a lack of mitochondrial fusion within skeletal 
muscle fibers is associated with a pathological profile which resembles mitochondrial 
myopathies associated with mtDNA depletion syndromes (Chen et al., 2010; Copeland, 
2008).  
When the respiratory function of myobundles was measured upon treatment with the three 
different statins, results indicated that there were no significant differences between the 
patient groups for any of the tested parameters. In agreement with the LDH-ATP data 
(section 4.3.2), cerivastatin had the most profound effect upon respiration. Though it could 
be argued that some of these effects may be attributable to loss of myobundle viability 
rather than mitochondrial dysfunction alone. Disturbances in oxidative metabolism were 
also evident in both the statin naïve and statin tolerant groups after treatment, this parallels 
with the idea that mitochondrial impairment can also occur in patients without muscle 
complaints or prior exposure to statins (Allard et al., 2018).  
An interesting observation garnered from the respirometry data was that proton leak 
appeared to decrease in response to atorvastatin and cerivastatin exposure for each patient 
group. Dysfunctional mitochondria often have elevated proton leak due to increased 
uncoupling protein (UCP) activity, inner mitochondrial membrane damage, complex 
inhibition or electron slippage. In contrast, reduced leak is often associated with reduced 
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UCP activity and enhanced respiratory chain integrity (Hill et al., 2012). This phenomenon 
may be explained by considering the bioenergetic status of the myobundles before the 
addition of drug. As a percentage of basal respiration, proton leak constituted a pooled 
average of 34.4 %, 29.2 % and 32.1 % of the statin naïve, tolerant and intolerant myobundles 
respectively (section 4.3.3). Native skeletal muscle is known to exhibit a high proportion of 
basal proton leak, a by-product of mild uncoupling to increase energy expenditure for 
thermogenesis, particularly in response to cold exposure or nutrient excess (Wijers et al., 
2008; Rolfe et al., 1999). Therefore, the reduction in proton leak may be suggestive of 
improved coupling in an attempt to maintain energetic homeostasis after drug treatment. In 
order to robustly assess the kinetics of proton conductance, both respiration and 
mitochondrial membrane potential must be quantified simultaneously as respiration alone 
is an indirect and oversimplified measure (Divakaruni and Brand, 2011). 
Failure to detect significant differences between patient groups, with particular reference to 
the statin-intolerant group, could be owing to a number of different factors. Firstly, the 
recruitment of patients through the LMB meant that identification of suitable candidates 
was performed via pre-surgical assessment. Therefore, encountering patients with a history 
of statin-intolerance was down to chance rather than through patient recall, resulting in 
lower participant numbers. Secondly, the statin-intolerant donors recruited to the study 
were categorised as SRM 1, tolerable myalgia without CK elevation. It may be that patients 
with a severe myopathy phenotype (SRM 3-5) would exhibit greater variation in metabolic 
parameters, though these cases are considerably rarer (Table 4.4). However, assessment of 
milder myopathy phenotypes is still of merit as they can lead to poor quality of life, reduced 
drug compliance and propagate failure to prevent adverse cardiovascular events (Alfirevic et 
al., 2014).   
Table 4.4 Statin-related myotoxicity (SRM) phenotype classifications and incidences, adapted from 
(Alfirevic et al., 2014). 
Classification Phenotype  Incidence  
SRM 0 CK elevation <4x ULN 1.5-26 % 
SRM 1 Myalgia, tolerable  190/100000 patient-years; 0.3-33 % 
SRM 2 Myalgia, intolerable  0.2-2/1000 patients 
SRM 3 Myopathy  5/100000 patient-years 
SRM 4  Severe myopathy  0.11 % 
SRM 5  Rhabdomyolysis  0.1-8.4/100000 patient-years  
Abbreviations: CK, creatine kinase; ULN, upper limit of normal.  
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In addition, the use of XF respirometry, a platform originally intended to monitor the 
respiratory function of cells grown in monolayer, yields inherently more variable OCR/ECAR 
readings when used in conjunction with three-dimensional, micro-tissue constructs. 
Improper or incomplete alignment of myobundles underneath the sensor cartridge probes 
results in measurements being taken over empty space thus precipitating variation between 
myobundles generated from the same donor.  
The endpoint measures used within this study represent a fraction of the interrogations 
which could be performed to assess mitochondrial health. Particularly, optimisation of the 
respiratory complex assays for use with the myobundles in tandem with mitochondrial 
genotyping may help to reveal some of the more subtle differences in metabolic enzyme 
activities between the patients groups whilst providing a deeper mechanistic insight to the 
nature of compound-induced mitochondrial liabilities. This is especially relevant as different 
statins may not affect the respiratory chain in the same manner (Nadanaciva et al., 2007; 
Herbert et al., 2018; Sirvent et al., 2012; Schirris et al., 2015).  
4.5 Conclusions 
Results from this chapter indicate that impairment of mitochondrial function occurs with 
statin administration regardless of patient status. However, the statin intolerant participants 
did not appear to be any more susceptible than the naïve or tolerant groups within this study, 
though this may be due to a combination of mild phenotypic severity and low participant 
numbers. Further longitudinal studies are required to determine if changes in mitochondrial 
function are an early event in the aetiology of myopathy and could therefore be used as a 
prognostic tool or be mitigated completely by enhancing mitochondrial function (Allard et 
al., 2018; Andreux et al., 2014). Crucially, this chapter demonstrates that it is important to 
consider not only the factors which may confer enhanced susceptibility to adverse drugs 
reactions but also those which are protective.  
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5.1 Introduction  
The principle aim of personalised medicine is to predict the clinical outcome of a given drug 
treatment in different patients with view to tailoring treatment regimens to the individual. 
Pharmacogenomics, the branch of science concerned with the interaction between genetic 
factors and drug response, forms one of the core components of personalised medicine 
(Schwab and Schaeffeler, 2012). By its very definition, pharmacogenomics encompasses the 
study of both the nuclear and mitochondrial genomes. However, the contribution of 
mitochondrial genome variation upon differential susceptibility to adverse drug reactions 
has, so far, been studied considerably less within the field (Chapter 1, section 1.6.8).  
Throughout human history the mitochondrial genome has accumulated single nucleotide 
polymorphisms (SNPs) which, in the absence of bi-parental recombination, have formed a 
nested phylogenetic tree (Neiman and Taylor, 2009). The major subdivisions of the global 
phylogeny are known as mtDNA haplogroups. Greater than 95 % of Europeans belong to one 
of ten macro-haplogroups, H, J, T, U, K (subgroup of U), M, I, V, W and X, each of which are 
defined by specific set of sequence variations. mtDNA haplogroups affect the assembly, 
stability and functionality of the mitochondrial respiratory chain, therefore mitochondrial 
genome variation has the propensity to confer enhanced or diminished risk of mitochondrial 
dysfunction under certain pathological conditions (Chinnery et al., 2010). Indeed there is a 
growing body of evidence indicating that mitochondrial dysfunction, as a downstream 
consequence of mitochondrial genome variation, is a critical component in the aetiology of 
a number of complex traits and diseases  (Hudson et al., 2014).  
Prior research concerning potential genetic determinants of statin-related myopathy (SRM) 
have been conducted extensively in the context of the nuclear genome. Early investigations 
focussed upon candidate genes hypothesised to play a role in SRM by virtue of their 
implication in the metabolism, transport or action of statins (Table 5.1) (Brunham et al., 
2018). However, whilst these studies have been successful in identifying potential 
associations between candidate genes and the development of SRM, most have not been 
widely replicated with the exception of the coding variant rs4149056 (p.Val174Ala) in the 
SLCO1B1 gene (Link et al., 2008). 
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Table 5.1 Examples of genetic variants, encoded by the nuclear genome, associated with elevated or 
diminished risk of statin-related myopathy. Table adapted from Brunham et al., 2018.  
 
To date there have been no large scale case-control studies examining the influence of 
mitochondrial genome variation upon susceptibility to statin-related myopathy. Small in 
vitro studies have demonstrated that fibroblasts isolated from patients with complex III 
deficiencies were more sensitive to statin lactones than those from healthy controls (Schirris 
et al., 2015). However, whilst complex III deficiencies are commonly associated with 
mutations in the mtDNA MT-CYB (cytochrome b subunit) gene, insufficiencies can also arise 
from mutations in one of several genes encoded by the nuclear genome (e.g. BCS1L and QP-
C) (Bénit et al., 2009). In addition, in vitro studies using trans-mitochondrial, cytoplasmic 
hybrid (cybrid) modelling have shown that an individual’s mtDNA background, specifically 
mutations in cytochrome c oxidase subunit 1 (COX1, T6124C, Met74Thr), affect the degree 
to which simvastatin affects prostate cancer progression (Sun et al., 2015).  Therefore, given 
the role of mitochondrial dysfunction in the aetiology of statin-related myopathy, there is 
rationale behind the hypothesis that inter-individual variation in the mitochondrial genome 
may contribute, at least in part, to an enhanced or diminished susceptibility to myopathic 
symptoms in patients. 
Gene Variant  Function of Encoded Protein  References  
SLCO1B1 rs4149056 Solute carrier organic anion 
transporter (liver) 
(Voora et al., 2009; Carr et al., 
2013; Brunham et al., 2012; 
Link et al., 2008) 
COQ2 rs4693075 Ubiquinone biosynthesis  (Ruano et al., 2011; Oh et al., 
2007) 
HTR7 rs1935349 Serotonin receptor  (Ruano et al., 2007) 
RYR1 rs118192172 Calcium channel (skeletal muscle) (Vladutiu et al., 2011) 
GATM rs9806699 Creatine biosynthesis  (Luzum et al., 2015; 
Mangravite et al., 2013; Floyd 
et al., 2014) 
CYP3A4 rs2740574 Drug metabolism  (Becker et al., 2010) 
CYP2D6 *4 Drug metabolism  (Mulder et al., 2001; Frudakis 
et al., 2007) 
UGT1A3 *2 Drug metabolism  (Riedmaier et al., 2010) 
ABCC2 rs717620 ATP-binding cassette transporter  (Becker et al., 2013) 
RYR2 rs2819742 Calcium channel (cardiac muscle) (Feng et al., 2012; Hubacek et 
al., 2015; Marciante et al., 
2011) 
CLCN1 rs55960271 Voltage-dependent chloride 
channel  
(Neroldova et al., 2016) 
VDR rs731236 Vitamin D3 receptor  (Ovesjo et al., 2016) 
ABCG2 rs2231142 ATP-binding cassette transporter (Mirosevic Skvrce et al., 2015) 
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The present chapter aimed to use a combination of next-generation sequencing (NGS) 
technology and bioinformatics analyses to identify and compare sequence variation across 
the entire mitochondrial genomes of both a healthy volunteer cohort consisting of 342 
individuals and a statin myopathy, case-control cohort consisting of 555 patients.  The use of 
NGS allowed for the identification of genome wide heteroplasmic variants in > 1 % of mtDNA 
copies; in contrast with other currently used mitochondrial sequencing methodologies such 
as Sanger sequencing that can only detect variants that are present in > 10 % of mtDNA 
copies (Kloss-Brandstatter et al., 2015). 
 To achieve this, genomic DNA was extracted from the whole blood of 264 statin myopathy 
cases (SRM 3-6), 291 statin-tolerant controls and 342 healthy volunteers prior to the use of 
multiplexed amplicon tagging (Fluidigm Access Array) to enable the simultaneous 
sequencing of samples (Illumina MiSeq). Concordance between four different variant calling 
methods were assessed after inputting data into HaploGrep2 for the classification of samples 
into their macro- and sub-haplogroups. Haplogroup frequencies were compared across 
groups to determine if there was a putative association between mitochondrial haplogroup 
and statin-related myopathy.  
5.1.1 Summary of Chapter Aims  
1. To perform next-generation whole mitochondrial genome sequencing of cohort 
samples. 
2. To perform classification of mitochondrial DNA variants into both macro- and sub-
haplogroups using HaploGrep2 software. 
3. To conduct an mtDNA haplogroup-disease association study for statin-related 
myopathy. 
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5.2 Methods  
5.2.1 Cohort  
The analysed statin myopathy case and tolerant control cohort were recruited as part of the 
PREDICTION-ADR consortium, funded by the EU Seventh Framework Programme, with study 
approval granted by the North West of England Research Ethics Committee: STAGE (REC 
reference number: 09/H1001/38) and MOLGEN (REC reference number: 09/H1005/28) . All 
participants gave written informed consent. Study eligibility and inclusion criteria have been 
published previously (Siddiqui et al., 2017a; Siddiqui et al., 2017b). 
Briefly, 555 patients (264 statin-related myopathy cases and 291 statin-tolerant controls) 
were recruited from four European centres (Liverpool, Dundee, Uppsala and Utrecht). The 
cohort consisted of 35 % female and 65 % male participants with a mean age of 71 years 
(range 39-93 years). All patients were of Caucasian descent. Most patients were receiving 
simvastatin (n=339) followed by atorvastatin (n=162), pravastatin (n=28), rosuvastatin 
(n=20), fluvastatin (n=5) and drug unknown (n=1).  
The analysed healthy volunteer cohort were selected from a study published by Faulkner et 
al., during which 1000 volunteers were recruited from the North West of England and 100 
mL whole blood was collected for DNA extraction (Faulkner et al., 2016; Alfirevic et al., 2012). 
The study was approved by the North West of England Research Ethics Committee and all 
participants gave written informed consent (REC reference number: 09/H1005/10). The most 
recently collected 342 samples of Caucasian descent were selected for analysis. The 
volunteer cohort was 63.7 % female and 36.3 % male with a mean age of 29 years (range 18-
60 years).  
Volunteers were eligible to take part in the study if they were healthy, aged between 18 and 
60 years and willing to donate one or more blood samples. Volunteers were excluded from 
participation if they had: donated blood to the transfusion services in the last four months, 
had any medical problems; inclusive of asthma, diabetes, epilepsy and anaemia or taken 
medicinal or recreation drugs within the last 6 weeks. Women were excluded if pregnant.  
5.2.2 DNA Extraction  
Genomic DNA was extracted from whole blood samples using the Chemagen magnetic 
separation module 1 (PerkinElmer, Buckinghamshire, UK). Briefly, the Chemagen module 
enables the separation of nucleic acids from biological samples through highly specific 
binding to M-polyvinyl alcohol (PVA) magnetic beads. The PVA beads are attracted to 
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magnetised rods that are inserted into the samples. The magnetised rods transfer the bead 
bound DNA through several washing and elution steps. The rod rotation, switched on after 
the deactivation of the electromagnet, efficiently resuspends the beads after each step. 
5.2.3 DNA Quality Control  
Quality control of the resultant DNA samples was performed using nanodrop 
spectrophotometry (Thermo Fisher Scientific, Loughborough, UK). Samples with an A260/230 
>1.8 and A260/280 >1.9 were deemed acceptable for downstream processing. Sample quality 
was also monitored using 2 % E-gel electrophoresis (Invitrogen, UK), with reference DNA 
ladder, Quick-Load 1 Kb DNA ladder (New England BioLabs, MA, USA) to ensure the absence 
of contaminants such as RNA (< 200 bp smear). 
5.2.4 DNA Quantification  
Sample DNA concentrations were determined by PicoGreen dsDNA Assay Kit (Life 
Technologies, UK) in accordance with the manufacturer’s instructions. PicoGreen is a 
fluorescent dye that binds to double–stranded DNA (dsDNA) and forms a luminescent 
complex when compared to the free dye in solution. Once bound, the DNA intercalation and 
electrostatic interactions immobilize the dye molecule resulting in a > 1000-fold increase in 
its fluorescent signal (Dragan et al., 2010). 
The DNA content of each sample was derived by reference to a DNA standard curve (2 µg/mL 
- 0 μg/mL in Tris-EDTA (TE) buffer). Black-walled plates were read on a VarioSkan plate reader 
(excitation ~480 nm/ emission ~520 nm). All samples were then diluted to 100 ng/µL using 
TE buffer (10 mM Tris, 0.1 mM EDTA, pH 8.0). 
5.2.5 Sequencing Preparation 
Next-generation, whole mitochondrial genome sequencing and all associated preparations 
were performed by the Centre for Genome Research (CGR) at the University of Liverpool. 
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5.2.5.1 Multiplex Primer Stock Plate 
In a DNA-free hood, a multiplex primer stock plate was prepared by combining six stock 
primer plates of individual primer pairs (60 µM) as depicted in Figure 5.1 (Fluidigm, CA, USA). 
5 µL from each of the 12 columns of the source plate were transferred into a corresponding 
single column in the destination plate to produce primer concentrations of 5 µM. Each well 
contained up to 12 forward and 12 reverse primers in a final volume of 60 µL per well. Three 
daughter plates were prepared from this plate each containing 20 µL. The plates were stored 
at -80 oC 
 
5.2.5.2 20X Primer Solutions   
In 96-well plates, 75 µL polymerase chain reaction (PCR)-grade water was combined with 20 
µL of the stock multiplex primer mix (5 µM) and 5 µL 20X Access Array Loading Reagent for 
a final primer concentration of 1 µM. Multiple copies of these working plates were produced 
and stored at -20 ᵒC to reduce exposing primers to repeated freeze thaw cycles.  
5.2.5.3  Access Array Integrated Fluidic Circuit (IFC) 
In 96-well plates, each patient sample (1 µL of 100 ng/µL DNA) was added to 4 µL of Pre-
sample mastermix solution, the constituents of which are outlined in Table 5.2. 
Figure 5.1 Preparation of multiplex primer stock plates by combining six stock primer plates of 
individual primer pairs. Image adapted from Fluidigm user guide.  
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Table 5.2 Access Array IFC pre-sample mastermix solution constituents.  
Reagent  Volume per Reaction (µL) Final Concentration  
10X FastStart High fidelity 
Reaction Buffer without 
MgCl2 (Roche)  
0.5 1X 
25 mM MgCl2 (Roche) 0.9 4.5 mM 
DMSO (Roche) 0.25 5 % 
10 mM dNTP Mix (Roche) 0.1 200 µM 
5 units/μL FastStart High 
Fidelity Enzyme Blend 
(Roche) 
0.05 0.05 units/μL 
20X Access Array Loading 
Reagent 
0.25 1X 
PCR Grade Water  1.95 N/A 
Abbreviations: MgCl2, magnesium chloride; DMSO, dimethyl sulfoxide; dNTP, deoxynucleotide; PCR, 
polymerase chain reaction.   
5.2.5.4 Priming the Access Array  
Prior to adding samples and primers, the integrated fluidic circuit (IFC) (Figure 5.2) was 
loaded with reagents in accordance with Table 5.3 and placed into the pre-PCR IFC controller 
before the Prime 151x script was run.  
 
 
Figure 5.2 The Access Array Integrated Fluidics Circuit (IFC) holds up to 48 samples and 48 groups of 
primers within its inlets. The IFC must also be loaded with harvesting and hydration solutions and 
control-line fluid. Image adapted from the Fluidigm user guide.  
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Table 5.3 Integrated Fluidics Circuit (IFC) reagent loading positions and volumes.  
 
Once priming of the Access Array cassette was complete, 4 µL of the prepared samples were 
loaded into the ICF samples inlets and 4 µL of 20X primer solution mix was added to the 
primer inlets as displayed in Figure 5.2. The cassette was returned to the Pre-PCR IFC and the 
Load Mix (151x v7) script was run, this procedure draws primer and samples from the inlets 
to the centre of the IFC ready for PCR. Upon completion of the script, the IFC was transferred 
to the Fluidigm FC1 cycler and the protocol AA48x 48 standard v1 was performed as 
described in Table 5.4.  
Table 5.4 FC1 thermal cycler protocol AA48x 48 standard v1 
 Temperature (ᵒC) Time (sec) Cycles 
Thermal Mix  50 120 1 
70 1200 
Hot Start  95 600 1 
PCR 95 15 10 
60 30 
72 60 
C0t Cycle  95 15 2 
80 30 
60 30 
72 60 
PCR Cycle  95 15 8 
60 30 
72 60 
C0t 95 15 2 
80 30 
60 30 
72 60 
PCR Cycle  95 15 8 
60 30 
72 60 
C0t 95 15 5 
80 30 
60 30 
Position  Reagent  Volume (µL) 
Accumulators Control-line fluid  300 
H1 1X Access Array Harvest Solution 700 
H2, H3 1X Access Array Harvest Solution 500 
H4 1X Access Array Hydration Solution v2 500 
Primer Inlets 20X Primer Solution 4 
Sample Inlets Sample Mastermix  4 
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72 60 
Extension 72 180 1 
Cool Down  10 hold - 
Abbreviations: C0t, PCR amplicon normalisation cycle. 
5.2.5.5 Sample Harvesting 
Following the amplification of samples in the FC1 thermal cycler, the IFC was removed and 
the remaining fluids in ports H1-4 were removed. An additional 700 µL 1X Access Array 
harvest solution was added to port H1 and 600 µL to ports H2-H4. 2 µL of 1X harvest solution 
was also loaded into each of the sample inlets. The IFC was then placed into the post-PCR IFC 
controller and the script harvest (151 v7) was run. Upon completion of the run, the IFC was 
removed and the harvested samples (~10-12 µL) were transferred to a new 96-well plate. 
The harvested sample plate was stored at -20 ᵒC. 
5.2.5.6 Attaching Sequence Barcodes   
A mastermix solution was prepared for the harvested samples (Table 5.5). 15 µL of Pre-Mix 
mastermix was combined with illumina barcodes (4 µL; Illumina, CA, USA) and 1 µL of a 100-
fold dilution of the harvested PCR product for a total reaction volume of 20 µL. The resultant 
96-well plates were then run on a thermal cycler in accordance to Table 5.6.  
Table 5.5 Mastermix constituents. 
Reagent  Volume per Reaction (µL) Final Concentration  
10X FastStart High fidelity Reaction 
Buffer without MgCl2 (Roche) 
2.0 1X 
25 mM MgCl2 (Roche) 3.6 4.5 mM 
DMSO (Roche) 1.0 5 % 
10 mM dNTP Mix (Roche) 0.4 200 μM 
5 units/μL FastStart High Fidelity 
Enzyme Blend (Roche) 
0.2 0.05 units/μL 
PCR Grade Water 7.8 N/A 
Abbreviations: MgCl2, magnesium chloride; DMSO, dimethyl sulfoxide; dNTP, deoxynucleotide; PCR, 
polymerase chain reaction.   
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Table 5.6 Thermal cycler protocol for the incorporation of sample specific Illumina barcodes and 
adaptor sequences for the identification of individual amplicons. 
Time (sec) Temperature (ᵒC) Cycles  
600 95 1 
15 95 
15 30 60 
60 72 
180 72 1 
 
5.2.5.7 Purification of PCR Products  
All barcoded amplicon produced by the Access Array IFC underwent further quality control 
measures using a Fragment Analyser™ (Thermo Fisher Scientific, MA, USA). The Fragment 
Analyser™ accelerates nucleic acid workflow through the automation of gel loading and 
sample injection. Each sample is injected into parallel capillaries which contain a pre-loaded, 
intercalating fluorescent dye. During gel electrophoresis, nucleic acid fragments migrate 
based upon size and bind to the dye. During migration, fragments pass a detection window 
where nucleic acid bound dye is excited by a light source and emits a fluorescent signal. 
When samples are compared against a calibration ladder of known size, the time required to 
pass the detection window and fluorescent emission can provide information on the 
fragment size and concentration respectively. Sample DNA concentrations were then 
measured using a Qubit™ dsDNA High Sensitivity Assay (Thermo Fisher Scientific, UK) 
according to the manufacturer’s instructions and read on a Qubit™ fluorometer. 
5.2.5.8 Sample Pooling  
Samples were pooled using the Mosquito_X1 (TTP Labtech, UK), allowing for the rapid 
transfer of small volumes without further dilution requirements. 1 μL of amplicon was 
extracted from each well of the 96-well plates to generate one pool per plate. The resultant 
libraries were cleaned with Ampure beads (Beckman Coulter, CA, USA) in a 1:1 ratio. This 
step enables the removal of unincorporated deoxynucleotides (dNTPs), primer dimers or 
other contaminants whilst stabilising and efficiently recovering the DNA.  
5.2.5.9 Bioanalyser Quality Control  
The quality and quantity of each of the sample pools was assessed using a 2100 Bioanalyzer 
(Agilent, CA, USA). The 2100 Bioanalyzer simultaneously uses electrophoresis and flow 
cytometry to assess each sample whilst consuming minimal volume. 1 μL of PCR product was 
assessed using chips from the Agilent DNA 1000 kit to determine if the product pool had the 
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expected size. The product was expected to be the sum of the target region and the length 
of the incorporated Illumina barcodes.  
5.2.5.10 Quantitative PCR (qPCR) 
Quantitative PCR (qPCR) was performed using an Illumina Library Quantification Kit on a 
Roche Light Cycler LC480II (Roche, Basal, Switzerland) according the manufacturer’s 
instructions (Kapa Biosystems, CA, USA) to determine sample pool quantity. The mastermix 
contains the engineered KAPA SYBER FAST DNA polymerase which amplifies GC- and AT-rich 
DNA fragments with similar efficiency. This enables the accurate quantification of next-
generation sequencing libraries through qPCR based methods. The sample pools were then 
combined in equimolar ratios before performing mitochondrial genome sequencing.  
5.2.6 Mitochondrial Genome Sequencing 
The template DNA was denatured by combining 5 μL non-denaturing library to 5 μL of 0.1 M 
NaOH and 5 μL 200 mM Tris-HCl (pH 8.0). The sample-library mix (10 pM) and Read1, Read2 
and Read3 sequencing primers were loaded into the MiSeq reagent cartridge (Illumina, CA, 
USA), pre-filled with clustering and sequencing reagents sufficient for one flow cell. Upon 
run initiation, libraries were transferred to the flow cell channel, a glass-based substrate from 
which cluster generation and the sequencing reactions are performed.  
The process began with cluster generation, whereby single DNA molecules were bound to 
the surface of the flow cell and bridge amplified. Clusters generated within the flow cell were 
imaged in smaller areas called tiles. This was achieved using light-emitting diodes (LED) and 
filter combinations specific to each of the four fluorescently labelled dideoxynucleotides. The 
imaging process was repeated for each sequencing cycle. Base calling, filtering and quality 
scoring was performed by MiSeq reporter software.  
5.2.7 Bioinformatics Analysis  
5.2.7.1 Sequence Alignment Tools  
Illumina sequencing generates a high volume of short reads therefore the use of fast and 
accurate read alignment tools are required. Sequencing reads were aligned to the revised 
Cambridge Reference Sequence (rCRS) (NC_012920) using the Burrows-Wheeler Alignment 
tool v0.7.12 (BWA-MEM algorithm) (Li and Durbin, 2009). The BWA is a fast read alignment 
software package which enables mapping of sequences of low divergence against a 
reference genome. The tool has reliable performance for 70-100 bp illumina reads.  
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5.2.7.2 Variant Calling Analysis  
Following the alignment of sequencing reads using BWA-MEM, the resultant output was 
delivered in standard sequence alignment/map (SAM) format. SAMtools (v0.1.18) was used 
to sort and index the data so that it was suitable for use with various variant calling software 
packages (Li et al., 2009).  
Variant calling was performed with the genome analysis toolkit (GATK) v3.2.2 using haploidy, 
diploidy and tenploidy settings and VarScan (minimum depth = 100, supporting reads = 5, 
base quality = >20, mapping quality = >20) v2.3.9 (McKenna et al., 2010; Koboldt et al., 2009). 
Whilst GATK is often considered the ‘gold standard’ variant caller for targeted, exome and 
whole-genome sequencing, this is not specifically in the context of the mitochondrial 
genome. Therefore, multiple variant calling tools and settings were employed so that 
concordance between results may be assessed. Each variant caller software package 
generated a variant calling format (VCF) file. The average number of reads was 43,115 with 
92.5 % mapped on target. The average depth (coverage) was 343.3X.  
5.2.7.3 Mitochondrial Haplogroup Calling  
Mitochondrial DNA haplogroups were assigned using the web application HaploGrep2 
(v2.1.0) by directly inputting VCF files generated by the variant callers. HaploGrep2 mediates 
the automated determination of haplogroups based upon the most recent iteration of the 
mtDNA phylogenetic tree (Phylotree build 17) (van Oven, 2015). The software provides the 
user with the 50 most probable haplogroups for a given sample (Weissensteiner et al., 2016). 
All samples with an error rate > 0 (missed 3 or more expected polymorphisms) and a low 
HaploGrep2 quality score < 80 % were removed from the analyses.  
5.2.8 Statistical Analysis 
All statistical analyses were performed using StatsDirect Version 3 (StatsDirect Ltd, UK). 
Statistical independence between macro-haplogroup frequencies for statin myopathy case 
and statin tolerant control groups was examined using a Chi-square 2-by-k contingency table 
(without trend). A p-value ≤ 0.05 was regarded as the significance threshold. Sample size 
calculations for independent case-control studies were performed using the following 
settings: number of controls per case (1), % power (80 %) and % alpha (5 %).  
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5.3 Results  
5.3.1 mtDNA Haplogroup Assignment  
The mitochondrial haplogroups of 264 statin myopathy cases, 291 statin tolerant controls 
and 342 healthy volunteers were resolved using HaploGrep2 software based upon the most 
recent iteration of Phylotree (build 17) (van Oven, 2015). Two variant callers were used; 
GATK with haploidy, diploidy and tenploidy settings and VarScan. All samples that did not 
meet the quality control (QC) criteria (section 5.2.7.3) were removed (error rate > 0, quality 
score < 80 %).  
The number of samples that passed QC in the PREDICTION-ADR cohort were similar across 
the VarScan and GATK haploidy/diploidy analyses, whereas the GATK tenploidy settings 
yielded fewer high quality samples.  In contrast, the number of samples that passed QC for 
the healthy volunteer cohort were more consistent across the different variant calling tools 
however GATK tenploidy still suffered the poorest yield of high quality samples (Table 5.7).  
Table 5.7 Number of samples that passed quality control (QC) in different variant calling analyses for 
the PREDICTION-ADR cohort and healthy volunteer cohort. 
 GATK haploidy GATK diploidy GATK tenploidy VarScan 
Cases 250 259 110 245 
Controls 276 286 137 264 
Healthy Volunteers 329 328 320 328 
Total 855 873 567 837 
 
Following QC analysis, macro-haplogroup assignment was compared between the four 
different variant callers for both the PREDICTION-ADR cohort and the healthy volunteer 
cohort (Table 5.8). Regarding the PREDICTION-ADR cohort (statin myopathy cases vs statin 
tolerant controls), GATK haploidy identified a total of 12 macro-haplogroups, GATK diploidy 
13, GATK tenploidy 10 and VarScan 11. Amongst the healthy volunteer cohort, GATK haploidy 
assigned samples into 17 macro-haplogroups, GATK diploidy 17, GATK tenploidy 17 and 
VarScan 17. As the GATK tenploidy macro-haplogroup distribution deviated significantly 
from the other variant calling methods for the PREDICTION-ADR cohort specifically, it was 
excluded from further analyses.
 168 
  
Table 5.8 mtDNA macro-haplogroup distributions of analysed samples for the variant calling tools GATK (haploidy/diploidy and tenploidy settings) and VarScan. 
 GATK haploidy GATK diploidy GATK tenploidy VarScan 
Haplogroup 
Myopathy 
Cases (%) 
Tolerant 
Controls (%) 
Healthy 
Volunteers (%) 
Myopathy 
Cases (%) 
Tolerant 
Controls (%) 
Healthy 
Volunteers (%) 
Myopathy 
Cases (%) 
Tolerant 
Controls (%) 
Healthy 
Volunteers (%) 
Myopathy 
Cases (%) 
Tolerant 
Controls (%) 
Healthy 
Volunteers (%) 
H 109 (43.6) 129 (46.7) 132 (40.1) 108 (41.7) 130 (45.5) 133 (40.5) 87 (79.1) 114 (83.2) 127 (39.7) 107 (44.4) 127 (48.1) 129 (39.3) 
U 36 (14.4) 34 (12.3) 56 (17.0) 37 (14.3)  34 (11.9) 56 (17.1) 7 (6.4) 6 (4.4) 56 (17.5)  33 (13.7) 34 (12.9) 57 (17.4) 
J 33 (13.2) 34 (12.3) 44 (13.4) 35 (13.5) 37 (12.9) 42 (12.8) 7 (6.4) 3 (2.2) 43 (13.4) 33 (13.7) 33 (12.5) 44 (13.4) 
T 25 (10.0) 27 (9.8) 28 (8.5) 28 (10.8) 28 (9.8) 28 (8.5) 1 (0.9) 0 (0.0) 26 (8.1) 29 (12.0) 26 (9.8) 29 (8.8) 
K 21 (8.4) 20 (7.2) 27 (8.2) 21 (8.1) 20 (7.0) 27 (8.2) 1 (0.9) 1 (0.7) 28 (8.8) 18 (7.5) 18 (6.8) 28 (8.5) 
M 1 (0.4) 0 (0.0) 1 (0.3) 1 (0.4) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
I 8 (3.2) 16 (5.8) 5 (1.5) 10 (3.9) 16 (5.6) 5 (1.5) 0 (0.0) 1 (0.7) 4 (1.3) 6 (2.5) 11 (4.2) 5 (1.5) 
V 8 (3.2) 8 (2.9) 15 (4.6) 8 (3.1) 8 (2.8) 15 (4.6) 6 (5.5)  6 (4.4) 14 (4.4) 8 (3.3) 9 (3.4) 14 (4.3) 
W 3 (1.2) 2 (0.7) 3 (0.9) 4 (1.5) 3 (1.0) 3 (0.9) 0 (0.0) 1 (0.7) 3 (0.9) 2 (0.8) 2 (0.8) 3 (0.9) 
X 6 (2.4) 4 (1.4)  9 (2.7) 6 (2.3) 4 (1.4) 9 (2.7) 0 (0.0) 1 (0.7) 9 (2.8) 4 (1.7) 3 (1.1) 9 (2.7) 
N 0 (0.0) 1 (0.4) 1 (0.3) 0 (0.0) 2 (0.7) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
R 0 (0.0) 0 (0.0) 1 (0.3) 1 (0.4) 3 (1.0) 1 (0.3) 1 (0.9) 4 (2.9) 1 (0.3) 1 (0.4) 0 (0.0) 1 (0.3) 
E 0 (0.0) 1 (0.4) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.4) 0 (0.0) 
A 0 (0.0) 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 3 (0.9) 0 (0.0) 0 (0.0) 3 (0.9) 
D 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
F 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
G 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
L 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0) 0 (0.0) 1 (0.3) 
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5.3.2 mtDNA Haplogroup Calling Concordance  
Concordance in haplogroup assignment between the variant calling tools was assessed for 
both the PREDICTION-ADR cohort (GATK haploidy, diploidy and VarScan) and the healthy 
volunteer cohort (GATK haploidy, diploidy, tenploidy and VarScan) at the macro-haplogroup 
level (e.g. H vs J) and at the sub-haplogroup level (e.g. H1 vs H1a). Only high quality samples 
(error rate < 0 and HaploGrep2 quality score > 80 %) were compared. From 555 PREDICTION-
ADR samples, 488 passed quality control across the three variant calling analyses (230 
myopathy cases and 258 tolerant controls). Of these samples, only one discordant macro-
haplogroup assignment was identified within the statin tolerant control group (Table 5.9). 
When examining the concordance of sub-haplogroup assignment for the same cohort, 
percentage matching dropped by 15.9 % and 11.8 % for the tolerant controls and myopathy 
cases respectively. 
Table 5.9 mtDNA macro- and sub-haplogroup concordance for the PREDICTION-ADR cohort (GATK 
haploidly, diploidy and VarScan). 
  
Total Number of 
Samples 
Concordant 
Calls 
Match (%) 
Macro-haplogroup 
assignment 
Tolerant Controls 258 257 99.6 
Myopathy Cases 230 230 100 
Sub-haplogroup 
Assignment 
Tolerant Controls 258 216 83.7 
Myopathy Cases 230 203 88.2 
  
From a total of 342 healthy volunteer samples, 308 passed quality control measures across 
the four variant calling analyses. Of these samples, four discordant macro-haplogroup 
assignments were identified (Table 5.10). Analysis of sub-haplogroup assignment for the 
same cohort resulted in a 24.1 % reduction in haplogroup matching across the four variant 
calling tools. 
Table 5.10 mtDNA macro- and sub-haplogroup concordance for the healthy volunteer cohort (GATK 
haploidly, diploidy, tenploidy and VarScan). 
  
Total Number of 
Samples 
Concordant 
Calls 
Match (%) 
Macro-haplogroup 
assignment 
Healthy 
Volunteers 
308 304 98.7 
Sub-haplogroup 
Assignment 
Healthy 
Volunteers 
308 230 74.6 
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5.3.3 Comparison of mtDNA Haplogroup Distribution to an Online Database 
Comparison of the five most commonly occurring macro-haplogroups to an online database 
of haplogroup distribution in Northern Europe showed close agreement between all 
observed frequencies (Eupedia, 2018). The distribution of macro-haplogroups in both cases 
and controls resembled that of the healthy volunteers and the Northern European 
population. The greatest deviation (10 %) was observed within Haplogroup H between the 
healthy volunteers and statin tolerant controls (Table 5.11).  
Table 5.11 Comparison of mtDNA macro-haplogroup frequencies in the PREDICTION-ADR and healthy 
volunteer cohorts to an online database (Eupedia, 2018). 
aMacro-haplogroup frequency calculated from data collated from England, Scotland, Sweden and the 
Netherlands (Eupedia, 2018). 
5.3.4 mtDNA Haplogroup Distribution between Statin Myopathy Cases and Statin 
Tolerant Controls  
When comparing marco-haplogroup frequencies from the PREDICTION-ADR cohort, 
statistical analyses revealed no significant relationship between myopathy cases and 
controls (Table 5.12). When further stratifying the statin myopathy cases according to 
disease severity, SRM 3 patients (defined as CK elevation >4X ULN, <10X ULN ± muscle 
symptoms, complete resolution on dechallenge) also showed no significant differences in 
haplogroup frequency when compared with the tolerant controls (Table 5.13). Similarly, SRM 
4 (CK elevation >10X ULN, <50X ULN + muscle symptoms, complete resolution on 
dechallenge) and SRM 5 (CK elevation >10X ULN, with evidence of renal failure + muscle 
symptoms or CK >50X ULN) patients examined as a compound group representing severe 
myopathy and rhabdomyolysis yielded statistically insignificant results (Table 5.14) (Alfirevic 
et al., 2014). 
 
 Frequency (%) 
Haplogroup Eupedia 
Databasea 
Healthy Volunteers 
(n=304) 
Tolerant Controls 
(n=257) 
Myopathy Cases 
(n=230) 
H 44.9 38.6 48.6 46.1 
U 16.8 17.5 13.2 14.3 
J 10.7 13.3 11.7 12.6 
T 9.2 8.4 9.7 10.9 
K 7.8 8.8 7.0 7.8 
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Table 5.12 mtDNA macro-haplogroup frequencies for statin tolerant controls and myopathy cases. 
Statistical independence between variables was calculated by Chi-square 2-by-k (without trend) test 
*p value < 0.05 **p value < 0.01 ***p value < 0.001.  
 
Table 5.13 mtDNA macro-haplogroup frequencies for statin tolerant controls and myopathy cases 
(SRM 3 only). Statistical independence between variables was calculated by Chi-square 2-by-k 
(without trend) test *p value < 0.05 **p value < 0.01 ***p value < 0.001.  
 Frequency (%) 
Haplogroup 
Myopathy Cases 
(n=230) 
Tolerant Controls 
(n=257) 
Statistics  
H 46.1 48.6 
Total Chi2 = 4.22 
Chi = 2.05 (9 DF) 
P = 0.89 
U 14.3 13.2 
J 12.6 11.7 
T 10.9 9.7 
K 7.8 7.0 
V 3.5 3.1 
I 2.2 4.3 
X 0.9 1.2 
W 1.7 0.8 
E 0.0 0.4 
 Frequency (%) 
Haplogroup 
Cases (SRM 3) 
(n=139) 
Tolerant Controls 
(n=257) 
Statistics 
H 46.8 48.6 
Total Chi2 = 2.56 
Chi = 1.6 (9 DF) 
P = 0.97 
U 12.9 13.2 
J 12.2 11.7 
T 9.4 9.7 
K 7.9 7.0 
V 4.3 3.1 
I 2.9 4.3 
X 2.2 1.2 
W 1.4 0.8 
E 0.0 0.4 
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Table 5.14 mtDNA macro-haplogroup frequencies for statin tolerant controls and myopathy cases 
(SRM 4 & 5 only). Statistical independence between variables was calculated by Chi-square 2-by-k 
(without trend) test *p value < 0.05 **p value < 0.01 ***p value < 0.001.  
 
5.3.5 Patient Stratification Based upon Statin Type  
The PREDICTION-ADR recruited patients were next stratified based upon the statin that they 
had been prescribed at the time of sample collection. Analyses were performed using 
patients who were receiving simvastatin and atorvastatin only. This was due to the relatively 
low number of samples retained from participants taking pravastatin (n=26), rosuvastatin 
(n=17) and fluvastatin (n=4) after filtering for concordant macro-haplogroup assignment and 
HaploGrep2 quality score. When examining the macro-haplogroup frequencies within both 
the atorvastatin (Table 5.15) and simvastatin (Table 5.16) patient sub-groups, there were no 
statistically significant relationships observed between mtDNA haplogroup and patient 
status. 
 
 
 
 
 
  
 
 Frequency (%) 
Haplogroup 
Cases (SRM 4 & 5) 
(n=84) 
Tolerant Controls 
(n=257) 
Statistics 
H 46.4 48.6 
Total Chi2 = 3.86 
Chi = 1.96 (9 DF) 
P = 0.91 
U 14.3 13.2 
J 13.1 11.7 
T 13.1 9.7 
K 8.3 7.0 
V 2.4 3.1 
I 1.2 4.3 
X 1.2 1.2 
W 0.0 0.8 
E 0.0 0.4 
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Table 5.15 mtDNA macro-haplogroup frequencies for statin tolerant controls and myopathy cases 
(atorvastatin only). Statistical independence between variables was calculated by Chi-square 2-by-k 
(without trend) test *p value < 0.05 **p value < 0.01 ***p value < 0.001. 
 
Table 5.16 mtDNA macro-haplogroup frequencies for statin tolerant controls and myopathy cases 
(simvastatin only). Statistical independence between variables was calculated by Chi-square 2-by-k 
(without trend) test *p value < 0.05 **p value < 0.01 ***p value < 0.001. 
 
 
 
 
 Frequency (%) 
Haplogroup 
Atorvastatin Cases 
(n=81) 
Atorvastatin Controls 
(n=66) 
Statistics 
H 50.0 46.9 
Total Chi2 = 3.45 
Chi = 1.85 (8 DF) 
P = 0.90 
U 13.6 13.6 
J 18.2 13.6 
T 4.5 4.9 
K 9.1 8.6 
V 1.5 3.7 
I 1.5 4.9 
X 1.5 2.5 
E 0.0 1.2 
 Frequency (%) 
Haplogroup 
Simvastatin Cases 
(n=161) 
Simvastatin Controls 
(n=131) 
Statistics 
H 45.0 49.7 
Total Chi2 = 2.16 
Chi = 1.47 (7 DF) 
P = 0.97 
U 14.5 13.7 
J 12.2 10.6 
T 13.7 12.4 
K 5.3 6.8 
V 3.8 3.1 
I 3.1 1.9 
X 1.5 0.6 
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5.3.6  Sample Size Calculations  
Sample size calculations were performed to determine the number of case and control 
samples that would be required to detect a positive correlation (odds ratio >1) at a range of 
different haplogroup frequencies (Table 5.17). Results indicated that the PREDICTION-ADR 
cohort was sufficiently sized to identify strong positive correlations between mtDNA 
haplogroup and patient status (odds ratio 4-5), however it was insufficiently sized to detect 
weaker correlations (odds ratio 2) particularly at haplogroup frequencies < 50 %. 
Table 5.17 Table of sample size calculations for different haplogroup frequencies.  
 Number of Required Cases and Controls 
Haplogroup Frequency (%) OR 5 OR 4 OR 2 
50 37 46 149 
20 34 46 187 
15 39 53 226 
10 49 68 307 
5 83 117 560 
Abbreviations: OR, odds ratio. 
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5.4 Discussion  
In this chapter, next generation, whole mitochondrial genome sequencing was performed 
on genomic DNA samples obtained from 342 healthy volunteers and a statin-related 
myopathy cohort consisting of 264 cases and 291 tolerant controls. This was followed by the 
comparison of several different methods of variant calling and the assignment of samples 
into their mtDNA sub-haplogroups using the web-based application HaploGrep2 (phylotree 
build 17) (van Oven, 2015; Weissensteiner et al., 2016).  
In the context of the nuclear genome, GATK software is often considered the ‘gold-standard’ 
for variant calling, though information regarding the tailoring of this software for the analysis 
of mtDNA sequencing data is limited (Liu et al., 2013). Mitochondrial DNA is a haploid 
molecule, however there can be hundreds to thousands of copies per cell. Consequently, 
previous studies have relied upon variant callers that were designed for haploid genomes, 
such as older versions of GATK’s Unified genotyper or custom designed algorithms (Guo et 
al., 2012; DePristo et al., 2011; Ye et al., 2014). 
Other studies, such as mtDNA SNP calling for the 1000 Genomes Project (Li et al., 2010; Ye 
et al., 2014) were performed using the diploid genotype caller GLFTools v3 (Li et al., 2009; 
Ye et al., 2014). However, using variant calling tools designed for polyploidy genomes can 
result in the classification of  high-level heteroplasmic sites as SNPs (Ye et al., 2014). 
Conversely, when lower mtDNA copy numbers are assumed, the likelihood that minor 
variants are assigned as erroneous sequence reads increases. Therefore, in order to mitigate 
these potential issues, GATK variant calling was performed using several ‘ploidy’ settings; 
haploidy, diploidy and tenploidy which assumes one, two and ten copies of the mitochondrial 
genome in addition to VarScan software (Koboldt et al., 2009, 2012). Only concordant macro-
haplogroup assignments with high HaploGrep2 quality scores (> 80 %) were carried forward 
for further analysis.  
More recently, a bioinformatics pipeline called MToolBox, which implements a highly 
automated computational strategy for extracting data from whole exome and whole genome 
sequencing datasets, has become popular for the reconstruction and analysis of the human 
mitochondrial genome (Calabrese et al., 2014). MToolBox can detect insertions and 
deletions (ins/dels) and assess the heteroplasmic fraction of variant alleles whilst providing 
a related confidence interval. In addition, it provides pathogenicity scores, profiles of 
genome variability and disease-associations for identified mitochondrial variants (Calabrese 
et al., 2014). Whilst the MToolBox workflow was not used within the present study, it is 
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particularly useful for datasets which have a high depth of sequencing (i.e. a high number of 
reads at each base position). Deep sequencing increases the likelihood that minor 
heteroplasmic variants are detected within a sample, therefore bioinformatics tools that are 
capable of accurately measuring this ‘heteroplasmic load’ are highly desirable.  
In this chapter, the use of next generation sequencing to identify SNPs from across the entire 
mitochondrial genome has allowed for the classification of patient samples into both their 
macro- and sub-haplogroups. This demonstrates progression from previous studies which 
have failed to assign sub-haplogroups due to the use of SNP array technologies, such as the  
Sequenom MassARRAY platform, to genotype samples (Guzmán-Fulgencio et al., 2013). In 
addition, whole genome sequencing has enabled the identification of SNPs in samples which 
are not necessarily characteristic of the assigned haplogroup. This may be of importance if 
the additional SNPs are non-synonymous and effect the structure or function of a 
mitochondrial protein of interest.  
Within this study, a significant association between mitochondrial macro-haplogroup and 
statin related myopathy was not identified. The distribution of mitochondrial haplogroups in 
both the case and control groups resembled that of the healthy volunteer cohort and the 
Northern European population (Eupedia, 2018). Stratification of the statin myopathy cases 
based upon phenotypic severity did not reveal any associations of statistical significance. Due 
to the genetic association between the coding variant rs4149056 (p.Val174Ala) in the 
SLCO1B1 gene being more closely associated with simvastatin-related myopathy, patients 
were also stratified based upon the type of statin that they were prescribed (Brunham et al., 
2012). In the case of both simvastatin and atorvastatin, the most abundant statins within the 
cohort, there were no overall associations identified between macro-haplogroup and patient 
status.  
It must be noted that haplogroup-disease association studies performed within this chapter 
have only considered the overarching patient macro-haplogroup (i.e. H vs J) despite each 
sample being assigned a higher resolution sub-haplogroup classification (i.e. H1 vs J1) by 
HaploGrep2 (Appendix III/IV). Clustering of samples into their respective macro-haplogroups 
disregards much of the diversity and mutational variation which defines each of the sub-
haplogroups. For example, macro-haplogroup H is the largest and most diverse of the 
European haplogroups and can be divided into more than 10 major subclades, each of which 
can be further subdivided themselves (Roostalu et al., 2007). However, within the 
PREDICTION-ADR cohort a total of 280 unique sub-haplogroups were identified, therefore 
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the frequency of each haplogroup would be exceptionally low within the sample population 
resulting in insufficient statistical power to detect change.  
One of the most significant drawbacks of the study was the extraction of genomic DNA from 
whole blood instead of skeletal muscle. Whilst collection of venous blood samples is easier, 
quicker and less invasive than performing skeletal muscle biopsies, few studies have 
examined how mtDNA heteroplasmic load varies across different tissues of the same 
individual. It is thought that in post-mitotic cells such as myocytes, mutations can accumulate 
over time due to mtDNA molecules being continuously destroyed and replicated in a process 
called relaxed replication. In heteroplasmic cells, it is possible that a mutated mtDNA 
molecule may be replicated more frequently than a wild-type molecule (e.g. a pathogenic 
deletion will result in an mtDNA molecule which is several kilobases shorter than the wild-
type molecule, allowing it replicate faster), thus changing the heteroplasmic load of a tissue 
over the course of a lifetime (Stewart and Chinnery, 2015; Schröder et al., 2015). Conversely, 
in rapidly dividing hematopoietic cells, mtDNA molecules are randomly segregated between 
daughter cells during mitosis in a process called vegetative segregation. If heteroplasmic 
variants are present, each cell may receive different proportions of wild-type and mutant 
mtDNA molecules. Therefore, mutant molecules may be lost more readily through selection 
or genetic drift (Stewart and Chinnery, 2015).  
It is also important to acknowledge that genomics, as a standalone approach, is insufficient 
as a means to aid drug development or completely resolve the mechanistic nature of adverse 
drug reactions. Biological networks are extremely complex and are affected by not only 
changes to genetic coding sequences but also transient responses to stimuli at the level of 
protein activity and posttranslational modification. Thus, an integrative systems 
pharmacology approach combining ‘multi-omic’ datasets as well patient history and 
functional in vitro experimentation, is necessary to achieve a better understanding of the 
biology behind drug response phenotypes (Schwab and Schaeffeler, 2012). This is particularly 
pertinent in the case of SRM given that previous genetics studies have identified multiple 
pathways that may lead to the development of myopathic symptoms in patients receiving 
statins, including altered pharmacokinetics, immunological responses, muscle regeneration, 
mitochondrial function and underlying susceptibility to inherited myopathy (Brunham et al., 
2018; Ghatak et al., 2010).  
In reference to the integration of in vitro studies, investigations concerning the effects of 
mitochondrial genome variation upon susceptibility to adverse drug reactions or disease 
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should ideally be supported by functional interrogations using trans-mitochondrial, 
cytoplasmic hybrid (cybrid) modelling (Figure 5.3). This technique involves the fusion of 
nucleated cells, which have undergone depletion of their endogenous mtDNA to form rho0 
cells, with non-nucleated cytoplasts (platelets) from donors of a known mitochondrial 
haplogroup. The ultimate goal being to re-populate the nucleated cell with mtDNA from the 
cytoplast, allowing for the generation of different cellular models with an identical nuclear 
background but variable mtDNA haplogroup (Wilkins et al., 2014). 
 
5.5 Conclusions  
In conclusion, this study represents the first mtDNA haplogroup-disease association study 
performed in the context of statin-related myopathy. Whilst no significant associations were 
identified between the clustered macro-haplogroups and patient status, differences may be 
detected when comparing individual sub-haplogroups. Such a study would better account 
for the accumulative mutations and by extension, the functional variations that are 
characteristic of the different mtDNA subclades, however it would require a far greater 
number of participants to adjust for the relatively low frequency of each sub-haplogroup. 
Future studies should also endeavour to compare the mtDNA haplogroup assignment 
concordance between whole blood and skeletal muscle biopsies from the same individuals 
to determine if blood is an appropriate surrogate sampling material.  
 
 
Figure 5.3 Cybrid generation technique. Cybrids are produced by combining cytoplasm from nucleated 
cells, depleted of their own endogenous mtDNA, with non-nucleated cells or cytoplasts. 
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6.1 Introduction  
Since their introduction, statins have been and will likely remain the pharmaceutical 
intervention strategy of choice for the treatment and prevention of cardiovascular and 
cerebrovascular disease.  Indeed, it is evident that statin pharmacotherapy will continue to 
play a critical role in the management of CVD as the global disease burden increases, not 
least due to its efficacy, cost-effectiveness and firm foothold in the clinical formulary 
(Weintraub, 2017). When considered in conjunction with factors such as alterations to 
patient eligibility guidelines and the rising prevalence of obesity, a disease heavily implicated 
in the pathogenesis of CVD, it is unsurprising to find that statin uptake, both in the UK and 
indeed globally, has been increasing significantly over time (O’Keeffe et al., 2016; Purcell, 
2013). 
As a consequence of the seemingly unwavering popularity of statins, investigations 
concerning the molecular and clinical determinants of statin-related myopathy, the most 
significant and commonly occurring barrier to atherosclerotic disease risk reduction, are both 
timely and absolutely necessary for the future of CVD management. This is particularly 
pertinent as statins are often prescribed on a ‘primary prevention’ basis to individuals 
without pre-existing atherosclerotic cardiovascular disease, thus potentiating adverse 
effects in otherwise ‘healthy’ individuals.  
Therefore, the overall risk of a patient developing an adverse drug reaction must be 
considered when initially prescribing statins and subsequently monitoring their usage over 
time. In order to maximise the benefits of pharmaceutical intervention whilst concomitantly 
reducing the potential for myopathic outcomes, understanding the dynamic interplay 
between the pharmacology of the drug and an individual’s underlying susceptibility to 
adverse effects is pivotal. However, establishment of myopathy risk is not only important for 
the prevention of myopathy in susceptible patients but also for the identification of factors 
which confer drug tolerance. This combined knowledge may help to enhance patient 
compliance with treatment regimens, improve quality of life and increase treatment efficacy 
thus helping to alleviate the absolute burden of CVD upon healthcare providers.  
Drug-induced mitochondrial dysfunction has been implicated as one of several putative 
mechanisms by which myopathic symptoms are potentiated in some statin recipients. 
Therefore, the overarching aim of this research was to first establish the differential effects 
of statin chemical species (i.e. inactive lactones versus active β-hydroxy acids) upon the 
functionality of the mitochondrial respiratory chain. Based upon these findings, the 
 182 
  
remainder of the thesis focussed upon the development of an advanced in vitro model of 
skeletal muscle to identify functional bioenergetic factors which may confer an enhanced or 
diminished risk of statin-mediated mitochondrial perturbations. Finally, a novel mtDNA 
haplogroup-disease association study was performed for a statin myopathy case-control 
cohort to determine if there was a link between mitochondrial genotype and patient status. 
6.2 The Mechanistic Nature of Statin-Induced Respiratory Dysfunction  
Investigations performed within this research identified complex II as a major, but not an 
exclusive site, of simvastatin-mediated respiratory dysfunction in L6 myocytes under acute 
and extended dosing regimens. In addition, it was noted that myobundles produced from 
statin-tolerant donors dedicated a greater proportion of their maximal respiratory output to 
spare respiratory capacity, a metabolic parameter which is thought to be partially governed 
by complex II activity (Pfleger et al., 2015). However, in order to bridge these observations 
together, interrogations of complex driven respiration in myobundles would be required at 
baseline and post statin exposure for each donor category (i.e. statin-naïve, tolerant and 
intolerant). This would help to clarify if complex II activity is indeed the source of elevated 
spare respiratory capacity in the statin-tolerant myobundles or if it originates from 
alternative and/or additional sites.  
It has been previously suggested that statin-induced respiratory dysfunction may be 
mitigated by enhancing an individual’s baseline respiratory function (Allard et al., 2018). This 
in essence forms the rationale behind the supplementation of ubiquinone (CoQ10) to statin 
recipients. By bolstering the mitochondrial ubiquinone pool with exogenously supplied 
CoQ10, endogenous biosynthetic deficits mediated by the inhibition of the mevalonate 
pathway may be addressed and electron transfer would, theoretically, cease to be impeded. 
However, in practice this yields conflicting results in patient studies, potentially due to the 
poor bioavailability of orally administered CoQ10 or a lack of a CoQ10 deficit in skeletal 
muscle all together (Bergamini et al., 2012; Laaksonen et al., 1996). Further in vitro 
investigations have demonstrated that by promoting convergent electron flow into the 
ubiquinone pool via the stimulation of glycerol-3-phosphate dehydrogenase (G3PDH) and 
the β-oxidation pathway, attenuation of phosphorylating respiration by several different 
statins can be partially reversed (Schirris et al., 2015). In addition, increased spare respiratory 
capacity, via complex II, has been shown to promote cellular survival via sirtuin-3 (SIRT3) 
dependent mechanisms in a number of different cell types (Nickens et al., 2013; Dhingra and 
Kirshenbaum, 2015; Yadava and Nicholls, 2007; Pfleger et al., 2015). SIRT3 influences 
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multiple pathways of mitochondrial oxidative metabolism and the rate of ROS production, 
therefore activation of SIRT3 or the metabolic sensor AMPK may be an effective means to 
partially attenuate statin-mediated mitochondrial dysfunction and promote cell survival in 
myocytes (Figure 6.1) (Ansari et al., 2017).  
 
Whilst not directly addressed within this thesis, it is also important to consider the effects 
that mitochondrial ageing and age-related dysfunction may have upon susceptibility to 
statin-related myopathy. Ageing is associated with the impairment of both the capacity and 
control of oxidative phosphorylation in skeletal muscle, particularly impacting upon the 
functionality of complexes I and IV but not complexes II and III (Desler et al., 2012). 
Figure 6.1 Succinate dehydrogenase (SDH), also known as complex II is comprised of four subunits 
(SDHA-D). Complex II regulates spare respiratory capacity (SRC) and cell survival as a functional link 
between the tricarboxylic acid (TCA) cycle and the electron transport chain (ETC). Complex II regulates 
SRC by increasing substrate flux coincident with increased metabolic demand through the TCA cycle 
and ETC. Pyruvate dehydrogenase kinase (PDK) negatively regulates complex II activity resulting in 
diminished SRC. The metabolic sensors AMP-activated protein kinase (AMPK) and metabolic 
regulators pyruvate dehydrogenase (PDH) and the NADH-dependent class III deacetylase Sirtuin-3 
(SIRT3), positively regulate SRC (Dhingra and Kirshenbaum, 2015). 
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Furthermore, accumulation of mtDNA mutations in post mitotic tissues, increased ROS-
mediated cellular damage and altered mitochondrial dynamics have also been noted in aged 
tissues (Chistiakov et al., 2014). A combination of these factors may contribute to the 
enhanced risk of statin-induced myopathies amongst the elderly (Deichmann et al., 2010). 
6.3 Predictive In Vitro Skeletal Micro-Tissue Modelling  
Adaptation of established tissue-engineering methodologies to generate micro-physiological 
models of human skeletal muscle within this thesis demonstrates marked progression, in 
relation to physiological relevance, from prior in vitro investigations performed using 
conventional myocyte culture. The ability to measure functional endpoints in a population 
or patient specific manner allows for the performance of pharmacological time- and dose-
response studies which were previously unavailable or extremely limited for isolated human 
skeletal muscle. Indeed, a study published after the completion of this work exemplified the 
utility of a myobundle model, integrated with an in situ force monitoring system, to examine 
the relationship between therapeutically relevant statin exposure (10 nM) and contractile 
force generation in a longitudinal, non-invasive manner (Zhang et al., 2018; Truskey, 2018).  
As noted, skeletal micro-tissue modelling is very much in its infancy, this provides ample 
scope to modify and tailor systems for a multitude of different purposes. From a 
pharmacological perspective, the functional integration of other human micro-physiological 
organ systems, such as hepatic models, with engineered skeletal muscle provides an exciting 
opportunity to examine the effect of xenobiotics and their metabolites upon muscular 
function (Vernetti et al., 2017). However, in order to realise the full potential of the 
myobundle model, more systematic manipulations of culture conditions are required to 
optimise the growth and differentiation of the myocytes. Skeletal muscle constructs, 
particularly those produced using human pluripotent stem cells (hPSC), suffer from 
incomplete maturation, expressing many foetal isoforms of muscle proteins compared to 
native adult muscle fibers (Martin et al., 2013).  
In addition, supplemental methods to manipulate the development of fast- and slow- twitch 
muscle fibers are needed. Satellite cells derived from muscle biopsies have been shown to 
adopt both the contractile and metabolic properties of their parental tissue, therefore 
constraining their initial phenotype in vitro (Khodabukus and Baar, 2015). This factor is also 
important to consider when examining the respiratory phenotypes of myobundles generated 
within this thesis, since tissue biopsy location varied from patient to patient.  
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A combination of electrical stimulation, use of specific media formulations, co-culture with 
neuronal cells or microRNAs could be used to bias differentiation to fast- or slow-twitch fiber 
types (Truskey, 2018). The ability to manipulate the contractile properties of micro-tissue 
constructs, derived from a single individual, would prove particularly useful in the study of 
fiber type selectivity during statin myopathy (Obayashi et al., 2011; Sidaway et al., 2009; 
Piette et al., 2016). For example, Westwood et al., have previously shown that fast-twitch 
muscle fibers are preferentially susceptible to statin-mediated necrosis, and the tissue 
distribution reflects the distribution of the plasma membrane monocarboxylate transporter 
isoform 4 (MCT4) (Westwood et al., 2005). Bioaccumulation of statins in fast-twitch muscle 
fibers may increase local cytoplasmic concentrations compared to plasma levels, although it 
remains to be determined if statins further bioaccumulate into the mitochondria (Westwood 
et al., 2005; Bonen, 2001; Dykens and Will, 2007). 
In summary, bioengineered skeletal micro-tissues present a novel platform from which to 
investigate statin-induced myopathy and will be an invaluable tool for investigating the 
pathophysiological mechanisms underpinning xenobiotic-induced myotoxicity within a 
personalised medicines context. Furthermore, the modelling holds the potential to be 
translated to other contractile tissue types such as cardiac or smooth muscle.  
6.4 Studying the Effect of Mitochondrial Genotype upon Susceptibility 
to Drug-Induced Myopathy 
The mitochondrial genotyping performed within this thesis did not identify any significant 
associations between mitochondrial macro-haplogroup and patient status in the context of 
statin-related myopathy. However, it is important to acknowledge that this was the first 
study of its kind to attempt to find a link between mtDNA genotype and SRM in a case-control 
cohort. Furthermore, statins are not the only compounds that are capable of perpetuating 
mitochondrial myopathy amongst recipients e.g. nucleoside-analogue reverse transcriptase 
inhibitors such as zidovudine and fialuridine (Dalakas, 2009). Indeed, a limited number of 
studies have successfully identified an association between mitochondrial haplogroup and 
drug-induced adverse effects in various organ systems to date (Hendrickson et al., 2009; 
Canter et al., 2010; Kampira et al., 2013; Micheloud et al., 2011). With this in mind, 
mitochondrial genotyping, as an underrepresented branch of pharmacogenomics, may serve 
as a useful tool for patient stratification under circumstances where mitochondrial genotype 
confers an enhanced risk to adverse effects mediated by drugs with known mitochondrial 
liabilities.  
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As mentioned in the preceding chapter, studies concerning the phenotypic effects of 
mitochondrial genome variation are often supported by functional studies using trans-
mitochondrial cybrid modelling. At present there is a distinct lack of cybrid models of 
musculoskeletal derivation, however previous studies have demonstrated that myocytes, 
particularly L6 cells and human primary myoblasts can successfully undergo partial mtDNA 
depletion to form respiratory deficient cells (Mercy et al., 2005; Park et al., 2005; Herzberg 
et al., 1993). Optimisation of mtDNA depletion protocols in an immortalised skeletal muscle 
line of human origin would first be required to produce true rho0 cells for cybrid generation 
(Mamchaoui et al., 2011; Bigot et al., 2009)  
As with any myocytes grown in a two-dimensional setting, the physiological relevance of the 
in vitro modelling may be improved by incorporating the cells into a 3D micro-tissue 
construct. Theoretically, if cybrids could be generated from an immortalised human cell line 
such as those described by Mamchaoui et al., with a proportion of remnant fibroblasts 
retained amongst the myocyte population, fabrication of functional myobundles with a 
homogeneous nuclear background and variable mtDNA genotype could be possible (Bigot et 
al., 2009; Mamchaoui et al., 2011; Wilkins et al., 2014). Such a model would be particularly 
beneficial for the acquisition of measurable force output data in tandem with high resolution 
respirometry to map the metabolic and contractile profiles of myobundles against mtDNA 
haplogroup (Davis et al., 2017a). However, the true feasibility of this is debatable due to the 
poor differentiation potential of myocytes which have undergone mtDNA depletion 
(Herzberg et al., 1993). Future work should also endeavour to integrate clinical data, 
mitochondrial genotyping and functional interrogations of mitochondrial respiration from 
the same individual as this was not achieved within the confines of this thesis.  
6.5 Concluding Remarks  
Statin-mediated mitochondrial dysfunction has a role to play in the development of 
myopathic symptoms amongst susceptible patients. However, what is less clear is the 
relative contributions of direct respiratory inhibition and/or modulation of peripheral 
pathways which interact with the wider mitochondrial signalling network, to the overall 
pathophysiological mechanism. Some studies suggest that mitochondrial dysfunction is 
more of a symptom, rather than a cause, of myopathy i.e. adverse mitochondrial effects do 
not precede the degeneration of myofibers (Schaefer et al., 2004). In contrast, others have 
recognised statin-induced respiratory dysfunction as an ‘initiator’ event which precipitates 
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the injurious effects of aberrant Ca2+ handling within myocytes (Sirvent, Mercier, et al., 2005; 
Sirvent et al., 2012).  
Furthermore, statin-induced myopathy does not often manifest acutely in recipients, 
generally taking several weeks or months of continuous treatment before a clinical 
phenotype is evident (Laufs et al., 2015). This parallels in nature with the ‘biochemical 
threshold’ theory of drug-induced mitochondrial dysfunction. According to this theory, it is 
possible to considerably inhibit the activity of one or several respiratory chain complexes for 
a period of time until a critical value is met (Rossignol et al., 2003). Therefore, it could be 
postulated that the initial mitochondrial insult by statins is subclinical or transient in the 
majority of tolerant individuals, yet amplified in patients who harbour additional genetic 
and/or functional bioenergetic defects that differentiate them from those who can be safety 
treated.  
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Appendix I 
USB file 1: LMB study sponsorship protocol  
USB file 2: LMB study approval  
Appendix II 
USB file 3: LMB patient clinical information table  
Appendix III 
Summary of concordant sub-haplogroup assignments for the PREDICTION-ADR cohort. 
Gender (1), male; gender (2) female. Status (1), tolerant control; status (2), statin myopathy 
case. SRM, statin-related myopathy classification in accordance with (Alfirevic et al., 2014). 
Sample ID Age Gender Status Statin SRM  Haplogroup 
446-
14.56_CGTATCTCGA.
fastq.gz 
61 1 1 Atorvastatin 0 
 
E1a1a1 
101-
STA10_0162_CAGCT
ATAGC.fastq.gz 
49 1 1 Simvastatin 0 
 
H 
423-
12.77_CTAGTCTCGT.f
astq.gz 
66 1 1 Pravastatin 0 
 
H 
104-
STA10_0182_GCAGT
ATGCG.fastq.gz 
58 1 1 Simvastatin 0 
 
H 
428-
94228632_GACGTCT
GCT.fastq.gz 
77 1 1 Simvastatin 0 
 
H+16129 
440-
9422570_GTACTCGC
GA.fastq.gz 
77 1 1 Atorvastatin 0 
 
H+16129 
109-
STA10_0203_GACTC
ATGCT.fastq.gz 
70 1 1 Simvastatin 0 
 
H1 
25-
U_4140_TGTGTGCAT
G.fastq.gz 
80 2 2 Simvastatin 
SRM
5 
 
H1 
530-
3095708_TACACAGT
AG.fastq.gz 
77 1 2 Pravastatin 
SRM
4 
 
H1 
254-SRS-
006_TTGTCACATC.fas
tq.gz 
55 1 2 Simvastatin 
SRM
3 
 
H1+152 
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439-
1919751_GCACGTAG
CT.fastq.gz 
59 1 1 Simvastatin 0 
 
H1 
504-
15.34_AGTGTGTCTA.
fastq.gz 
58 1 1 Simvastatin 0 
 
H1 
179-
STA10_0627_ATGTC
ATGCT.fastq.gz 
67 1 1 Simvastatin 0 
 
H10a 
348-
hdf11_ACTCAGTTAC.
fastq.gz 
72 1 1 Atorvastatin 0 
 
H10e 
408-
1349403_GTGTATGC
GT.fastq.gz 
78 1 2 Simvastatin 
SRM
4 
 
H1+16189 
411-
1919689_GAGTGTCA
CT.fastq.gz 
60 2 2 Simvastatin 
SRM
4 
 
H1+16239 
410-
1902535_CATGTCGT
CA.fastq.gz 
72 1 2 Simvastatin 
SRM
3 
 
H11a 
57-
STA15_0967_TACATC
GCTG.fastq.gz 
75 1 2 Simvastatin 
SRM
5 
 
H11a 
28-
U_4507_GAGTGCATC
T.fastq.gz 
61 1 2 Atorvastatin 
SRM
4 
 
H11a1 
181-
STA10_0640_ATACA
GTCTC.fastq.gz 
70 1 1 Pravastatin 0 
 
H10e1 
599-STAGE-
945_GGTCAGTGTA.fa
stq.gz 
75 2 2 Atorvastatin 
SRM
4 
 
H11a1 
371-
lhc147_ATCTGTCCAT.
fastq.gz 
70 1 1 Atorvastatin 0 
 
H10e1 
186-
STA10_0665_ACGAT
ACACT.fastq.gz 
77 2 1 Pravastatin 0 
 
H10f 
123-
STA10_0267_TGTAC
AGCGA.fastq.gz 
70 1 1 Simvastatin 0 
 
H11a2a1 
307-CMS-
003_GCAGATAAGT.fa
stq.gz 
57 1 2 Rosuvastatin 
SRM
4 
 
H11a2a 
451-
1412838_TCACGCTA
TG.fastq.gz 
71 1 1 Simvastatin 0 
 
H11a2a1 
489-
2468936_TATCTCAT
GC.fastq.gz 
57 1 2 Atorvastatin 
SRM
3 
 
H11a2a 
373-
liv192_AGTGGCAGGT
.fastq.gz 
81 2 1 Atorvastatin 0 
 
H13a1a 
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591-NEW-
6_TTGTTGCTGT.fastq
.gz 
0 2 2 NK 0 
 
H11a7 
442-
1348383_CATGCATC
AT.fastq.gz 
79 2 2 Simvastatin 
SRM
3 
 
H13a1a 
395-
14.67_CTCTGGACGA.
fastq.gz 
60 1 1 Atorvastatin 0 
 
H15a1 
454-
2506310_TGATCAGT
CA.fastq.gz 
68 2 2 Simvastatin 
SRM
3 
 
H16 
323-STAGE-
1039_GTACTAAGAG.
fastq.gz 
57 1 2 Simvastatin 
SRM
3 
 
H1a 
214-
STA10_0379_GGTTG
GAGTT.fastq.gz 
67 1 1 Simvastatin 0 
 
H16 
249-CIS-
005_TGGAGCATGT.fa
stq.gz 
74 1 2 Atorvastatin 
SRM
3 
 
H1a1 
278-STA15-
127_TGGATGACAT.fa
stq.gz 
61 1 2 Simvastatin 
SRM
3 
 
H1a1 
65-
STA10_0722_TACTG
AGCTG.fastq.gz 
66 1 2 Simvastatin 
SRM
3 
 
H1a1 
298-WES-
002_TCTCGGATAG.fa
stq.gz 
46 1 2 Simvastatin 
SRM
3 
 
H1a1a1 
455-
2782503_TGATACTC
TG.fastq.gz 
67 2 2 Simvastatin 
SRM
3 
 
H1ab 
566-
13506803_CGAGCTA
GCA.fastq.gz 
49 1 1 Atorvastatin 0 
 
H1a 
146-
STA10_0428_GACGA
TCGCA.fastq.gz 
82 2 1 Atorvastatin 0 
 
T1a1 
52-
STA15_0943_GCTCA
TATGC.fastq.gz 
67 1 2 Atorvastatin 
SRM
3 
 
H1ag1 
538-
33167893_GCTGACA
GAG.fastq.gz 
69 2 2 Pravastatin 
SRM
4 
 
H1am 
54-
STA15_0315_TAGCG
CGTAG.fastq.gz 
80 1 2 Simvastatin 
SRM
3 
 
H1am 
183-
STA10_0655_AGAGA
TATCA.fastq.gz 
82 2 1 Simvastatin 0 
 
H1at1a 
269-STA15-
922_TCGAGGTACT.fa
stq.gz 
71 1 2 Simvastatin 
SRM
3 
 
H1ao1 
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351-
hdf2_AGTGGTGATC.f
astq.gz 
84 1 1 Simvastatin 0 
 
H1at1a 
365-
bvh822_AAGTACACT
C.fastq.gz 
53 1 1 Atorvastatin 0 
 
H1b1+16362 
561-
13.55_AGACTATATC.
fastq.gz 
64 1 1 Simvastatin 0 
 
H1b1+16362 
120-
STA10_0260_GAGAC
TATGC.fastq.gz 
68 1 1 Pravastatin 0 
 
H1ba 
403-
1413948_TACATCGC
TG.fastq.gz 
81 1 1 Simvastatin 0 
 
H1bb 
435-
1922963_GAGTGCAT
CT.fastq.gz 
66 1 2 Atorvastatin 
SRM
3 
 
H1ap1 
571-
14160844_GATATAT
GTC.fastq.gz 
68 2 1 Simvastatin 0 
 
H1bb 
519-
1352001_TGTACAGC
GA.fastq.gz 
57 1 1 Atorvastatin 0 
 
H1bk 
212-
STA10_0361_GATGG
TTGTA.fastq.gz 
46 1 1 Simvastatin 0 
 
H1bs 
188-
STA10_0671_ATCGC
TACAT.fastq.gz 
70 1 1 Simvastatin 0 
 
H1c 
13-
U_3609_GAGCTAGT
GA.fastq.gz 
68 2 2 Simvastatin 
SRM
5 
 
H1b1 
234-STA10-
0079_TTGTCCTTGC.f
astq.gz 
60 1 2 Simvastatin 
SRM
3 
 
H1b1e 
198-
STA10_0198_GTGAA
GGTAA.fastq.gz 
62 1 1 Atorvastatin 0 
 
H1c 
427-
1922786_GACTGTAC
GT.fastq.gz 
85 2 1 Simvastatin 0 
 
H1c 
14-
U_3636_CGTGCTGTC
A.fastq.gz 
76 1 2 Simvastatin 
SRM
5 
 
H1bs 
171-
STA10_0555_ACAGT
CATAT.fastq.gz 
55 1 1 Simvastatin 0 
 
K1a1b1 
332-BUT-
003_CCAGAACAGA.f
astq.gz 
55 1 2 Simvastatin 
SRM
3 
 
H1c 
360-
yft38_CATCAACATG.f
astq.gz 
64 2 1 Simvastatin 0 
 
H1c11 
 192 
  
177-
STA10_0604_ATCACT
CATA.fastq.gz 
67 1 1 Simvastatin 0 
 
N1a1a1a2 
579-
9.46_GCGTAGACGA.f
astq.gz 
72 2 1 Simvastatin 0 
 
H1c9a 
39-
STA15_0098_CAGTC
AGAGT.fastq.gz 
60 1 2 Simvastatin 
SRM
4 
 
H1c 
151-
STA10_0455_AGAGT
CGCGT.fastq.gz 
61 1 1 Atorvastatin 0 
 
H1e1a6 
169-
STA10_0543_ACATA
GTATC.fastq.gz 
55 1 1 Simvastatin 0 
 
H1e1b1 
110-
STA10_0206_GTCTG
ATACG.fastq.gz 
70 1 1 Simvastatin 0 
 
H1g1 
508-
1351728_GTGACGTA
CG.fastq.gz 
61 2 1 Simvastatin 0 
 
H1g1 
583-
14.58_ACTGATGTAG.
fastq.gz 
61 2 1 Atorvastatin 0 
 
H1g1 
585-
2.27_TAGTACTAGA.f
astq.gz 
88 2 1 Simvastatin 0 
 
H1j 
541-
14125416_GACTCAT
GCT.fastq.gz 
82 1 1 Simvastatin 0 
 
H1j7 
468-
3152195_GTCGTGTA
CT.fastq.gz 
77 2 2 Simvastatin 
SRM
3 
 
H1c8 
15-
U_3637_GATCGTCTC
T.fastq.gz 
58 1 2 Simvastatin 
SRM
5 
 
H1e1b1 
195-
STA10_0165_TAGGT
GGAAT.fastq.gz 
61 1 1 Simvastatin 0 
 
H1m 
2-
U_2986_GTGTATGCG
T.fastq.gz 
65 1 2 Atorvastatin 
SRM
4 
 
H1g 
311-NEW-
004_GGAACACAGG.f
astq.gz 
33 1 2 Atorvastatin 
SRM
5 
 
H1g1 
74-
STA10_0749_TAGTCT
GTCA.fastq.gz 
61 1 2 Simvastatin 
SRM
3 
 
H1m 
64-
STA10_0695_GAGAT
CAGTC.fastq.gz 
73 2 2 Simvastatin 
SRM
3 
 
H1n+146 
245-CIS-
001_TGTTCGATAG.fa
stq.gz 
63 1 2 Simvastatin 
SRM
3 
 
H1n1 
 193 
  
356-
yft53_AAGCGTAGAA.
fastq.gz 
83 2 1 Atorvastatin 0 
 
H1z 
128-
STA10_0326_GCGAG
ATGTA.fastq.gz 
79 1 1 Atorvastatin 0 
 
H24a 
418-
1902966_TATCGATG
CT.fastq.gz 
55 1 1 Atorvastatin 0 
 
H24a 
96-
STA10_0030_GTAGT
ACACA.fastq.gz 
56 2 1 Simvastatin 0 
 
H24a 
29-
U_4511_TGCGTAGTC
G.fastq.gz 
47 1 2 Simvastatin 
SRM
4 
 
H1n4 
279-STA15-
222_GATCCTGAGC.fa
stq.gz 
63 1 2 Atorvastatin 
SRM
3 
 
H1o 
226-
STA10_0667_TATGG
TAAGG.fastq.gz 
39 2 1 Simvastatin 0 
 
H27a 
30-
U_4602_CTGTGTCGT
C.fastq.gz 
73 2 2 Atorvastatin 
SRM
5 
 
H1o 
483-
19025711_GTGCGCT
AGT.fastq.gz 
62 2 1 Simvastatin 0 
 
H27a 
478-
2712168_GTGATACT
GA.fastq.gz 
65 2 2 Simvastatin 
SRM
3 
 
H1v 
18-
U_3879_CATGTCGTC
A.fastq.gz 
55 1 2 Simvastatin 
SRM
5 
 
H27a 
308-NEW-
001_GTCGGCTCTA.fa
stq.gz 
69 2 2 Atorvastatin 
SRM
3 
 
H27a 
285-STA15-
424_TAGCTTCACT.fas
tq.gz 
72 1 2 Atorvastatin 
SRM
4 
 
H28 
211-
STA10_0344_GGTGT
CTTGT.fastq.gz 
62 1 1 Simvastatin 0 
 
H2a1a 
523-
1418638_ACGTGCTC
TG.fastq.gz 
73 1 1 Atorvastatin 0 
 
H2a1a1 
6-
U_3430_GCGTCGTGT
A.fastq.gz 
69 1 2 Simvastatin 
SRM
5 
 
H28a 
207-
STA10_0300_TGTGA
ATCTC.fastq.gz 
72 1 1 Atorvastatin 0 
 
H2a1e1a 
567-
14175862_CGATCGA
CTG.fastq.gz 
77 1 1 Simvastatin 0 
 
H2a2b1a1 
 194 
  
87-BUT-
001_GTGATACTGA.fa
stq.gz 
65 2 2 Rosuvastatin 
SRM
3 
 
H2a1+146 
103-
STA10_0181_GCACG
CGTAT.fastq.gz 
69 2 1 Atorvastatin 0 
 
H2a2b4 
346-
elh64_AATGCAGTGT.
fastq.gz 
68 1 1 Atorvastatin 0 
 
H2a2b5a 
524-
1550080_TACATGAT
AG.fastq.gz 
62 1 1 Atorvastatin 0 
 
H2a3 
150-
STA10_0453_TAGCA
TACAG.fastq.gz 
58 2 1 Simvastatin 0 
 
H3 
173-
STA10_0568_AGCAT
CTATA.fastq.gz 
51 1 1 Simvastatin 0 
 
H3 
487-
1418960_GAGATCAG
TC.fastq.gz 
62 1 1 Atorvastatin 0 
 
H3 
456-
2890272_GCGTCGTG
TA.fastq.gz 
48 1 2 Simvastatin 
SRM
4 
 
H2a1a1 
134-
STA10_0346_CTAGC
AGATG.fastq.gz 
59 2 1 Simvastatin 0 
 
H3+152 
275-STA15-
946_CTGCGAATGT.fa
stq.gz 
61 2 2 Atorvastatin 
SRM
3 
 
H2a2b1a1 
121-
STA10_0261_CAGAG
CTAGT.fastq.gz 
68 2 1 Simvastatin 0 
 
H31a 
415-
1419837_GTGAGAGA
CA.fastq.gz 
87 1 1 Simvastatin 0 
 
H39 
461-
1551326_TCTCTGTG
CA.fastq.gz 
61 1 1 Simvastatin 0 
 
H39 
470-
3872933_CTATGCGA
TC.fastq.gz 
61 2 2 Simvastatin 
SRM
3 
 
H2a2b4 
485-
1350713_TACGCTGC
TG.fastq.gz 
48 1 1 Simvastatin 0 
 
H3ao 
119-
STA10_0241_CGAGC
TAGCA.fastq.gz 
76 1 1 Simvastatin 0 
 
H3b1b1 
424-
1927529_CTGTACGT
GA.fastq.gz 
62 1 2 Fluvastatin 
SRM
3 
 
H3+152 
450-
1351865_CACTATGT
CG.fastq.gz 
84 2 1 Simvastatin 0 
 
H3g3 
 195 
  
22-
U_4024_GTCATGCGT
C.fastq.gz 
56 1 2 Rosuvastatin 
SRM
4 
 
H30b 
600-STAGE-
1062_GTAATGGAGT.
fastq.gz 
74 1 2 Atorvastatin 
SRM
4 
 
H39b 
516-
3525461_TCATATCG
CG.fastq.gz 
69 1 2 Atorvastatin 
SRM
3 
 
H3aa 
45-
STA15_0863_TATGC
GCTGC.fastq.gz 
53 2 2 Simvastatin 
SRM
3 
 
H3ag 
237-IOW-
003_CAGGTCACAT.fa
stq.gz 
61 1 2 Simvastatin 
SRM
3 
 
M1a1i 
117-
STA10_0231_CACAT
ACAGT.fastq.gz 
71 1 1 Simvastatin 0 
 
H3v+16093 
41-
STA15_0141_GTATG
AGCAC.fastq.gz 
78 1 2 Atorvastatin 
SRM
3 
 
H3b1a 
317-STAGE-
168_TCGAACTGCA.fa
stq.gz 
73 2 2 Simvastatin 
SRM
3 
 
H3b1b1 
88-SWB-
001_CTAGATCTGA.fa
stq.gz 
59 1 2 Rosuvastatin 
SRM
3 
 
H3b1b1 
244-RNS-
001_GTGGCTTCGT.fa
stq.gz 
72 2 2 Atorvastatin 
SRM
5 
 
U4b1b1a 
201-
STA10_0223_GGTCA
GTGTA.fastq.gz 
79 1 1 Simvastatin 0 
 
H3y 
528-
94226690_TACGTAT
AGC.fastq.gz 
55 2 2 Fluvastatin 
SRM
4 
 
H3g1b 
167-
STA10_0538_ATCAT
ATCTC.fastq.gz 
68 2 1 Simvastatin 0 
 
H41a 
136-
STA10_0349_GCAGC
TGTCA.fastq.gz 
82 1 1 Simvastatin 0 
 
H45 
406-
1413490_TGTGTCAC
TA.fastq.gz 
78 1 1 Simvastatin 0 
 
H45 
217-
STA10_0435_TACTA
GGATC.fastq.gz 
67 1 1 Atorvastatin 0 
 
H4a1a+195 
507-
9423813_CGCAGAGC
AT.fastq.gz 
75 1 1 Pravastatin 0 
 
H4a1a1 
215-
STA10_0380_TGGTG
TCCGT.fastq.gz 
54 1 1 Atorvastatin 0 
 
H4a1a1a1a 
 196 
  
11-
U_3598_CGCTGTAGT
C.fastq.gz 
79 1 2 Simvastatin 
SRM
5 
 
H3h 
503-
2976706_AGTCAGAC
GC.fastq.gz 
71 1 2 Simvastatin 
SRM
3 
 
H3h 
107-
STA10_0197_TGCGA
GACGT.fastq.gz 
58 1 1 Simvastatin 0 
 
H4a1a3 
596-STAGE-
241_GTGAAGGTAA.f
astq.gz 
62 1 2 Atorvastatin 
SRM
3 
 
H3t 
580-
5.3_GAGACTATGC.fa
stq.gz 
81 2 1 Atorvastatin 0 
 
H5 
16-
U_3775_GTGCTGTCG
T.fastq.gz 
66 1 2 Simvastatin 
SRM
4 
 
H3v+16093 
259-STA15-
468_GTAGCCAGTA.fa
stq.gz 
59 1 2 Atorvastatin 
SRM
3 
 
K1c2 
26-
U_4429_GAGTGTCAC
T.fastq.gz 
73 1 2 Simvastatin 
SRM
4 
 
W 
92-HES-
005_CTATACAGTG.fa
stq.gz 
72 1 2 Simvastatin 
SRM
3 
 
H4a1a1 
500-
2661416_TATAGAGA
TC.fastq.gz 
58 1 2 Simvastatin 
SRM
4 
 
H4a1a1a 
469-
3782293_GATCGTCT
CT.fastq.gz 
52 1 2 Atorvastatin 
SRM
4 
 
H4a1a1a1a 
525-
1919257_ACAGTCAT
AT.fastq.gz 
85 2 1 Simvastatin 0 
 
H52 
357-
yft60_GACAGCAAGC.
fastq.gz 
70 1 1 Atorvastatin 0 
 
H58a 
98-
STA10_0132_AGTGT
GTCTA.fastq.gz 
75 1 1 Simvastatin 0 
 
H5a1 
296-IOW-
004_GTGTTCGGTC.fa
stq.gz 
73 1 2 Simvastatin 
SRM
3 
 
H4a1a3 
66-
STA10_0723_TAGTA
GCGCG.fastq.gz 
66 1 2 Simvastatin 
SRM
3 
 
H4a1a3 
27-
U_4441_CTAGTCTCG
T.fastq.gz 
65 2 2 Atorvastatin 
SRM
5 
 
U5b1e1 
59-
STA10_0025_GACTG
TACGT.fastq.gz 
67 2 2 Simvastatin 
SRM
3 
 
H4a1c 
 197 
  
338-STAGE-
377_CATACCTGAT.fa
stq.gz 
87 1 2 Simvastatin 
SRM
4 
 
H5 
274-STA15-
896_TTGCAGATCA.fa
stq.gz 
65 1 2 Atorvastatin 
SRM
3 
 
K1c2 
235-TEL-
002_CCTGTGTAGA.fa
stq.gz 
74 2 2 Simvastatin 
SRM
3 
 
H5a1 
250-SRS-
001_GAAGGAGATA.f
astq.gz 
72 1 2 Atorvastatin 
SRM
4 
 
H5a1 
180-
STA10_0634_GCTGA
CAGAG.fastq.gz 
70 1 1 Pravastatin 0 
 
H5a1d 
280-STA15-
298_GTCGGTCTGA.fa
stq.gz 
80 2 2 Rosuvastatin 
SRM
3 
 
H2a2b4 
246-CIS-
002_TCATTCAGTG.fa
stq.gz 
87 2 2 Atorvastatin 
SRM
5 
 
H5a1c1a 
283-STA15-
420_GGTCGTGCAT.fa
stq.gz 
82 2 2 Atorvastatin 
SRM
4 
 
T1a1 
584-
8.7_TCTACGACAT.fas
tq.gz 
74 2 1 Atorvastatin 0 
 
H5a1g1 
89-SWB-
002_TATCAGTCTG.fa
stq.gz 
54 2 2 Rosuvastatin 
SRM
3 
 
H5a1c1a 
438-
1419430_GCTCATAT
GC.fastq.gz 
80 2 1 Atorvastatin 0 
 
H5b 
288-
STA10_0075_TTCGTT
CCTG.fastq.gz 
39 1 1 Simvastatin 0 
 
H2a2a1 
289-
STA10_0239_CACTG
CTTGA.fastq.gz 
92 1 1 Simvastatin 0 
 
I1f 
97-
STA10_0131_TGCTA
CATCA.fastq.gz 
69 1 1 Simvastatin 0 
 
H5b1 
290-
STA10_0248_TCTAG
CGTGG.fastq.gz 
69 1 1 Simvastatin 0 
 
J1c2 
228-STA10-
0001_GGTAGAATGA.
fastq.gz 
77 1 2 Simvastatin 
SRM
5 
 
H5a1d 
276-STA15-
56_CTGTTCTAGC.fast
q.gz 
77 1 2 Pravastatin 
SRM
3 
 
H5a1d 
133-
STA10_0343_GCACT
AGACA.fastq.gz 
58 1 1 Simvastatin 0 
 
H5b3 
 198 
  
17-
U_3858_TGAGCGTG
CT.fastq.gz 
66 1 2 Simvastatin 
SRM
5 
 
H5a8 
297-WES-
001_CTCAAGAAGC.fa
stq.gz 
64 1 2 Simvastatin 
SRM
3 
 
U2e1a1 
286-STA15-
561_CAGATGTCCT.fa
stq.gz 
79 1 2 Simvastatin 
SRM
3 
 
H5b1 
23-
U_4064_CTATGCGAT
C.fastq.gz 
69 2 2 Atorvastatin 
SRM
5 
 
H5d 
262-STA15-
532_CGATCCTATA.fa
stq.gz 
79 1 2 Atorvastatin 
SRM
3 
 
H66a 
302-
STA15_895_TCCTTGT
TCT.fastq.gz 
61 1 2 Simvastatin 
SRM
3 
 
H6a1a 
243-HES-
012_TCTTGTTCAC.fas
tq.gz 
48 1 2 
Rosuvastatin 
Ezetimibe 
SRM
3 
 
H6a1a 
185-
STA10_0662_AGTCA
GACGC.fastq.gz 
67 1 1 Simvastatin 0 
 
H6a1a 
162-
STA10_0512_TCGAT
ATCTA.fastq.gz 
73 2 1 Fluvastatin 0 
 
H6a1a3 
306-BUT-
006_GTATAACGCT.fa
stq.gz 
69 1 2 Simvastatin 
SRM
3 
 
K1a1b1 
149-
STA10_0452_AGTCA
TCGCA.fastq.gz 
46 1 1 Atorvastatin 0 
 
H6a1b 
55-
STA15_0467_CGTCA
CAGTA.fastq.gz 
72 1 2 Simvastatin 
SRM
3 
 
H6a1a 
510-
9423545_GACGATCG
CA.fastq.gz 
80 2 1 Simvastatin 0 
 
H6a1b2 
546-
19191805_AGTCATC
GCA.fastq.gz 
84 1 1 Simvastatin 0 
 
H6a1b2 
106-
STA10_0188_GCTAC
TAGCG.fastq.gz 
78 1 1 Simvastatin 0 
 
H6a1b3 
202-
STA10_0233_GTAAT
GGAGT.fastq.gz 
74 1 1 Simvastatin 0 
 
H6a1b3a 
192-
STA10_0102_ATCGC
ATAGA.fastq.gz 
69 1 1 Atorvastatin 0 
 
H6a1b4 
263-STA15-
685_TGACTAGCTT.fa
stq.gz 
65 1 2 Simvastatin 
SRM
3 
 
H6a1a3 
 199 
  
400-
1902114_TGTGCTCG
CA.fastq.gz 
65 2 2 Simvastatin 
SRM
3 
 
H6a1a3 
148-
STA10_0448_ACATG
TCTGA.fastq.gz 
72 1 1 Simvastatin 0 
 
H6c 
319-STAGE-
171_GAGCACGGAA.f
astq.gz 
73 1 2 Simvastatin 
SRM
3 
 
J1c2c1a 
498-
1417238_ACTCGATA
GT.fastq.gz 
68 1 1 Simvastatin 0 
 
H7a1b 
321-STAGE-
974_TGCTGGCTTG.fa
stq.gz 
72 2 2 Simvastatin 
SRM
3 
 
J1c5c1 
190-
STA10_0683_AGCAG
TACTC.fastq.gz 
65 1 1 Simvastatin 0 
 
H7c2 
63-
STA10_0685_CAGCT
GAGTA.fastq.gz 
53 1 2 Simvastatin 
SRM
3 
 
H6a1a3 
170-
STA10_0550_ATGTA
TAGTC.fastq.gz 
65 1 1 Simvastatin 0 
 
H7c3 
513-
2870440_ATGTATAG
TC.fastq.gz 
53 1 2 Atorvastatin 
SRM
3 
 
H6a1b2e 
194-
STA10_0158_GTGTG
GTTGT.fastq.gz 
62 1 1 Simvastatin 0 
 
H7c3 
361-
yft51_TGGCTACGCT.f
astq.gz 
86 2 1 Simvastatin 0 
 
H7d 
533-
29449712_GACTAGT
CAG.fastq.gz 
92 2 2 Simvastatin 
SRM
3 
 
H7a1b 
10-
U_3594_CGCTATCAG
T.fastq.gz 
76 2 2 Atorvastatin 
SRM
6 
 
H7d 
557-
1349121_CAGAGAGT
CA.fastq.gz 
88 2 1 Simvastatin 0 
 
H7d1 
592-WES-
5_GTGTGGTTGT.fast
q.gz 
74 2 2 Simvastatin 
SRM
5 
 
H89 
342-STAGE-
1009_AGGTAAGAGG.
fastq.gz 
46 1 2 Atorvastatin 
SRM
3 
 
HV0+195 
277-STA15-
103_CACTTGTGTG.fa
stq.gz 
37 1 2 Atorvastatin 
SRM
3 
 
HV15 
472-
1551358_CAGTCAGA
GT.fastq.gz 
91 2 1 Simvastatin 0 
 
H7i1 
 200 
  
301-
STA15_297_CCAAGA
AGAA.fastq.gz 
68 2 2 Atorvastatin 
SRM
3 
 
HV1b2 
314-WES-
003_GAAGCGCACT.fa
stq.gz 
70 1 2 Simvastatin 
SRM
5 
 
HV22 
232-STA10-
0065_GCGTCTGAAT.f
astq.gz 
66 1 2 Simvastatin 
SRM
3 
 
HV5a 
341-STAGE-
607_TCTGGTCTCA.fa
stq.gz 
72 1 2 Simvastatin 
SRM
3 
 
X2b+226 
187-
STA10_0666_AGCGA
GTATG.fastq.gz 
53 1 1 Atorvastatin 0 
 
H80 
344-
elh53_GCACTGTTGC.
fastq.gz 
53 1 1 Atorvastatin 0 
 
J2a1a1a2 
496-
15513540_CTGATGC
AGA.fastq.gz 
70 2 1 Simvastatin 0 
 
H8c2 
597-STAGE-
417_TGTTGTGGTA.fa
stq.gz 
78 2 2 Simvastatin 
SRM
3 
 
I1a1b 
521-
1412711_GATACACT
GA.fastq.gz 
82 1 1 Simvastatin 0 
 
HV0 
105-
STA10_0186_TGATA
GAGAG.fastq.gz 
76 2 1 Simvastatin 0 
 
HV5a 
367-
bvh836_ATGCCTATC
A.fastq.gz 
51 1 1 Atorvastatin 0 
 
HV9 
157-
STA10_0486_AGTGT
ACTCA.fastq.gz 
64 2 1 Atorvastatin 0 
 
I1a1 
142-
STA10_0402_CAGAG
AGTCA.fastq.gz 
80 1 1 Atorvastatin 0 
 
I1a1e 
114-
STA10_0224_CAGTC
TACAT.fastq.gz 
64 2 1 Pravastatin 0 
 
I2 
125-
STA10_0280_TCACA
GCATA.fastq.gz 
67 1 1 Simvastatin 0 
 
I2 
131-
STA10_0340_CGACG
CTGAT.fastq.gz 
71 1 1 Rosuvastatin 0 
 
I2 
359-
yft72_CGCGACTTGT.f
astq.gz 
52 1 1 Atorvastatin 0 
 
H6a1b3 
602-STAGE-
1087_GGAAGTAAGG.
fastq.gz 
55 1 2 Atorvastatin 
SRM
3 
 
I2a2 
 201 
  
137-
STA10_0369_ACGTA
TCATC.fastq.gz 
59 2 1 Simvastatin 0 
 
I2 
362-
bvh894_ACGCGGACT
A.fastq.gz 
64 2 1 Simvastatin 0 
 
I5a 
223-
STA10_0629_GAATG
GAAGA.fastq.gz 
74 1 1 Pravastatin 0 
 
I3 
354-
yft45_ACGCAGGAGT.
fastq.gz 
75 1 1 Atorvastatin 0 
 
I5a2 
320-STAGE-
378_GCTCTAACAT.fa
stq.gz 
71 1 2 Simvastatin 
SRM
4 
 
J1b1a1 
238-RLS-
002_GCCATGTCAT.fa
stq.gz 
84 2 2 Atorvastatin 
SRM
5 
 
J1b1a1a 
164-
STA10_0522_TGAGA
TCATA.fastq.gz 
76 2 1 Atorvastatin 0 
 
J1b1a1 
203-
STA10_0254_CTCGTT
ATTC.fastq.gz 
73 1 1 Simvastatin 0 
 
J1b1a1+146 
200-
STA10_0212_GTTGA
TGAGT.fastq.gz 
70 2 1 Simvastatin 0 
 
J1b1a1e 
486-
1416484_TCGCGTGA
GA.fastq.gz 
53 2 1 Simvastatin 0 
 
J1b1a1e 
506-
1350764_CAGTCTAC
AT.fastq.gz 
68 1 1 Simvastatin 0 
 
J1b2 
99-
STA10_0137_TCATAT
CGCG.fastq.gz 
71 2 1 Simvastatin 0 
 
J1b2 
369-
bvh843_ATAGCCGTG
T.fastq.gz 
61 1 1 Atorvastatin 0 
 
J1c 
582-
9.43_GCAGCTGTCA.f
astq.gz 
72 2 1 Simvastatin 0 
 
J1c15 
299-
STA15_894_CTCTGG
ACGA.fastq.gz 
77 1 2 Simvastatin 
SRM
3 
 
J1b1a1a 
86-AUS-
002_CGTCTATGAT.fa
stq.gz 
67 1 2 Atorvastatin 
SRM
6 
 
J1b1a1a 
425-
1348441_TATAGCAC
GC.fastq.gz 
80 1 1 Simvastatin 0 
 
J1c1a 
481-
3326934_GTGCTGTC
GT.fastq.gz 
53 1 2 Atorvastatin 
SRM
4 
 
J1c1a 
 202 
  
517-
3811166_TGCGAGAC
GT.fastq.gz 
58 1 2 Atorvastatin 
SRM
3 
 
J1c1b1a 
335-STAGE-
741_GACAGGTGAC.f
astq.gz 
70 2 2 Simvastatin 
SRM
5 
 
J1c1e 
526-
11.17_ATGTCATGCT.f
astq.gz 
69 1 1 Atorvastatin 0 
 
J1c1d 
143-
STA10_0412_TCGAT
CGACA.fastq.gz 
73 2 1 Atorvastatin 0 
 
J1c1g1 
208-
STA10_0303_CTAATC
GTGT.fastq.gz 
66 1 1 Simvastatin 0 
 
J1c1g1 
112-
STA10_0215_GCGTA
GACGA.fastq.gz 
61 1 1 Pravastatin 0 
 
J1c2 
147-
STA10_0444_TCATCA
TGCG.fastq.gz 
73 1 1 Simvastatin 0 
 
J1c2 
443-
14.33_CTATACAGTG.
fastq.gz 
62 1 1 Pravastatin 0 
 
J1c2 
404-
1348286_TACTGAGC
TG.fastq.gz 
75 1 1 Simvastatin 0 
 
J1b1a1 
337-STAGE-
507_CACGAAGAGC.f
astq.gz 
66 2 2 Simvastatin 
SRM
3 
 
J1c1e 
465-
2941761_CATGAGTG
TA.fastq.gz 
84 2 2 Simvastatin 
SRM
3 
 
J1c2 
53-
STA15_0150_CACTAT
GTCG.fastq.gz 
76 1 2 Atorvastatin 
SRM
3 
 
J1c2b1 
116-
STA10_0230_TACAC
AGTAG.fastq.gz 
53 1 1 Atorvastatin 0 
 
J1c2b3 
69-
STA10_0730_TCTGA
GCGCA.fastq.gz 
77 1 2 Atorvastatin 
SRM
3 
 
J1c2b5 
294-TEL-
004_GGACAGATGG.f
astq.gz 
69 1 2 Simvastatin 
SRM
3 
 
J1c2h 
158-
STA10_0489_TGATG
TATGT.fastq.gz 
50 1 1 Atorvastatin 0 
 
J1c2c1 
484-
9423349_CGCAGTCT
AT.fastq.gz 
79 2 1 Simvastatin 0 
 
J1c3b 
102-
STA10_0179_TCGAT
GCGCT.fastq.gz 
76 1 1 Simvastatin 0 
 
J1c3b1a 
 203 
  
166-
STA10_0532_ATCAG
TGTAT.fastq.gz 
76 2 1 Atorvastatin 0 
 
J1c3b1a 
334-NWL-
003_TTGTCGAGAC.fa
stq.gz 
55 2 2 Simvastatin 
SRM
3 
 
J1c3b 
42-
STA15_0373_CGAGT
GCTGT.fastq.gz 
54 1 2 Atorvastatin 
SRM
3 
 
W5a1a 
535-
16660007_ACGATCA
CAT.fastq.gz 
69 1 2 Simvastatin 
SRM
3 
 
J1c3e1 
266-STA15-
736_TCGCTGAACA.fa
stq.gz 
71 1 2 Atorvastatin 
SRM
5 
 
J1c3g 
520-
1919808_CGACGCTG
AT.fastq.gz 
86 2 1 Simvastatin 0 
 
J1c3b2 
422-
1419266_TCAGTGTC
TC.fastq.gz 
70 1 2 Simvastatin 
SRM
3 
 
J1c3g 
204-
STA10_0294_GGAAG
TAAGG.fastq.gz 
57 1 1 Atorvastatin 0 
 
J1c5 
494-
1417258_CTCAGCAG
TG.fastq.gz 
68 2 1 Simvastatin 0 
 
J1c5 
49-
STA15_0900_CTGCA
TGATC.fastq.gz 
69 1 2 Atorvastatin 
SRM
3 
 
J1c4 
587-
15.39_CGAGACGACA
.fastq.gz 
57 2 1 Atorvastatin 0 
 
J1c5 
258-STA15-
157_TTACACGTTC.fas
tq.gz 
90 2 2 Simvastatin 
SRM
5 
 
J1c5 
550-
30303706_ATACAGT
CTC.fastq.gz 
52 1 2 Pravastatin 
SRM
3 
 
J1c5 
62-
STA10_0677_CGTAC
TACGT.fastq.gz 
55 1 2 Atorvastatin 
SRM
4 
 
J1c5b 
130-
STA10_0339_GTGAC
GTACG.fastq.gz 
72 1 1 Atorvastatin 0 
 
J1c8a 
218-
STA10_0537_GTCTC
AATGT.fastq.gz 
69 2 1 Atorvastatin 0 
 
J1c8a 
512-
2760345_TCGATATC
TA.fastq.gz 
64 2 2 Simvastatin 
SRM
4 
 
J1c7a 
447-
14.49_TGCGTAGTCG.
fastq.gz 
61 1 1 Simvastatin 0 
 
J1d1a1 
 204 
  
562-
1350455_CATAGACG
TG.fastq.gz 
79 2 1 Simvastatin 0 
 
J2a1a1a 
100-
STA10_0149_TACGT
ATAGC.fastq.gz 
65 2 1 Atorvastatin 0 
 
K1a 
83-HES-
003_TAGAGTCTGT.fa
stq.gz 
71 2 2 Simvastatin 
SRM
3 
 
J1c8a 
457-
3164036_CGTGCTGT
CA.fastq.gz 
55 1 2 Simvastatin 
SRM
4 
 
J2a2a1a1 
60-
STA10_0159_GCACG
TAGCT.fastq.gz 
52 2 2 Simvastatin 
SRM
5 
 
J2b1a 
73-
STA10_0748_CGTAT
GATGT.fastq.gz 
63 1 2 Atorvastatin 
SRM
3 
 
J2b1a 
358-
yft68_CTGACCGAGA.
fastq.gz 
77 1 1 Atorvastatin 0 
 
K1a+150 
421-
1418027_CGCTGTAG
TC.fastq.gz 
78 2 2 Simvastatin 
SRM
3 
 
J2b1b1 
495-
1417002_CAGAGCTA
GT.fastq.gz 
80 1 1 Simvastatin 0 
 
K1a+195 
577-
2.72_ATCTAGATCA.fa
stq.gz 
86 2 1 Simvastatin 0 
 
K1a+195 
295-TEL-
005_CTTACGTTGC.fa
stq.gz 
57 2 2 Atorvastatin 
SRM
3 
 
K1a+150 
363-
bvh812_AGAGGTCG
GA.fastq.gz 
69 1 1 Simvastatin 0 
 
K1a10a 
576-
13.28_AGAGATATCA.
fastq.gz 
65 2 1 Atorvastatin 0 
 
K1a1b2a1a 
127-
STA10_0316_CGATC
GACTG.fastq.gz 
80 2 1 Simvastatin 0 
 
K1a3a1b 
191-
STA10_0684_ATCTA
GATCA.fastq.gz 
66 1 1 Atorvastatin 0 
 
K1a4a1 
210-
STA10_0307_GGATA
GGATC.fastq.gz 
70 2 1 Atorvastatin 0 
 
K1a4a1e 
24-
U_4098_TGCTATGCT
G.fastq.gz 
44 1 2 Atorvastatin 
SRM
3 
 
K1a+195 
537-
26046556_ACATATA
CGT.fastq.gz 
64 1 2 Fluvastatin 
SRM
4 
 
K1a+195 
 205 
  
449-
1550253_TATGCGCT
GC.fastq.gz 
71 2 1 Simvastatin 0 
 
K1a4a1f 
399-
1550575_TGTGTGCA
TG.fastq.gz 
67 2 2 Atorvastatin 
SRM
3 
 
K1a4a1 
420-
1412729_TGCTCGTA
GT.fastq.gz 
56 2 2 Simvastatin 
SRM
4 
 
K1a4a1 
539-
14.37_ATCGCTACAT.f
astq.gz 
62 1 1 Atorvastatin 0 
 
K1a4d 
257-SRS-
009_GTTCTTCGTA.fas
tq.gz 
74 1 2 Simvastatin 
SRM
5 
 
K1a4a1a2a 
518-
14204883_TACTGCA
GCG.fastq.gz 
77 2 1 Simvastatin 0 
 
K1b1a1d1 
304-
STA15_501_TGGACT
CAGA.fastq.gz 
74 2 2 Pravastatin 
SRM
3 
 
K1a4a1b2 
140-
STA10_0388_GACTA
GTCAG.fastq.gz 
59 2 1 Simvastatin 0 
 
K2a 
324-STAGE-
308_GAAGTCAAGC.f
astq.gz 
68 1 2 Simvastatin 
SRM
3 
 
K1a4a1e 
466-
3058235_CGTCTATG
AT.fastq.gz 
54 1 2 Simvastatin 
SRM
3 
 
K1a4a1f 
248-CIS-
004_GTAGAAGTGG.f
astq.gz 
75 1 2 Atorvastatin 
SRM
3 
 
K1c1 
273-STA15-
889_CTAAGTCATG.fa
stq.gz 
77 1 2 Atorvastatin 
SRM
3 
 
K1c1 
549-
31580991_AGCATCT
ATA.fastq.gz 
45 2 2 Pravastatin 
SRM
4 
 
K1c1 
129-
STA10_0328_CTGAT
GCAGA.fastq.gz 
69 1 1 Simvastatin 0 
 
K2a6 
588-
11.35_ATGCTGCGCT.
fastq.gz 
68 2 1 Simvastatin 0 
 
K2a6 
475-
1350481_CAGCTGAG
TA.fastq.gz 
75 2 1 Simvastatin 0 
 
H 
460-
15507730_GTCTACT
GTC.fastq.gz 
81 2 1 Simvastatin 0 
 
K2b1a1a 
551-
35695882_ATGCTAG
AGA.fastq.gz 
57 1 2 Pravastatin 
SRM
4 
 
K1c2 
 206 
  
479-
11.6_CTACTGATGA.f
astq.gz 
68 1 1 Fluvastatin 0 
 
B5a1d 
93-HES-
006_TGATACTCTG.fa
stq.gz 
59 1 2 Simvastatin 
SRM
3 
 
K1d 
463-
1412537_CGTACTAC
GT.fastq.gz 
82 2 1 Simvastatin 0 
 
T1a1 
82-HES-
002_TATCGATGCT.fa
stq.gz 
61 1 2 Simvastatin 
SRM
4 
 
K2a7 
480-
3090330_GATGTAGC
GT.fastq.gz 
45 2 2 Simvastatin 
SRM
3 
 
K2b1a1 
581-
2.24_GCGAGATGTA.f
astq.gz 
88 2 1 Simvastatin 0 
 
T1a1 
222-
STA10_0622_CATCT
GGAGT.fastq.gz 
52 2 1 Simvastatin 0 
 
T1a1k2 
462-
1922104_TAGCGCGT
AG.fastq.gz 
71 1 1 Simvastatin 0 
 
T2 
196-
STA10_0187_TGTAG
GTGGA.fastq.gz 
57 1 1 Simvastatin 0 
 
T2a1a 
394-
1.68_TCTCGGATAG.f
astq.gz 
90 2 1 Atorvastatin 0 
 
T2a1a 
490-
3051533_CTAGATCT
GA.fastq.gz 
60 2 2 Simvastatin 
SRM
4 
 
J1b1a1a 
491-
3643161_GTAGTACA
CA.fastq.gz 
62 2 2 Simvastatin 
SRM
3 
 
I1a1 
492-
3684114_TGCTACAT
CA.fastq.gz 
42 1 2 Simvastatin 
SRM
3 
 
I1a1 
284-STA15-
423_CAGGCTCAGT.fa
stq.gz 
80 1 2 Atorvastatin 
SRM
4 
 
T1a1 
326-STAGE-
989_GTCCAGACAT.fa
stq.gz 
71 1 2 Simvastatin 
SRM
4 
 
T1a1 
256-SRS-
008_TGTCAGCTTA.fa
stq.gz 
69 1 2 Simvastatin 
SRM
4 
 
T2a1a 
396-
1412062_GTATCGTC
GT.fastq.gz 
67 1 2 Simvastatin 
SRM
3 
 
T2a1a2 
138-
STA10_0382_AGTAT
CGTAC.fastq.gz 
89 1 1 Simvastatin 0 
 
T2b 
 207 
  
499-
1.5_CACGAGATGA.fa
stq.gz 
91 2 1 Simvastatin 0 
 
H2a2b3 
5-
U_3429_GTGCGTGT
GT.fastq.gz 
70 
0 (2 
plink) 
2 Simvastatin 
SRM
4 
 
T2b 
81-HES-
001_TGTGTCACTA.fa
stq.gz 
70 1 2 Pravastatin 
SRM
3 
 
T2a1b1a1a2 
84-HES-
004_CATGCATCAT.fa
stq.gz 
68 2 2 Simvastatin 
SRM
4 
 
T2a1b1a1b 
242-HES-
011_TTGCTTAGTC.fas
tq.gz 
66 1 2 Simvastatin 
SRM
4 
 
T2b 
416-
1550626_TAGTAGCG
CG.fastq.gz 
79 2 1 Simvastatin 0 
 
T2b 
251-SRS-
002_CGAATGTATG.fa
stq.gz 
60 2 2 Simvastatin 
SRM
6 
 
T2b 
260-STA15-
502_TGAGAAGGTA.f
astq.gz 
70 1 2 Atorvastatin 
SRM
3 
 
T2b 
558-
1349883_TAGCATAC
AG.fastq.gz 
75 1 1 Simvastatin 0 
 
T2b 
430-
1349088_TAGAGTCT
GT.fastq.gz 
81 2 2 Atorvastatin 
SRM
3 
 
T2b 
467-
3079482_TCAGCGAT
AT.fastq.gz 
73 2 2 Simvastatin 
SRM
4 
 
T2b 
8-
U_3434_GATGTAGC
GT.fastq.gz 
57 
0 (2 
plink) 
2 Simvastatin 
SRM
5 
 
T2b 
509-
1348220_AGTATCGT
AC.fastq.gz 
79 1 1 Simvastatin 0 
 
H2a2a1 
229-STA10-
0003_TTCTCATCGT.f
astq.gz 
81 1 2 Rosuvastatin 
SRM
3 
 
T2b13 
340-STAGE-
875_ATTGTGGAGT.fa
stq.gz 
91 1 2 Simvastatin 
SRM
4 
 
T2b16 
132-
STA10_0341_CTACG
ATCAG.fastq.gz 
61 1 1 Simvastatin 0 
 
T2b19 
315-WES-
004_GCATGCCAGT.fa
stq.gz 
65 1 2 Simvastatin 
SRM
3 
 
T2b17a 
572-
19198989_ATCATAT
CTC.fastq.gz 
89 1 1 Simvastatin 0 
 
T2b21 
 208 
  
505-
762806_GCTACTAGC
G.fastq.gz 
60 1 2 Simvastatin 
SRM
3 
 
T2b19 
570-
19191508_AGAGTCG
CGT.fastq.gz 
85 1 1 Simvastatin 0 
 
T2b24a 
122-
STA10_0262_CGCAG
AGCAT.fastq.gz 
84 1 1 Simvastatin 0 
 
T2b2b 
206-
STA10_0299_CGTCTT
CTTA.fastq.gz 
73 2 1 Simvastatin 0 
 
T2b2b 
375-
lth87_AGGAGAAGGA
.fastq.gz 
56 1 1 Atorvastatin 0 
 
T2b2b 
563-
1902283_AGCAGTAC
TC.fastq.gz 
81 2 1 Simvastatin 0 
 
T2b2b 
398-
1420561_TGAGCGTG
CT.fastq.gz 
61 1 2 Simvastatin 
SRM
3 
 
T2b2b1 
265-STA15-
707_TCGAATGTGC.fa
stq.gz 
68 1 2 Rosuvastatin 
SRM
4 
 
T2b3+151 
160-
STA10_0495_TAGTA
CTAGA.fastq.gz 
62 1 1 Simvastatin 0 
 
T2b33 
542-
14.48_CACATACAGT.
fastq.gz 
61 1 1 Pravastatin 0 
 
T2b35 
477-
2385599_TGTCGTCA
TA.fastq.gz 
56 2 2 Simvastatin 
SRM
3 
 
T2b33 
91-IOW-
001_TATGTACGTG.fa
stq.gz 
21 1 2 Simvastatin 
SRM
4 
 
T2b34 
458-
3374947_GTCATGCG
TC.fastq.gz 
74 2 2 Simvastatin 
SRM
3 
 
T2b3b 
434-
1550142_GTGCTCAT
GT.fastq.gz 
58 2 2 Simvastatin 
SRM
3 
 
T2b4 
152-
STA10_0456_TCTAC
GACAT.fastq.gz 
60 1 1 Atorvastatin 0 
 
T2b4a1 
272-STA15-
713_GGTCTGGTGT.fa
stq.gz 
70 1 2 Rosuvastatin 
SRM
3 
 
T2b4b 
417-
1418404_TAGTCTGT
CA.fastq.gz 
62 1 1 Simvastatin 0 
 
T2b4b 
531-
3259933_ACGTCAGT
AT.fastq.gz 
74 2 2 Simvastatin 
SRM
4 
 
J1c12a 
 209 
  
247-CIS-
003_GTGGAGAGCT.f
astq.gz 
62 1 2 Simvastatin 
SRM
3 
 
T2b5 
322-STAGE-
1021_TGCATGGAGC.
fastq.gz 
81 1 2 Simvastatin 
SRM
5 
 
T2b7a2 
368-
bvh838_ACTGTAGGA
C.fastq.gz 
74 1 1 Atorvastatin 0 
 
T2b8 
184-
STA10_0657_ATGCT
GCGCT.fastq.gz 
76 1 1 Simvastatin 0 
 
T2c1+146 
111-
STA10_0209_ACTAG
CTGTC.fastq.gz 
70 2 1 Atorvastatin 0 
 
U2e1a1 
565-
14121555_ACTAGCT
GTC.fastq.gz 
82 1 1 Simvastatin 0 
 
U2e2a1a 
19-
U_3880_TCAGTGTCT
C.fastq.gz 
64 
0 (1 
plink) 
2 Simvastatin 
SRM
5 
 
U2e1a1c 
253-SRS-
005_GAATAGCTGA.fa
stq.gz 
52 1 2 Atorvastatin 
SRM
6 
 
U2e1b 
293-TEL-
003_GAGATTGCTA.fa
stq.gz 
71 2 2 Simvastatin 
SRM
3 
 
U2e1b1 
407-
13.61_TATCAGTCTG.f
astq.gz 
64 1 1 Atorvastatin 0 
 
U4a 
501-
2762832_ACATAGTA
TC.fastq.gz 
64 1 2 Pravastatin 
SRM
3 
 
U3a1 
168-
STA10_0539_AGTAG
ATCAT.fastq.gz 
65 1 1 Simvastatin 0 
 
U4a1b1 
225-
STA10_0663_TGGTG
CTGGA.fastq.gz 
76 1 1 Simvastatin 0 
 
U4a1d 
545-
19197807_GATGACT
ACG.fastq.gz 
55 1 1 Simvastatin 0 
 
T1a1 
153-
STA10_0460_CACGA
GATGA.fastq.gz 
60 1 1 Simvastatin 0 
 
U4b1b1a 
559-
1351716_TGATGTAT
GT.fastq.gz 
70 1 1 Simvastatin 0 
 
U4b1b1b 
372-
liv167_ACTTAGAGAG
.fastq.gz 
65 1 1 Atorvastatin 0 
 
U5a1a1 
595-NWL-
6_TTAGTGGTGA.fast
q.gz 
50 1 2 Rosuvastatin 
SRM
3 
 
U4a1b 
 210 
  
305-BUT-
005_GGCATCATGC.fa
stq.gz 
47 1 2 Simvastatin 
SRM
4 
 
U4b1b1 
374-
lth86_ATGAGGTCGT.
fastq.gz 
53 2 1 Atorvastatin 0 
 
U5a1a1 
464-
1417627_TAGACGTG
CT.fastq.gz 
61 1 1 Atorvastatin 0 
 
U5a1a1d 
555-
1419931_ACTGCGTG
TC.fastq.gz 
67 1 1 Simvastatin 0 
 
J1c3a1 
556-
15.59_CTAGCAGATG.
fastq.gz 
53 1 1 Simvastatin 0 
 
I4a1 
224-
STA10_0646_GGCTG
TGATC.fastq.gz 
67 1 1 Simvastatin 0 
 
U5a1a1d1 
436-
12.72_GCGATGATGA
.fastq.gz 
66 1 1 Atorvastatin 0 
 
U5a1b 
327-STAGE-
872_GAGACCTCTA.fa
stq.gz 
75 2 2 Simvastatin 
SRM
3 
 
U4b1b1 
598-STAGE-
365_GTTGATGAGT.fa
stq.gz 
62 1 2 Rosuvastatin 
SRM
3 
 
U4b2 
339-STAGE-
1018_GACGTGCTTC.f
astq.gz 
55 1 2 Rosuvastatin 
SRM
3 
 
U4c1 
412-
1919850_GATGCGAG
CT.fastq.gz 
54 1 2 Simvastatin 
SRM
4 
 
U4c1 
564-
15517418_GCACGCG
TAT.fastq.gz 
88 2 1 Simvastatin 0 
 
X2b8 
527-
14176609_AGCGAGT
ATG.fastq.gz 
65 2 2 Pravastatin 
SRM
4 
 
U4c1 
267-STA15-
890_GCGTTATTGC.fa
stq.gz 
89 1 2 Simvastatin 
SRM
3 
 
U4c2 
448-
1902115_TGTCGAGT
CA.fastq.gz 
86 2 1 Simvastatin 0 
 
U5a1b 
497-
1349653_ACGTATCA
TC.fastq.gz 
66 1 1 Atorvastatin 0 
 
U5a1b 
213-
STA10_0365_CCTCGT
TGTT.fastq.gz 
61 1 1 Simvastatin 0 
 
U5a1b+16362 
236-IOW-
002_GATAAGAAGG.f
astq.gz 
77 2 2 Atorvastatin 
SRM
5 
 
U5a1a1 
 211 
  
432-
1420121_GTCGTCGT
CT.fastq.gz 
77 2 2 Atorvastatin 
SRM
3 
 
U5a1a1 
178-
STA10_0610_AGCTC
TGTGA.fastq.gz 
73 1 1 Simvastatin 0 
 
U5a1b1d 
155-
STA10_0470_ACGTG
CTCTG.fastq.gz 
81 1 1 Simvastatin 0 
 
U5a1b1d+16093 
4-
U_3428_GTCGTCGTC
T.fastq.gz 
65 1 2 Simvastatin 
SRM
5 
 
U5a1a1b 
444-
1551206_GTGCGTGT
GT.fastq.gz 
76 2 2 Simvastatin 
SRM
4 
 
U5a1a2a 
364-
bvh818_AATCGAGCG
T.fastq.gz 
47 1 1 Atorvastatin 0 
 
U5a1b1f 
471-
1412699_CTGTAGTG
CG.fastq.gz 
63 1 1 Atorvastatin 0 
 
U5a2c1 
514-
13.11_AGCTCTGTGA.
fastq.gz 
65 1 1 Pravastatin 0 
 
U5b1+16189+@1
6192 
255-SRS-
007_CTGGAGGCTA.fa
stq.gz 
54 2 2 Atorvastatin 
SRM
6 
 
U5a1a2a1 
231-STA10-
0063_CGCTAATGTA.f
astq.gz 
85 2 2 Simvastatin 
SRM
3 
 
U5a1b+16362 
309-NEW-
002_TTCGATAGCA.fa
stq.gz 
58 1 2 Atorvastatin 
SRM
6 
 
U5a1b1 
141-
STA10_0399_GATGA
CTACG.fastq.gz 
74 1 1 Simvastatin 0 
 
U5b1b1+@1619
2 
586-
3.59_AGTAGATCAT.f
astq.gz 
84 2 1 Pravastatin 0 
 
J2a1a1a 
347-
hdf1_ATATGGTGGA.f
astq.gz 
65 2 1 Atorvastatin 0 
 
U5b1c1a 
589-
2.66_ATCGCATAGA.f
astq.gz 
86 2 1 Atorvastatin 0 
 
J2a1a1a2 
46-
STA15_0923_TCTCTG
TGCA.fastq.gz 
69 2 2 Simvastatin 
SRM
3 
 
U5a1b1 
529-
33000015_CGATGAC
AGA.fastq.gz 
55 1 2 Atorvastatin 
SRM
3 
 
U5a1c2a1 
21-
U_3959_CGTATCTCG
A.fastq.gz 
69 
0 (2 
plink) 
2 Simvastatin 
SRM
5 
 
U5a1d1 
 212 
  
310-NEW-
003_GTCTAGCAGG.fa
stq.gz 
72 1 2 Simvastatin 
SRM
3 
 
U5a1e 
593-WES-
6_TAGGTGGAAT.fast
q.gz 
79 1 2 Atorvastatin 
SRM
4 
 
I2d 
292-NWL-
001_GTCGTAACAC.fa
stq.gz 
40 1 2 Simvastatin 
SRM
4 
 
U5a2b4 
94-HES-
007_TCAGCGATAT.fa
stq.gz 
61 1 2 Simvastatin 
SRM
3 
 
U5a2d1a 
165-
STA10_0525_CTACAT
ACTA.fastq.gz 
73 1 1 Simvastatin 0 
 
U5b2a2b1 
220-
STA10_0580_GGTGT
TAGTG.fastq.gz 
75 2 1 Simvastatin 0 
 
U5b2b 
135-
STA10_0347_CATGA
TACGC.fastq.gz 
75 1 1 Simvastatin 0 
 
U5b2b1a1 
349-
yft25_AAGTGCGATG.
fastq.gz 
49 1 1 Simvastatin 0 
 
U5b2b1a1 
156-
STA10_0481_ACGAT
CACAT.fastq.gz 
58 1 1 Simvastatin 0 
 
U5b2b3a1 
578-
7.67_GCAGTATGCG.f
astq.gz 
76 2 1 Simvastatin 0 
 
U8a1a2 
61-
STA10_0643_TCACG
CTATG.fastq.gz 
65 2 2 Simvastatin 
SRM
4 
 
T2a1b1a1b 
594-WES-
7_TGTAGGTGGA.fast
q.gz 
89 2 2 Atorvastatin 
SRM
3 
 
U5b2a1a2 
95-HES-
008_CTACTGATGA.fa
stq.gz 
72 1 2 Simvastatin 
SRM
3 
 
U5b2a2b 
476-
1412620_GTGACTCG
TC.fastq.gz 
66 1 1 Simvastatin 0 
 
V+@16298 
603-STAGE-
1198_CGGTGTGTGT.f
astq.gz 
68 1 2 Simvastatin 
SRM
4 
 
U5b2b4a 
77-
STA10_0752_TATCAT
GTGC.fastq.gz 
54 1 2 Simvastatin 
SRM
3 
 
U5b3g 
71-
STA10_0732_GTGAC
TCGTC.fastq.gz 
61 1 2 Atorvastatin 
SRM
3 
 
U4b1a2a 
72-
STA10_0747_TCGAG
TAGCG.fastq.gz 
36 1 2 Rosuvastatin 
SRM
3 
 
T1a1 
 213 
  
113-
STA10_0221_CTCAG
CAGTG.fastq.gz 
62 1 1 Simvastatin 0 
 
V+@72 
370-
lth37_TCACGACGAA.
fastq.gz 
60 1 1 Simvastatin 0 
 
V+@72 
75-
STA10_0750_TGTCTC
TATC.fastq.gz 
79 2 2 Simvastatin 
SRM
3 
 
X2b5 
40-
STA15_0135_CGCAG
TCTAT.fastq.gz 
54 1 2 Atorvastatin 
SRM
3 
 
V 
452-
9422668_TCTGAGCG
CA.fastq.gz 
81 1 1 Atorvastatin 0 
 
V10a 
58-
STA10_0020_GTGAG
AGACA.fastq.gz 
66 2 2 Simvastatin 
SRM
5 
 
V+@72 
271-STA15-
560_TTCGAGCTAT.fa
stq.gz 
42 1 2 Simvastatin 
SRM
3 
 
V10a 
401-
1902376_GTATGAGC
AC.fastq.gz 
77 1 2 Simvastatin 
SRM
3 
 
V10a 
409-
1350561_CGCTATCA
GT.fastq.gz 
81 1 2 Simvastatin 
SRM
3 
 
V16 
31-
U_5078_CTGTAGTGC
G.fastq.gz 
81 2 2 Simvastatin 
SRM
4 
 
V1a1 
352-
yft35_ACTTCTTAGC.f
astq.gz 
76 1 1 Atorvastatin 0 
 
V15a 
197-
STA10_0195_TTAGT
GGTGA.fastq.gz 
71 1 1 Simvastatin 0 
 
V1a 
534-
35310006_ACATGTC
TGA.fastq.gz 
66 2 2 Rosuvastatin 
SRM
3 
 
V2 
543-
13516475_TCACAGC
ATA.fastq.gz 
83 2 1 Atorvastatin 0 
 
V2c 
532-
14204227_CTACGAT
CAG.fastq.gz 
86 2 2 Pravastatin 
SRM
3 
 
V24 
80-TEL-
001_TATCTCATGC.fas
tq.gz 
67 1 2 Simvastatin 
SRM
3 
 
W5 
9-
U_3593_GAGTGATC
GT.fastq.gz 
66 1 2 Simvastatin 
SRM
3 
 
J1c2e 
209-
STA10_0305_CTCTTA
GTTC.fastq.gz 
69 2 1 Simvastatin 0 
 
W1g 
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205-
STA10_0298_CGGTG
TGTGT.fastq.gz 
82 1 1 Simvastatin 0 
 
W3a1c 
493-
830046_TGATAGAGA
G.fastq.gz 
69 1 2 Simvastatin 
SRM
3 
 
X2b4 
50-
STA15_0901_CGCGT
ATCAT.fastq.gz 
58 2 2 Atorvastatin 
SRM
3 
 
X2b4a1 
502-
2789467_ATCACTCA
TA.fastq.gz 
55 1 2 Simvastatin 
SRM
3 
 
X2b4a1 
118-
STA10_0236_CACAG
TGATG.fastq.gz 
73 1 1 Simvastatin 0 
 
X2c1a 
377-
lth93_ATTAGCGAGT.f
astq.gz 
68 1 1 Atorvastatin 0 
 
X2g 
 
Appendix IV 
Summary of healthy volunteer cohort concordant sub-haplogroup assignments. 
Sample ID Gender  Haplogroup  
352 Male A2+(64) 
126 Male A2v 
355 Female D1 
80 Female F1e3 
159 Male G2a5 
17 Female H 
251 Male H 
165 Female H1+16189 
353 Male H1+16189 
284 Female H1+16239 
52 Female H10e1 
380 Female H11a+152 
335 Female H11a1 
336 Male H11a1 
219 Female H11a2a 
218 Female H11a2a1 
357 Male H14b1 
342 Female H17 
341 Female H1a 
144 Male H1a1 
211 Female H1a1 
178 Female H1a1a1 
272 Female H1af1b 
373 Female H1ai 
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337 Female H1am 
230 Female H1au1a 
141 Female H1b1+16362 
213 Male H1b1+16362 
41 Female H1bb 
48 Female H1bs 
12 Female H1c 
210 Male H1c 
181 Female H1c1 
377 Female H1c3 
168 Male H1e2 
367 Male H1g1 
378 Female H1g1 
347 Male H1j 
365 Female H1j 
305 Female H1m 
103 Female H1q3 
287 Female H24a 
204 Female H27c 
81 Male H2a1e1a1 
112 Female H2a2b1a1 
60 Male H3 
274 Female H31a 
95 Female H39 
201 Female H39b 
195 Male H3ap 
217 Male H3ap 
13 Female H3aq 
258 Male H3aq 
319 Female H3ar 
54 Female H42a 
82 Male H49a1 
108 Male H4a1 
19 Female H4a1a1a 
107 Male H4a1a1a 
162 Male H4a1a1a 
346 Female H4a1a2a 
10 Female H4a1c 
157 Female H5 
222 Male H56 
45 Female H58a 
69 Female H5a1 
102 Female H5a1 
127 Male H5a1 
245 Male H5a1c1a 
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292 Male H5a1g1 
326 Male H5b1 
320 Female H5b4 
31 Female H5s 
349 Female H65a 
55 Female H6a1a3 
42 Female H6a1b 
27 Female H6a1b4 
280 Female H6a2a 
177 Male H6b2 
194 Female H6c 
288 Male H6c 
311 Female H7 
64 Male H7a1b 
382 Male H7b 
282 Female H8c2 
207 Female HV0+195 
150 Female HV0d 
340 Male HV0d 
345 Female HV4a1 
249 Male I1a1 
370 Female I2a2 
255 Female I5a2 
100 Female J1c+16261 
53 Female J1c1a 
376 Female J1c1a 
192 Female J1c1b2a 
316 Female J1c1c 
90 Female J1c1e 
176 Female J1c1e 
225 Female J1c2 
306 Male J1c2 
359 Female J1c2c1 
38 Female J1c2h 
199 Female J1c2l 
22 Female J1c2m 
203 Female J1c2r 
114 Male J1c3b 
134 Female J1c3b 
197 Male J1c3b 
142 Female J1c3e2 
343 Female J1c3f 
3 Female J1c3g 
43 Female J1c3g 
295 Male J1c3g 
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50 Male J1c5 
83 Male J1c5 
154 Female J1c5f 
329 Male J1c8a 
118 Male J2a1a1a 
158 Female J2a1a1a 
172 Female J2a1a1a2 
117 Male J2b2 
368 Female K1a+150 
202 Male K1a+195 
323 Female K1a1b1a 
236 Male K1a1b1f 
315 Female K1a30a 
79 Female K1a3a2 
314 Female K1a4a1 
224 Female K1a4a1a2b 
289 Female K1a4a1a2b 
70 Male K1a4a1b 
20 Female K1a4a1d 
85 Male K1a4a1e 
145 Female K1b1a1d1 
264 Male K1c1 
67 Female K1c1b 
209 Male K1c2 
265 Female K1c2 
309 Male K1d 
16 Male K2a 
273 Female K2a 
58 Female K2a3 
358 Female K2a3 
132 Female N1b1b1 
93 Male R5a2 
29 Male T1a1 
44 Female T1a1 
71 Male T1a1 
6 Female T1a1a1 
293 Female T1a1a1 
379 Female T2 
98 Female T2a1b1a 
331 Female T2a1b1a 
109 Male T2b 
153 Female T2b 
246 Female T2b 
348 Male T2b 
247 Female T2b17a 
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61 Male T2b21 
40 Female T2b28 
171 Female T2b2b 
369 Male T2b2b1 
73 Female T2b3 
84 Male T2b4 
226 Male T2c1+146 
15 Female T2e 
235 Female T2e 
72 Female T2e1a 
14 Male U1a1a1 
36 Female U1a1a1 
310 Female U1b3 
384 Female U2e1'2'3 
366 Male U2e1a1 
381 Female U2e2a1a 
96 Female U3a1 
254 Male U3a1 
65 Male U3a1c 
2 Female U3a1c1 
228 Female U4a2b 
99 Female U4b1a1a1 
33 Male U4b1a2b 
270 Male U4b1b1 
115 Male U4b1b1a 
267 Male U4b1b1a 
317 Female U4b1b1a 
32 Female U4b1b1b 
248 Male U5a1+@16192 
11 Female U5a1a1 
18 Female U5a1a1 
188 Male U5a1a1 
304 Female U5a1a1 
51 Female U5a1b1 
239 Female U5a1b1g 
330 Male U5a1d1 
242 Female U5a1f1a1 
253 Female U5a1f1a1 
261 Female U5a1h 
299 Female U5a1h 
78 Female U5a1i1 
383 Male U5a1i1 
298 Male U5a2+16362 
283 Female U5a2a1+152 
35 Female U5a2a2 
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205 Female U5a2a2 
74 Male U5b1d1c 
240 Female U5b2a1b 
105 Female U5b2a2b1 
183 Female U5b2a3a 
68 Female U5b2b4a 
215 Female U5b3b1 
56 Male U8a1a3 
25 Female V+@16298 
129 Male V12 
77 Female V15a 
234 Female V15a 
277 Female V15a 
339 Male V15a 
354 Female V15a 
268 Female V19 
37 Male V9a2 
275 Female W1+119 
47 Female W5a1a 
121 Female W5a2 
324 Female X2+225+@16223 
110 Female X2b+226 
116 Male X2b+226 
138 Female X2b+226 
257 Male X2b5 
193 Female X2c1a 
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